<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD) - Herath, SC - 2018 | Cochrane Library</title> <meta content="Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD) - Herath, SC - 2018 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009764.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD) - Herath, SC - 2018 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009764.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD009764.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD)" name="citation_title"/> <meta content="Samantha C Herath" name="citation_author"/> <meta content="Westmead Public Hospital" name="citation_author_institution"/> <meta content="Rebecca Normansell" name="citation_author"/> <meta content="St George's, University of London" name="citation_author_institution"/> <meta content="rnormans@sgul.ac.uk" name="citation_author_email"/> <meta content="Samantha Maisey" name="citation_author"/> <meta content="St George's University of London" name="citation_author_institution"/> <meta content="Phillippa Poole" name="citation_author"/> <meta content="University of Auckland" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="10" name="citation_issue"/> <meta content="10.1002/14651858.CD009764.pub3" name="citation_doi"/> <meta content="2018" name="citation_date"/> <meta content="2018/10/30" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009764.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009764.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009764.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Amoxicillin [adverse effects, therapeutic use]; Anti-Bacterial Agents [adverse effects, *therapeutic use]; Antibiotic Prophylaxis [*methods]; Aza Compounds [therapeutic use]; Azithromycin [adverse effects, therapeutic use]; Clarithromycin [therapeutic use]; Clavulanic Acid [adverse effects, therapeutic use]; *Disease Progression; Drug Administration Schedule; Erythromycin [therapeutic use]; Fluoroquinolones; Moxifloxacin [therapeutic use]; Pulmonary Disease, Chronic Obstructive [*drug therapy]; *Quality of Life; Quinolines [therapeutic use]; Randomized Controlled Trials as Topic; Roxithromycin [adverse effects, therapeutic use]; Trimethoprim, Sulfamethoxazole Drug Combination [adverse effects, therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009764.pub3&amp;doi=10.1002/14651858.CD009764.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009764.pub3&amp;doi=10.1002/14651858.CD009764.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009764.pub3&amp;doi=10.1002/14651858.CD009764.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009764.pub3&amp;doi=10.1002/14651858.CD009764.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009764.pub3&amp;doi=10.1002/14651858.CD009764.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009764.pub3&amp;doi=10.1002/14651858.CD009764.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009764.pub3&amp;doi=10.1002/14651858.CD009764.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009764.pub3&amp;doi=10.1002/14651858.CD009764.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009764.pub3&amp;doi=10.1002/14651858.CD009764.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009764.pub3&amp;doi=10.1002/14651858.CD009764.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009764.pub3&amp;doi=10.1002/14651858.CD009764.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009764.pub3&amp;doi=10.1002/14651858.CD009764.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009764.pub3&amp;doi=10.1002/14651858.CD009764.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009764.pub3&amp;doi=10.1002/14651858.CD009764.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009764.pub3&amp;doi=10.1002/14651858.CD009764.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009764.pub3&amp;doi=10.1002/14651858.CD009764.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009764.pub3&amp;doi=10.1002/14651858.CD009764.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009764.pub3&amp;doi=10.1002/14651858.CD009764.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009764.pub3&amp;doi=10.1002/14651858.CD009764.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009764.pub3&amp;doi=10.1002/14651858.CD009764.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009764.pub3&amp;doi=10.1002/14651858.CD009764.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009764.pub3&amp;doi=10.1002/14651858.CD009764.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009764.pub3&amp;doi=10.1002/14651858.CD009764.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="JmNqPX1V";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD009764\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD009764\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009764\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009764\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","ms","fr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD009764.pub3",title:"Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD)",firstPublishedDate:"Oct 30, 2018 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Airways Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=JmNqPX1V&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009764.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009764.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD009764.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD009764.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009764.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD009764.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Conclusiones de los autores&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Antecedentes&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Objetivos&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Métodos&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Discusión&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD009764.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD009764.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD009764.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD009764.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>19791 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD009764.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009764.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009764.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009764.pub3/full#CD009764-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009764.pub3/full#CD009764-sec-0095"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009764.pub3/full#CD009764-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009764.pub3/full#CD009764-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009764.pub3/full#CD009764-sec-0035"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009764.pub3/full#CD009764-sec-0036"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009764.pub3/full#CD009764-sec-0059"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009764.pub3/full#CD009764-sec-0087"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009764.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009764.pub3/appendices#CD009764-sec-0100"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009764.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009764.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/table_n/CD009764StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/table_n/CD009764StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009764.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009764.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009764.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009764.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009764.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD009764.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2018 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD)</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009764.pub3/information#CD009764-cr-0002">Samantha C Herath</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009764.pub3/information#CD009764-cr-0003"><i class="icon corresponding-author fa fa-envelope"></i>Rebecca Normansell</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009764.pub3/information#CD009764-cr-0004">Samantha Maisey</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009764.pub3/information#CD009764-cr-0005">Phillippa Poole</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/information/en#CD009764-sec-0117">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 30 October 2018 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD009764.pub3">https://doi.org/10.1002/14651858.CD009764.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD009764-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009764-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009764-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009764-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD009764-abs-0003">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD009764-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD009764-abs-0001" lang="en"> <section id="CD009764-sec-0001"> <h3 class="title" id="CD009764-sec-0001">Background</h3> <p>There has been renewal of interest in the use of prophylactic antibiotics to reduce the frequency of exacerbations and improve quality of life in chronic obstructive pulmonary disease (COPD). </p> </section> <section id="CD009764-sec-0002"> <h3 class="title" id="CD009764-sec-0002">Objectives</h3> <p>To determine whether or not regular (continuous, intermittent or pulsed) treatment of COPD patients with prophylactic antibiotics reduces exacerbations or affects quality of life. </p> </section> <section id="CD009764-sec-0003"> <h3 class="title" id="CD009764-sec-0003">Search methods</h3> <p>We searched the Cochrane Airways Group Trials Register and bibliographies of relevant studies. The latest literature search was performed on 27 July 2018. </p> </section> <section id="CD009764-sec-0004"> <h3 class="title" id="CD009764-sec-0004">Selection criteria</h3> <p>Randomised controlled trials (RCTs) that compared prophylactic antibiotics with placebo in patients with COPD. </p> </section> <section id="CD009764-sec-0005"> <h3 class="title" id="CD009764-sec-0005">Data collection and analysis</h3> <p>We used the standard Cochrane methods. Two independent review authors selected studies for inclusion, extracted data, and assessed risk of bias. We resolved discrepancies by involving a third review author. </p> </section> <section id="CD009764-sec-0006"> <h3 class="title" id="CD009764-sec-0006">Main results</h3> <p>We included 14 studies involving 3932 participants in this review. We identified two further studies meeting inclusion criteria but both were terminated early without providing results. All studies were published between 2001 and 2015. Nine studies were of continuous macrolide antibiotics, two studies were of intermittent antibiotic prophylaxis (three times per week) and two were of pulsed antibiotic regimens (e.g. five days every eight weeks). The final study included one continuous, one intermittent and one pulsed arm. The antibiotics investigated were azithromycin, erythromycin, clarithromycin, doxycyline, roxithromycin and moxifloxacin. The study duration varied from three months to 36 months and all used intention‐to‐treat analysis. Most of the pooled results were of moderate quality. The risk of bias of the included studies was generally low. </p> <p>The studies recruited participants with a mean age between 65 and 72 years and mostly at least moderate‐severity COPD. Five studies only included participants with frequent exacerbations and two studies recruited participants requiring systemic steroids or antibiotics or both, or who were at the end stage of their disease and required oxygen. One study recruited participants with pulmonary hypertension secondary to COPD and a further study was specifically designed to asses whether eradication of <i>Chlamydia pneumoniae</i> reduced exacerbation rates. </p> <p>The co‐primary outcomes for this review were the number of exacerbations and quality of life. </p> <p>With use of prophylactic antibiotics, the number of participants experiencing one or more exacerbations was reduced (odds ratio (OR) 0.57, 95% CI 0.42 to 0.78; participants = 2716; studies = 8; moderate‐quality evidence). This represented a reduction from 61% of participants in the control group compared to 47% in the treatment group (95% CI 39% to 55%). The number needed to treat for an additional beneficial outcome with prophylactic antibiotics given for three to 12 months to prevent one person from experiencing an exacerbation (NNTB) was 8 (95% CI 5 to 17). The test for subgroup difference suggested that continuous and intermittent antibiotics may be more effective than pulsed antibiotics (P = 0.02, I² = 73.3%). </p> <p>The frequency of exacerbations per patient per year was also reduced with prophylactic antibiotic treatment (rate ratio 0.67; 95% CI 0.54 to 0.83; participants = 1384; studies = 5; moderate‐quality evidence). Although we were unable to pool the result, six of the seven studies reporting time to first exacerbation identified an increase (i.e. benefit) with antibiotics, which was reported as statistically significant in four studies. </p> <p>There was a statistically significant improvement in quality of life as measured by the St George's Respiratory Questionnaire (SGRQ) with prophylactic antibiotic treatment, but this was smaller than the four unit improvement that is regarded as being clinically significant (mean difference (MD) ‐1.94, 95% CI ‐3.13 to ‐0.75; participants = 2237; studies = 7, high‐quality evidence). </p> <p>Prophylactic antibiotics showed no significant effect on the secondary outcomes of frequency of hospital admissions, change in forced expiratory volume in one second (FEV1), serious adverse events or all‐cause mortality (moderate‐quality evidence). There was some evidence of benefit in exercise tolerance, but this was driven by a single study of lower methodological quality. </p> <p>The adverse events that were recorded varied among the studies depending on the antibiotics used. Azithromycin was associated with significant hearing loss in the treatment group, which was in many cases reversible or partially reversible. The moxifloxacin pulsed study reported a significantly higher number of adverse events in the treatment arm due to the marked increase in gastrointestinal adverse events (P &lt; 0.001). Some adverse events that led to drug discontinuation, such as development of long QTc or tinnitus, were not significantly more frequent in the treatment group than the placebo group but pose important considerations in clinical practice. </p> <p>The development of antibiotic resistance in the community is of major concern. Six studies reported on this, but we were unable to combine results. One study found newly colonised participants to have higher rates of antibiotic resistance. Participants colonised with moxifloxacin‐sensitive pseudomonas at initiation of therapy rapidly became resistant with the quinolone treatment. A further study with three active treatment arms found an increase in the degree of antibiotic resistance of isolates in all three arms after 13 weeks treatment. </p> </section> <section id="CD009764-sec-0007"> <h3 class="title" id="CD009764-sec-0007">Authors' conclusions</h3> <p>Use of continuous and intermittent prophylactic antibiotics results in a clinically significant benefit in reducing exacerbations in COPD patients. All studies of continuous and intermittent antibiotics used macrolides, hence the noted benefit applies only to the use of macrolide antibiotics prescribed at least three times per week. The impact of pulsed antibiotics remains uncertain and requires further research. </p> <p>The studies in this review included mostly participants who were frequent exacerbators with at least moderate‐severity COPD. There were also older individuals with a mean age over 65 years. The results of these studies apply only to the group of participants who were studied in these studies and may not be generalisable to other groups. </p> <p>Because of concerns about antibiotic resistance and specific adverse effects, consideration of prophylactic antibiotic use should be mindful of the balance between benefits to individual patients and the potential harms to society created by antibiotic overuse. Monitoring of significant side effects including hearing loss, tinnitus, and long QTc in the community in this elderly patient group may require extra health resources. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD009764-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009764-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009764-abs-0009">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009764-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD009764-abs-0008">Français</a> </li> <li class="section-language"> <a class="" href="full/ms#CD009764-abs-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD009764-abs-0006">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD009764-abs-0005" lang="en"> <h3>Preventative antibiotic therapy for people with COPD</h3> <p><b>What is COPD?</b> </p> <p>COPD is a common chronic respiratory disease mainly affecting people who smoke now or have done so previously. It could become the third leading cause of death worldwide by 2020. People with COPD experience gradually worsening shortness of breath and cough with sputum (phlegm) because of permanent damage to their airways and lungs. Those with COPD may have flare‐ups (or exacerbations) most commonly with respiratory infections. Exacerbations may lead to further irreversible loss of lung function, as well as days off work, hospital admission, reduction in quality of life, or even death. </p> <p><b>Why did we do this review?</b> </p> <p>We wanted to find out if giving antibiotics to prevent a flare‐up ('prophylactic' antibiotics) would reduce the frequency of flare‐ups and improve quality of life. Studies that were taken into consideration used either continuous prophylactic antibiotics (every day), or antibiotics that were used intermittently (three times per week) or pulsed (e.g. for five days every eight weeks) </p> <p><b>What evidence did we find?</b> </p> <p>We carried out the latest search for studies in July 2018. We found 14 randomised controlled trials (RCTs) involving 3932 participants. All studies were published between 2001 and 2015. Nine studies were of continuous antibiotics, two studies were of intermittent antibiotic prophylaxis and two were of pulsed antibiotics. The final study included one continuous, one intermittent, one pulsed and one placebo arm. The antibiotics investigated were azithromycin, erythromycin, clarithromycin, roxithromycin, doxycycline and moxifloxacin. On average, the people involved in the studies were 65 to 72 years old and had moderate or severe COPD. Three studies included participants with frequent exacerbations and two of the studies recruited participants requiring steroid tablets or antibiotics or both, or who were at the end stage of their disease and required oxygen. One study only included people with a particular complication of COPD, involving the heart and blood vessels in the lungs (known as pulmonary hypertension). </p> <p><b>Results and conclusions</b> </p> <p>We found that, with the use of antibiotics, the number of participants who developed an exacerbation reduced markedly. For every eight participants treated, one person would be prevented from suffering an exacerbation. However, not all the antibiotic regimens had the same impact on exacerbations. The results suggested that antibiotics given at least three times per week may be more effective than antibiotics given daily for a few days followed by a break of several weeks. We also found there may have been a benefit on patient‐reported quality of life with the antibiotics. On the other hand, use of antibiotics did not significantly affect the number of deaths due to any cause, the frequency of hospitalisation, or the loss of lung function during the study period. </p> <p>Even though there may be fewer exacerbations with antibiotics, there are considerable drawbacks of taking antibiotics. First, there were specific adverse events associated with the antibiotics, which differed according to the antibiotic used; second, patients have to take antibiotics regularly for months or years; finally, the resulting increase in antibiotic resistance will have implications for both individual patients and the wider community through reducing the effectiveness of currently available antibiotics. </p> <p>Because of concerns about antibiotic resistance and specific adverse effects, consideration of prophylactic antibiotic use should be mindful of the balance between benefits to individual patients and the potential harms to society created by antibiotic overuse. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD009764-sec-0095" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009764-sec-0095">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009764-sec-0164">Español</a> </li> </nav> </div> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD009764-sec-0095"></div> <h3 class="title" id="CD009764-sec-0096">Implications for practice</h3> <section id="CD009764-sec-0096"> <p>Use of prophylactic macrolide antibiotics for a period of up to 12 months is likely to reduce the number of patients with one or more exacerbations, exacerbation frequency, increase the median time to first exacerbation and improve health‐related quality of life. Benefits appear to be driven by continuous and intermittent macrolide regimens, with pulsed regimens being less effective. However, the benefits need to be balanced against the risk of harm, notably antibiotic resistance, and the cost and adherence implications for the patient and the health care system, as well as potential costs of monitoring for adverse effects. </p> <p>Reducing the frequency of exacerbations would reduce healthcare costs and might be expected to preserve lung function and quality of life, as well as lower the risk of mortality, although we did not find evidence of any of the latter in this review. In part, this is due to the dearth of studies that have addressed the frequency and duration of hospital admissions and the relatively small numbers of participants in most of the studies; that is, the studies were underpowered to measure these outcomes.The more recent studies did not address the days of disability or hospital admissions and therefore there was no additional contribution in this area since the 2013 review. </p> <p>The benefit in prevention of exacerbations was seen in the type of participants that were included in the studies. These participants had at least moderately severe COPD and were mostly frequent exacerbators. Evidence available from a single study suggests that individuals over 65 years benefited more than younger individuals. Hence, carefully identifying the patient group that would benefit most from the use of prophylactic antibiotics is of paramount importance. </p> <p>Although the selection of patients for prophylactic antibiotics is critical, the evidence base for making statements about patient selection is poor since not all studies have used the same selection criteria, only three studies used frequent exacerbations as an inclusion criterion, and only two studies screened for bronchiectasis with CT imaging. </p> <p>There are some potentially serious adverse effects with prophylactic antibiotics. Furthermore, development of antibiotic resistance remains of major concern. This is particularly so for those patients colonised with pseudomonas. More broadly, there are calls worldwide to reduce the total amount of antibiotics prescribed. Hence, even though the NNTs to prevent one person having an exacerbation were relatively small, this has to be balanced with the risks of harm either to that individual or indirectly to others via antibiotic resistance. So far, the evidence suggests that, with the use of prophylactic antibiotics, the sputum bacterial load reduces. However, included studies reported that, in participants with ongoing bacterial isolation, the isolates had increased resistance to the given antibiotic, sometimes demonstrating a MIC with a four‐fold rise at the end of the study period. One study that had follow‐up to 36 months had demonstrated that the rise in MIC may be transient and may return to baseline with cessation of antibiotics during the follow‐up period. Therefore, there remains uncertainty about the long‐term effects of the use of prophylactic antibiotics in the bacterial milieu in the community in terms of developing persistent resistance in this era of constant fear of developing 'super‐bugs'. </p> </section> <h3 class="title" id="CD009764-sec-0097">Implications for research</h3> <section id="CD009764-sec-0097"> <p>While there is a growing body of evidence to support the use of prophylactic antibiotics in people with COPD, better identification of the subsets of patients who would benefit most would be of great value in future research, so as to deliver targeted treatment to the right patient. Future trialists should ensure that the study population is well characterised, with a particular focus on the potential effect modifiers of prophylactic antibiotic therapy, including underlying bronchiectasis, exacerbation frequency, bacterial colonisation, and baseline FEV1. Future studies that incorporate potential biomarkers might be useful for patient selection. Importantly, participants in all arms of clinical studies of prophylactic antibiotics should receive the full package of evidence‐based interventions in COPD, as well as the study interventions. </p> <p>At present, there is a larger body of data available for the use of continuous antibiotic use and their benefit in comparison to intermittent or pulsed antibiotics. It would be worthwhile exploring the benefit of intermittent or pulsed antibiotics further as administering them less frequently may improve patient adherence, reduce adverse effects, and costs to both the patient and healthcare systems. Head‐to‐head comparisons of pulsed versus intermittent versus continuous antibiotics would be useful in this context. Furthermore, shorter placebo‐controlled studies through winter months, when exacerbations are more common, might be useful to determine if this is a pragmatic strategy. Regimens which focus on winter months only might also improve adherence and reduce costs, but this needs to be tested in a trial setting. </p> <p>Duration of hospital admissions and days of disability due to an exacerbation were not well addressed in the studies. Future studies should document these outcomes. Additionally, a cost‐effectiveness analysis would be useful. Most of the costs in severe COPD are related to hospitalisation. On the face of it, antibiotics may be cheaper than some inhalers, but there are hidden costs, such as the cost of screening for adverse effects and the direct and indirect costs of antimicrobial resistance. </p> <p>A challenge is how to balance the benefits of antibiotic therapy to the individual over the potential harms to the community through antibiotic resistance. The maximal duration of continuous prophylactic antibiotics was 12 months, and for pulsed antibiotics it was 36 months. Hence, there are no data on the impact of very long‐term antibiotic use on antibiotic resistance patterns in the community. The latter will require local surveillance and the correlation of resistance and prescribing patterns. This will help us understand if the higher MIC noted during the use of prophylactic antibiotics would return to baseline when antibiotics were discontinued and after how long, which would enable us to determine the need for 'breaks' from treatment, as well as determine the duration of these 'breaks'. If persistent resistance patterns are identified despite these measures, this would increase the need for caution in the use of prophylactic antibiotics. Furthermore, modelling of resistance detected in trials at a population level might be a useful approach. </p> <p>Yet to be determined is whether prophylactic antibiotics are able to alter the rate of deterioration of lung function in COPD and, if they do, whether this is due to antibiotic or anti‐inflammatory effects. This would be a helpful advance in the understanding of the pathophysiology of this common and debilitating disease. Long‐term follow‐up studies of participants who have been in prophylactic antibiotic studies may help to answer these questions. Identifing biomarkers of inflammation in these patients would also help if antibiotics with anti‐inflammatory effects work better in this group. </p> <p>Future studies directed at the use of inhaled antibiotics, which may result in fewer systemic effects and higher local concentrations, would be useful in reducing potential side effects of oral prophylactic antibiotic therapy. Such studies were excluded from this review. </p> <p>Studies looking into continuous or intermittent antibiotic therapy in clear relation to other interventions that are useful for frequent exacerbators would help determine the advantages and disadvantages of antibiotic therapy over the already established measures used to reduce exacerbations. The subgroup analysis conducted of one of the included studies (<a href="./references#CD009764-bbs2-0001" title="AlbertRK , ConnettJ , BaileyWC , CasaburiR , CooperJA , CrinerGJ , et al. Azithromycin for prevention of exacerbations of COPD. New England Journal of Medicine2011;365:689‐98. HanMK , TayobN , MurrayS , DransfieldMT , WashkoG , ScanlonPD , et al. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. American Journal of Respiratory and Critical Care Medicine2014;189(12):1503‐8. MartinezFJ , ConnettJ , VoelkerH , CrinerGJ , HanMK , MakeBJ , et al. Chronic azithromycin therapy decreases the risk of re‐hospitalization in patients with COPD. American Journal of Respiratory and Critical Care Medicine2013;187:A4383. O'ReillyPJ , JacksonPL , WellsJM , DransfieldMT , ScanlonPD , Blalock , JE . Sputum PGP is reduced by azithromycin treatment in patients with COPD and correlates with exacerbations. BMJ Open2013;3(12):e004140. WoodruffPG , ChatilaW , ConnettJE , CrinerGJ , CurtisJL , DransfieldMT , et al. Tumour necrosis factor receptor‐75 and risk of COPD exacerbation in the azithromycin trial. European Respiratory Journal2014;43:295–8. ">Albert 2011</a>) suggests that further exploration of the modifying effect of baseline treatments such as LAMA, LABA, and ICS is warranted. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD009764-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD009764-sec-0029"></div> <div class="table" id="CD009764-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Antibiotics versus placebo for COPD</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Antibiotics versus placebo for COPD (data from pulsed and continuous courses of antibiotics presented in the same table)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> Adults (aged 40 or over) with COPD presenting with 1 or more exacerbations in the previous year. The two larger studies (<a href="./references#CD009764-bbs2-0001" title="AlbertRK , ConnettJ , BaileyWC , CasaburiR , CooperJA , CrinerGJ , et al. Azithromycin for prevention of exacerbations of COPD. New England Journal of Medicine2011;365:689‐98. HanMK , TayobN , MurrayS , DransfieldMT , WashkoG , ScanlonPD , et al. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. American Journal of Respiratory and Critical Care Medicine2014;189(12):1503‐8. MartinezFJ , ConnettJ , VoelkerH , CrinerGJ , HanMK , MakeBJ , et al. Chronic azithromycin therapy decreases the risk of re‐hospitalization in patients with COPD. American Journal of Respiratory and Critical Care Medicine2013;187:A4383. O'ReillyPJ , JacksonPL , WellsJM , DransfieldMT , ScanlonPD , Blalock , JE . Sputum PGP is reduced by azithromycin treatment in patients with COPD and correlates with exacerbations. BMJ Open2013;3(12):e004140. WoodruffPG , ChatilaW , ConnettJE , CrinerGJ , CurtisJL , DransfieldMT , et al. Tumour necrosis factor receptor‐75 and risk of COPD exacerbation in the azithromycin trial. European Respiratory Journal2014;43:295–8. ">Albert 2011</a>; <a href="./references#CD009764-bbs2-0010" title="SethiS , JonesPW , TheronMS , MiravitllesM , RubinsteinE , WedzichaJA , et al. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized control trial. Respiratory Research2010;11:10. ">Sethi 2010</a>) recruited participants who required systemic steroids or antibiotics for exacerbations or participants on supplemental oxygen </p> <p><b>Settings:</b> Outpatients presenting to hospital clinics </p> <p><b>Intervention:</b> Administration of an oral prophylactic antibiotic continuously or intermittently </p> <p><b>Comparison:</b> Administration of a placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Antibiotics versus placebo</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of people with one or more exacerbations</b> </p> <p>WMD of follow‐up of 49 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>606 per 1,000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>468 per 1,000</b> </p> <p>(393 to 546)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.57</b> </p> <p>(0.42 to 0.78)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2716<br/> (8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Subgroup analysis of continuous versus intermittent versus pulsed antibiotics suggested that pulsed antibiotics were less effective at reducing exacerbations (P = 0.01 for subgroup difference; I<sup>2</sup> = 77.3%) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Rate of exacerbation per patient/year</b> </p> <p>WMD of follow‐up 54 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Rate ratio 0.67</b> </p> <p>(0.54 to 0.83)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1384</p> <p>(5 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate</b><sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Test for subgroup difference between continuous and intermittent antibiotics not significant (P = 0.38; I<sup>2</sup> = 0%) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HRQoL, SGRQ (total score)</b><br/> Scale from: 0 to 100. SGRQ comprises responses to 50 items, 0 being the best possible score and 100 the worst.<br/> WMD of follow‐up 48 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in SGRQ ranged across control groups from a <b>0.9 unit increase to a 5.7 unit decrease</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean HRQoL (SGRQ total score) in the intervention group was <b>1.94 lower</b> (3.13 lower to 0.75 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2237<br/> (7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>High</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The minimally clinically important response to treatment is described as 4 points</p> <p>Test for subgroup differences between continuous, intermittent and pulsed antibiotics not significant (P = 0.35; I² = 5.2%) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b><br/> WMD of follow‐up 70 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>78 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>68 per 1,000</b> </p> <p>(53 to 88)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.87</b> </p> <p>(0.66 to 1.15)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3309<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Test for subgroup differences between continuous, intermittent and pulsed antibiotics not significant (P = 0.60; I² = 0%) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b><br/> WMD of follow‐up 51 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>253 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>229 per 1,000</b> </p> <p>(200 to 262)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.88</b> </p> <p>(0.74 to 1.05)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2978<br/> (9 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See <a href="#CD009764-sec-0071">Effects of interventions</a> for specific adverse events related to the individual antibiotics. </p> <p>Test for subgroup differences between continuous, intermittent and pulsed antibiotics not significant (P = 0.60; I² = 0%) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Any adverse event</b> </p> <p>WMD of follow‐up 47 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>640 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>655 per 1,000</b><br/> (551 to 748) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 1.07</b><br/> (0.69 to 1.67) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>512<br/> (4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Test for subgroup differences between continuous, intermittent and pulsed antibiotics not significant (P = 0.28), I² = 21.9%) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FEV1 (mL)</b> </p> <p>WMD of follow‐up 26 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean FEV1 in the control group ranged from <b>1,000 to 2,320 mL</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean FEV1 in the intervention group was <b>20.21 mL higher</b> (26.19 lower to 66.61 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>658<br/> (6 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MCID for this outcomes was approximately 100 mLs. Mean difference and confidence interval lied within this MCID. </p> <p>Test for subgroup differences between continuous, intermittent and pulsed antibiotics not significant (P = 0.37; I² = 0.6%) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> was the mean control group risk across studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <sup><b>F</b> EV1: forced expiratory volume in 1 second; <b>HRQoL</b> : health‐related quality of life; <b>MCID</b>: minimum clinically important difference;</sup><b>OR:</b> Odds ratio; <sup><b>SGRQ</b>: St George's respiratory questionnaire</sup><b>WMD</b>: weight mean duration </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Clinical and statistical heterogeneity between studies (I<sup>2</sup> = 58%), partly explained by antibiotic regimen. Downgraded once for inconsistency </p> <p><sup>2</sup> Clinical and statistical heterogeneity between trials (I<sup>2</sup> = 52%). Downgraded once for inconsistency<br/> <sup>3</sup> Confidence intervals included the possibility that prophylactic antibiotics may increase or decrease mortality or adverse events. Downgraded once for imprecision </p> <p><sup>4</sup>Confidence interval included both a decrease or increase in FEV1 associated with the intervention. However, the mean difference and confidence interval lay within the MCID. No downgrade </p> <p><sup>5</sup>Studies contributing majority of weight in analysis reported outcome at approximately 3 months. Duration may be too short to detect a difference in lung function between groups. Downgraded once for indirectness </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD009764-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009764-sec-0030">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009764-sec-0127">Español</a> </li> </nav> </div> </div> <section class="background" lang="en"> <div class="section-header" id="CD009764-sec-0030"></div> <section id="CD009764-sec-0031"> <h3 class="title" id="CD009764-sec-0031">Description of the condition</h3> <p>The Global Initiative for Chronic Obstructive Lung Diseases (GOLD) defines chronic obstructive pulmonary disease (COPD) as "a common, preventable and treatable disease, that is characterised by persistent respiratory symptoms and airflow limitation that is due to airway and/or alveolar <i>(small air sacs within the lungs where gas exchange takes place)</i> abnormalities usually caused by significant exposure to noxious particles or gases" (<a href="./references#CD009764-bbs2-0073" title="Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2018 report). goldcopd.org/wp‐content/uploads/2017/11/GOLD‐2018‐v6.0‐FINAL‐revised‐20‐Nov_WMS.pdf (accessed prior to 20 July 2018). ">GOLD 2018</a>). It has become a leading cause of morbidity and mortality worldwide, with latest figures suggesting it was responsible for approximately 3.2 million deaths globally in 2015, making it the fourth leading cause of death that year (<a href="./references#CD009764-bbs2-0098" title="World Health Organization. Chronic obstructive pulmonary disease. www.who.int/respiratory/copd/en/ (accessed 18 November 2011). ">WHO</a>). Projections estimate it will become the third leading cause of death worldwide by 2020, due to an aging global population with prolonged exposure to COPD risk factors (<a href="./references#CD009764-bbs2-0073" title="Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2018 report). goldcopd.org/wp‐content/uploads/2017/11/GOLD‐2018‐v6.0‐FINAL‐revised‐20‐Nov_WMS.pdf (accessed prior to 20 July 2018). ">GOLD 2018</a>). COPD in high‐income countries is almost exclusively a disease of tobacco smoking, although a small proportion of nonsmokers have COPD secondary to passive smoking or genetic diseases, including alpha<sub>1</sub> antitrypsin deficiency (nonsmokers with COPD are usually excluded from clinical trials). In lower‐income countries the major risk factor is indoor pollution (burning wood for heating or biomass fuels for cooking) which contributes more than smoking to the disease burden (<a href="./references#CD009764-bbs2-0098" title="World Health Organization. Chronic obstructive pulmonary disease. www.who.int/respiratory/copd/en/ (accessed 18 November 2011). ">WHO</a>). Most reported deaths due to COPD are from high‐ and middle‐income countries; however, it is estimated that 90% of COPD‐related deaths occur in low‐middle‐income countries, where population‐based prevention strategies are either inaccessible or not implemented (<a href="./references#CD009764-bbs2-0098" title="World Health Organization. Chronic obstructive pulmonary disease. www.who.int/respiratory/copd/en/ (accessed 18 November 2011). ">WHO</a>). </p> <p>COPD is diagnosed by spirometry (a type of breathing assessment) and clinical symptoms of dyspnoea (difficulty breathing), chronic cough, or sputum production and a history of exposure to known risk factors, e.g. smoking. To make the diagnosis, a post‐bronchodilator cut‐off of a ratio of forced expiratory volume in one second to forced vital capacity (FEV1/FVC) less than 0.7 is used as an objective measure of airflow limitation. To individualise the management of COPD for each patient, GOLD has developed staging systems to classify severity. Patients are graded from stage one to stage four according to spirometric criteria, with stage one representing mild airflow obstruction (FEV1 ≥ 80% predicted), stage two moderate (FEV1 &lt; 80% but ≥ 50% predicted), stage three severe (FEV1 &lt; 50% but ≥ 30% predicted) and stage four very severe (FEV1 &lt; 30%) (<a href="./references#CD009764-bbs2-0073" title="Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2018 report). goldcopd.org/wp‐content/uploads/2017/11/GOLD‐2018‐v6.0‐FINAL‐revised‐20‐Nov_WMS.pdf (accessed prior to 20 July 2018). ">GOLD 2018</a>). However, the most recent report de‐emphasises FEV1 as a useful prognostic tool at an individual level and instead focuses on functional limitation and symptoms to guide therapy for stable COPD (Group A: 0 to 1 exacerbations not leading to hospital admission and COPD assessment test (CAT) score &lt; 10 or Modified Medical Research Council Dyspnea Scale (MMRC) 0 to 1; group B: 0 to 1 exacerbations not leading to hospital admission and CAT ≥ 10 or MMRC ≥ 2; group C: ≥ 2 exacerbations or ≥ 1 exacerbation leading to hospital admission and CAT &lt; 10 or MMRC 0 to 1; group D: ≥ 2 exacerbations or ≥ 1 exacerbation leading to hospital admission and CAT ≥ 10 or MMRC ≥ 2)). </p> <p>Many people with COPD experience acute exacerbations, which are defined as "an acute worsening of respiratory symptoms that result in additional therapy" (<a href="./references#CD009764-bbs2-0073" title="Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2018 report). goldcopd.org/wp‐content/uploads/2017/11/GOLD‐2018‐v6.0‐FINAL‐revised‐20‐Nov_WMS.pdf (accessed prior to 20 July 2018). ">GOLD 2018</a>). Exacerbations of COPD range in severity between individuals, have a substantial impact on quality of life and contribute to overall disease progression (<a href="./references#CD009764-bbs2-0073" title="Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2018 report). goldcopd.org/wp‐content/uploads/2017/11/GOLD‐2018‐v6.0‐FINAL‐revised‐20‐Nov_WMS.pdf (accessed prior to 20 July 2018). ">GOLD 2018</a>). Therefore, preventing and treating exacerbations is an important part of COPD management in order to improve quality of life and prognostic outcomes. Exacerbations of COPD are a common cause of days off work and hospital admissions (<a href="./references#CD009764-bbs2-0093" title="Thoracic Society of Australia and New Zealand (New Zealand Branch). Standards for adult respiratory and sleep services in New Zealand. www.health.govt.nz/system/.../standardsforadultrespiratoryandsleepservices.doc (accessed prior to 20 July 2018). ">TSANZ 2004</a>), and so have a significant socioeconomic impact globally. Furthermore the long‐term prognosis following hospitalisation for an exacerbation of COPD is poor, with a five‐year mortality rate of approximately 50% (<a href="./references#CD009764-bbs2-0073" title="Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2018 report). goldcopd.org/wp‐content/uploads/2017/11/GOLD‐2018‐v6.0‐FINAL‐revised‐20‐Nov_WMS.pdf (accessed prior to 20 July 2018). ">GOLD 2018</a>). </p> <p>Respiratory infections are known triggers for COPD exacerbations, with current evidence suggesting that viral infections account for the majority of exacerbations (<a href="./references#CD009764-bbs2-0073" title="Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2018 report). goldcopd.org/wp‐content/uploads/2017/11/GOLD‐2018‐v6.0‐FINAL‐revised‐20‐Nov_WMS.pdf (accessed prior to 20 July 2018). ">GOLD 2018</a>; <a href="./references#CD009764-bbs2-0100" title="WoodheadM , BlasiF , EwigS , GarauJ , HuchonG , LevenM , et al. Guidelines for the management of adult lower respiratory tract infections. Clinical Microbiology and Infection2011;17(6):E1‐E59. [https://doi.org/10.1111/j.1469‐0691.2011.03672.x] ">Woodhead 2011</a>). However, bacterial respiratory infections and changes in the local environment, such as an increase in air pollution, are also recognised as exacerbation triggers (<a href="./references#CD009764-bbs2-0086" title="PapiA , LuppiF , FrancoF , FabbriLM . Pathophysiology of exacerbations of chronic obstructive pulmonary disease. Proceedings of the American Thoracic Society2006;3:3. [http://www.atsjournals.org/doi/full/10.1513/pats.200512‐125SF] ">Papi 2006</a>). The role of bacteria in exacerbations is an area that has been greatly studied, yet remains controversial. It has been demonstrated that respiratory bacterial loads are greater in patients with stable COPD compared to healthy individuals, and that the bacterial loads increase with disease severity (<a href="./references#CD009764-bbs2-0069" title="BeasleyV , JoshiP , SinganayagamA , MolyneauxP , JohnstonSL , MalliaP . Lung microbiology and exacerbations in COPD. International Journal of Chronic Obstructive Pulmonary Disease2012;7:555‐69. [DOI: 10.2147/COPD.S28286; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3437812/] ">Beasley 2012</a>). However, the high bacterial isolation rates in stable COPD makes it difficult to identify a causative role of bacteria in exacerbations. Despite this, studies do suggest an increase in bacterial infection rates amongst participants with acute COPD exacerbations (<a href="./references#CD009764-bbs2-0069" title="BeasleyV , JoshiP , SinganayagamA , MolyneauxP , JohnstonSL , MalliaP . Lung microbiology and exacerbations in COPD. International Journal of Chronic Obstructive Pulmonary Disease2012;7:555‐69. [DOI: 10.2147/COPD.S28286; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3437812/] ">Beasley 2012</a>). <a href="./references#CD009764-bbs2-0099" title="WilkinsonT , HurstJ , PereraW , WilksM , DonaldsonG , WedzichaJ . Effects of interactions between lower airway bacterial and rhinoviral infections in exacerbations of COPD. Chest2006;129(2):317‐24. [http://www.sciencedirect.com/science/article/pii/S0012369215387523?via%3Dihub] ">Wilkinson 2006</a> found that the prevalence of potentially pathogenic microorganisms rose from 48.2% at baseline in stable COPD participants to 69.6% in the same group of participants at the time of an exacerbation. The most commonly isolated bacterial organisms in COPD exacerbations include "<i>Haemophilus influenzae</i> (11% of all exacerbating participants), <i>Streptococcus pneumoniae</i> (10%), <i>Moraxella catarrhalis</i> (10%) and <i>Pseudomonas aeruginosa</i> (4%), with Gram‐negative bacteria occurring more rarely" (<a href="./references#CD009764-bbs2-0089" title="SapeyE , StockleyRA . COPD exacerbations 2: aetiology. Thorax2006;61(3):250‐8. ">Sapey 2006</a>). </p> <p>There are numerous evidence‐based approaches that aim to reduce the number of COPD exacerbations. An essential first step is the avoidance of cigarette smoke and air pollution, wherever possible. Furthermore, vaccination against influenza is a universally accepted measure to prevent COPD exacerbations. Vaccination for pneumococcal disease may also reduce pneumonia and COPD exacerbations (<a href="./references#CD009764-bbs2-0080" title="LeeTA , PharmD , WeaverFM . Impact of pneumococcal vaccination on pneumonia rates in patients with COPD and asthma. Journal of General Internal Medicine2007;22(1):62‐7. ">Lee 2007</a>). Inhaled medications shown to reduce exacerbation frequency include tiotropium, a long‐acting muscarinic antagonist (LAMA, <a href="./references#CD009764-bbs2-0094" title="TashkinDP , CelliB , SennS , BurkhartD , KestenS , MenjogeS , et al. 4‐year trial of tiotropium in chronic obstructive pulmonary disease. New England Journal of Medicine2008;359:1543‐54. ">UPLIFT 2008</a>), long‐acting beta agonists (LABA, <a href="./references#CD009764-bbs2-0096" title="WangJ , NieB , XiongW , XuY . Effect of long‐acting beta‐agonists on the frequency of COPD exacerbations: a meta‐analysis. Journal of Clinical Pharmacy and Therapeutics2012;37:204‐11. ">Wang 2012</a>) and corticosteroids (ICS, <a href="./references#CD009764-bbs2-0092" title="KardosP , WenckerM , GlaabT , VogelmeierC . Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2007;175(144):149. ">TORCH 2007</a>). Oral medications shown to reduce exacerbations include phosphodiesterase 4 (PDE<sub>4</sub>) inhibitors (<a href="./references#CD009764-bbs2-0072" title="ChongJ , LeungB , PooleP . Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2017, Issue 9. [DOI: 10.1002/14651858.CD002309.pub3] ">Chong 2017</a>) and mucolytic agents (drugs that help break down sputum making it easier to cough up) (<a href="./references#CD009764-bbs2-0087" title="PooleP , BlackPN , CatesCJ . Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2012, Issue 8. [DOI: 10.1002/14651858.CD001287.pub4] ">Poole 2012</a>). </p> </section> <section id="CD009764-sec-0032"> <h3 class="title" id="CD009764-sec-0032">Description of the intervention</h3> <p>One approach to reduce exacerbation frequency has been to use prophylactic antibiotics. The word prophylactic comes from the Greek for 'an advance guard', an apt term for a measure taken to fend off a disease or another unwanted consequence. A prophylactic intervention is a medication or treatment designed and used to prevent a disease from occurring. Thirty years ago, the use of prophylactic antibiotics was common for chronic bronchitis in both the United Kingdom and elsewhere, but concerns over effectiveness and antibiotic resistance led to a decline in this approach.  </p> </section> <section id="CD009764-sec-0033"> <h3 class="title" id="CD009764-sec-0033">How the intervention might work</h3> <p>COPD is characterised by persistent airways inflammation due to chronic bacterial colonisation of the damaged respiratory epithelium (the layer of cells lining the airways) leading to the continuing release of bacterial and host‐mediated pro‐inflammatory factors and additional epithelial damage (<a href="./references#CD009764-bbs2-0083" title="MatkovicZ , MiravitllesM . Chronic bronchial infection in COPD. Is there an infective phenotype?. Respiratory Medicine2013;107:10‐22. ">Matkovic 2013</a>; <a href="./references#CD009764-bbs2-0090" title="SethiS , MurphyTF . Infection in the pathogenesis and course of chronic obstructive pulmonary disease. New England Journal of Medicine2008;359:2355‐65. ">Sethi 2008</a>). In an exacerbation, there is superimposed acute inflammation (<a href="./references#CD009764-bbs2-0077" title="HurstJR , PereraWR , WilkinsonTMA , DonaldsonGC , WedzichaJA . Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2006;173:71‐8. ">Hurst 2006</a>). By reducing bacterial colonisation, chronic antibiotic therapy could help in reducing progression of the disease by breaking the above vicious cycle. In addition, some antibiotics have intrinsic anti‐inflammatory properties (<a href="./references#CD009764-bbs2-0081" title="MartinezFJ , CurtisJL , AlberyR . Role of macrolide therapy in chronic obstructive pulmonary disease. International Journal of Chronic Obstructive Pulmonary Disease2008;3:331‐50. [PUBMED: 18990961] ">Martinez 2008</a>). </p> </section> <section id="CD009764-sec-0034"> <h3 class="title" id="CD009764-sec-0034">Why it is important to do this review</h3> <p>This review incorporates and builds upon earlier Cochrane reviews.The most recent review concluded that the "use of continuous prophylactic macrolide antibiotics for a period of up to 12 months is likely to reduce the number of patients with exacerbations and exacerbation frequency, increase the median time to first exacerbation and possibly health‐related quality of life" (<a href="./references#CD009764-bbs2-0101" title="HerathS , PooleP . Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD). Cochrane Database of Systematic Reviews2013, Issue 11. [DOI: 10.1002/14651858.CD009764.pub2] ">Herath 2013</a>). However, adverse effects and the potential for the development of antibiotic resistance remain a concern. Since the 2013 review, a number of new studies into prophylactic antibiotic use in COPD have been published. Given the fine balance between the need to reduce exacerbation frequency in COPD, with the threat of widespread antibiotic resistance, it is important that the most up‐to‐date research is incorporated into this review, so that physicians and patients can make well informed decisions before embarking on long‐term treatment. This updated review also expands on the analysis of specific prophylactic antibiotic regimens including continuous, intermittent, and pulsed regimens to determine their relative efficacy and safety. Furthermore, many of the new studies have included more comprehensive assessments of quality of life indicators, which were not previously explored in great detail. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD009764-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009764-sec-0035">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009764-sec-0132">Español</a> </li> </nav> </div> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD009764-sec-0035"></div> <p>To determine whether or not regular (continuous, intermittent or pulsed) treatment of COPD patients with prophylactic antibiotics reduces exacerbations or affects quality of life. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD009764-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009764-sec-0036">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009764-sec-0133">Español</a> </li> </nav> </div> </div> <section class="methods" lang="en"> <div class="section-header" id="CD009764-sec-0036"></div> <section id="CD009764-sec-0037"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD009764-sec-0038"> <h4 class="title">Types of studies</h4> <p>Randomised controlled trials of antibiotic versus placebo. Trials comparing different antibiotics head‐to‐head will form the basis of another review. We planned to include cluster‐randomised trials and crossover trials, if found. </p> </section> <section id="CD009764-sec-0039"> <h4 class="title">Types of participants</h4> <p>We included studies of adults (older than 18 years of age) with a diagnosis of COPD, as defined by the American Thoracic Society, European Respiratory Society or GOLD, with airflow obstruction evident by spirometry (post‐bronchodilator FEV1 of less than 80% of the predicted value and an FEV1/FVC of 0.7 or less). The review included studies only if they confirmed diagnosis with lung function testing (spirometry). </p> <p>We excluded studies of participants with bronchiectasis, asthma, or genetic diseases, such as cystic fibrosis or primary ciliary dyskinesia (which may also lead to chronic airflow limitation as part of a secondary process). Where we encountered trials that included participants with these diseases in addition to participants with COPD, we only extracted the data for the participants with COPD, where the data were presented separately. However, although the studies excluded participants with clinical presentation of bronchiectasis, computed tomography (CT) screening to confirm radiological evidence of bronchiectasis was performed only in two studies (<a href="./references#CD009764-bbs2-0001" title="AlbertRK , ConnettJ , BaileyWC , CasaburiR , CooperJA , CrinerGJ , et al. Azithromycin for prevention of exacerbations of COPD. New England Journal of Medicine2011;365:689‐98. HanMK , TayobN , MurrayS , DransfieldMT , WashkoG , ScanlonPD , et al. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. American Journal of Respiratory and Critical Care Medicine2014;189(12):1503‐8. MartinezFJ , ConnettJ , VoelkerH , CrinerGJ , HanMK , MakeBJ , et al. Chronic azithromycin therapy decreases the risk of re‐hospitalization in patients with COPD. American Journal of Respiratory and Critical Care Medicine2013;187:A4383. O'ReillyPJ , JacksonPL , WellsJM , DransfieldMT , ScanlonPD , Blalock , JE . Sputum PGP is reduced by azithromycin treatment in patients with COPD and correlates with exacerbations. BMJ Open2013;3(12):e004140. WoodruffPG , ChatilaW , ConnettJE , CrinerGJ , CurtisJL , DransfieldMT , et al. Tumour necrosis factor receptor‐75 and risk of COPD exacerbation in the azithromycin trial. European Respiratory Journal2014;43:295–8. ">Albert 2011</a> and <a href="./references#CD009764-bbs2-0015" title="DjaminRS , UzunS , ErmensAAM , KerstensR , HoogstedenHC , AertsJGJV , et al. Which predictors in COPD patients with the frequent exacerbator phenotype predict the treatment response to maintenance therapy with azithromycin?. European Respiratory Journal2016;48:PA3713. UzunS , DjaminRS , AertsJGJV , Van DerEerdenMM . Patients with COPD Gold C &amp; D: the effect of long‐term treatment with azithromycin on exacerbation risk assessed by the Gold Framework. American Journal of Respiratory and Critical Care Medicine2014;189:A5967. UzunS , DjaminRS , KluytmansJA , MulderPG , Van't VeerNE , ErmensAA , et al. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double‐blind,placebo‐controlled trial. Lancet Respiratory Medicine2014;2(5):361‐8. UzunS , DjaminRS , MulderPGH , KluytmansJAJW , PelleAJ , Van't VeerNE , et al. Effect of azithromycin maintenance treatment in patients with frequent exacerbations of COPD (columbus): a randomized, double‐blind, placebo‐controlled trial. American Journal of Respiratory and Critical Care Medicine2014;189:A2884. ">Uzun 2014</a>) prior to study entry. </p> </section> <section id="CD009764-sec-0040"> <h4 class="title">Types of interventions</h4> <p>We included studies of oral antibiotics, including penicillin (amoxycillin, amoxicillin, clavulanic acid), tetracycline (doxycycline, tetracycline), quinolones (ciprofloxacin, moxifloxacin), macrolides (clarithromycin, erythromycin, roxithromycin, azithromycin) and sulphonamides (co‐trimoxazole), administered in appropriate doses for a period of at least three months. </p> </section> <section id="CD009764-sec-0041"> <h4 class="title">Types of outcome measures</h4> <section id="CD009764-sec-0042"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD009764-list-0001"> <li> <p>Number of exacerbations, using an accepted definition. This included total numbers of participants with one or more exacerbation as well as the frequency of exacerbations in the study period and time to first exacerbation. </p> </li> <li> <p>Health‐related quality of life, using an accepted measure such as the St George's Respiratory Questionnaire (SGRQ) (<a href="./references#CD009764-bbs2-0078" title="JonesP . St George's Respiratory Questionnaire Manual Version 2.3. www.healthstatus.sgul.ac.uk/SGRQ_download/SGRQ%20Manual%20June%202009.pdf (accessed prior to 20 July 2018). ">Jones 2009</a>) or Chronic Respiratory Diseases Questionnaire (CRQ) (<a href="./references#CD009764-bbs2-0074" title="GuyattG , BermanL , TownsendM , PugsleyS , ChambersL . A measure of quality of life for clinical trials in chronic lung disease. Thorax1987;42:773‐8. ">Guyatt 1987</a>). </p> </li> </ol> </p> </section> <section id="CD009764-sec-0043"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD009764-list-0002"> <li> <p>Duration and severity (using an accepted definition) of exacerbations;</p> </li> <li> <p>Days of disability (defined as days where the participant was unable to undertake normal activities); </p> </li> <li> <p>Frequency and duration of hospital admissions;</p> </li> <li> <p>Reduction in lung function from baseline, as measured by FEV1 and FVC;</p> </li> <li> <p>Drug resistance as measured by microbial sensitivity;</p> </li> <li> <p>Death due to all‐cause mortality, as well as due to respiratory causes;</p> </li> <li> <p>Adverse effects.</p> </li> </ol> </p> </section> </section> </section> <section id="CD009764-sec-0044"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD009764-sec-0045"> <h4 class="title">Electronic searches</h4> <p>We searched the Cochrane Airways Trials Register up to 27 July 2018 with no restrictions on language or type of publication. The Cochrane Airways Trials Register is maintained by the information specialist for Cochrane Airways and contains studies identified from the following sources: </p> <p> <ol id="CD009764-list-0003"> <li> <p>Monthly searches of the Cochrane Central Register of Controlled Trials (CENTRAL), through the Cochrane Register of Studies (CRS); </p> </li> <li> <p>Weekly searches of MEDLINE Ovid SP;</p> </li> <li> <p>Weekly searches of Embase Ovid SP;</p> </li> <li> <p>Monthly searches of PsycINFO Ovid SP;</p> </li> <li> <p>Monthly searches of CINAHL EBSCO (Cumulative Index to Nursing and Allied Health Literature);</p> </li> <li> <p>Monthly searches of AMED EBSCO (Allied and Complementary Medicine);</p> </li> <li> <p>Handsearches of the proceedings of major respiratory conferences.</p> </li> </ol> </p> <p>Studies contained in the Trials Register are identified through search strategies based on the scope of Cochrane Airways. Details of these strategies, as well as a list of handsearched conference proceedings, are in <a href="./appendices#CD009764-sec-0101">Appendix 1</a>. See <a href="./appendices#CD009764-sec-0107">Appendix 2</a> for search terms used to identify studies for this review. </p> <p>We conducted a search of ClinicalTrials.gov with the search strategy in <a href="./appendices#CD009764-sec-0108">Appendix 3</a> up to 27 July 2018. For the 2018 update, we managed references using Rayyan (<a href="./references#CD009764-bbs2-0085" title="OuzzaniM , HammadyH , FedorowiczZ , ElmagarmidA . Rayyan — a web and mobile app for systematic reviews. Systematic Reviews2016;5(1):210. [DOI: 10.1186/s13643‐016‐0384‐4] ">Ouzzani 2016</a>). </p> </section> <section id="CD009764-sec-0046"> <h4 class="title">Searching other resources</h4> <p>We checked the reference lists of all eligible primary studies and review articles for additional references. For the original review, we contacted authors of <a href="./references#CD009764-bbs2-0006" title="MygindLH , PedersenC , VestboJ , ChristensenJJ , Frimodt‐MollerN , KristiansenIS , et al. A randomised, placebo‐controlled 3 years study of prophylactic azithromycin in 575 patients with chronic obstructive pulmonary disease. European Respiratory Society 20th Annual Congress; 2010 Sep 18‐22; Barcelona. 2010. ">Mygind 2010</a> and asked them to supply the data from their unpublished study. For the 2018 update, we contacted the authors of all newly included studies and we are grateful for the responses received from the authors of <a href="./references#CD009764-bbs2-0003" title="BerkhofFF , Doornewaard‐ten HertogNE , UilSM , KerstjensHAM , Van denBergJWK . Azithromycin and cough‐specific health status in patients with chronic obstructive pulmonary disease and chronic cough: a randomised controlled trial. Respiratory Research2013;14(1):125. BerkhofFF , TenHertogNE , UilSM , KerstjensHAM , Van DenBergJK , CACTUS study group. Randomized controlled trial of prophylactic azithromycin on cough‐specific health status in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2013;187:A2449. ">Berkhof 2013</a>; <a href="./references#CD009764-bbs2-0011" title="ShafuddinE , MillsGD , HolmesMD , PoolePJ , MullinsPR , BlackPN . A double‐blind, randomised, placebo‐controlled study of roxithromycin and doxycycline combination, roxithromycin alone, or matching placebo for 12 weeks in adults with frequent exacerbations of chronic obstructive pulmonary disease. Journal of Negative Results in Biomedicine2015;14:15. [DOI: 10.1186/s12952‐015‐0034‐8] ">Shafuddin 2015</a>; <a href="./references#CD009764-bbs2-0012" title="SimpsonJL , PowellH , BainesKJ , MilneD , CoxsonHO , HansbroPM , et al. The effect of azithromycin in adults with stable neutrophilic COPD: a double blind randomised, placebo controlled trial. PLOS One2014;9(8):e105609. ">Simpson 2014</a> and <a href="./references#CD009764-bbs2-0015" title="DjaminRS , UzunS , ErmensAAM , KerstensR , HoogstedenHC , AertsJGJV , et al. Which predictors in COPD patients with the frequent exacerbator phenotype predict the treatment response to maintenance therapy with azithromycin?. European Respiratory Journal2016;48:PA3713. UzunS , DjaminRS , AertsJGJV , Van DerEerdenMM . Patients with COPD Gold C &amp; D: the effect of long‐term treatment with azithromycin on exacerbation risk assessed by the Gold Framework. American Journal of Respiratory and Critical Care Medicine2014;189:A5967. UzunS , DjaminRS , KluytmansJA , MulderPG , Van't VeerNE , ErmensAA , et al. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double‐blind,placebo‐controlled trial. Lancet Respiratory Medicine2014;2(5):361‐8. UzunS , DjaminRS , MulderPGH , KluytmansJAJW , PelleAJ , Van't VeerNE , et al. Effect of azithromycin maintenance treatment in patients with frequent exacerbations of COPD (columbus): a randomized, double‐blind, placebo‐controlled trial. American Journal of Respiratory and Critical Care Medicine2014;189:A2884. ">Uzun 2014</a>. We have checked the references of the included and excluded studies from the previous review on chronic bronchitis for possible studies (<a href="./references#CD009764-bbs2-0091" title="StaykovaT , BlackPN , ChackoEE , PooleP . Prophylactic antibiotic therapy for chronic bronchitis. Cochrane Database of Systematic Reviews2003, Issue 1. [DOI: 10.1002/14651858.CD004105] ">Staykova 2003</a>). </p> </section> </section> <section id="CD009764-sec-0047"> <h3 class="title" id="CD009764-sec-0047">Data collection and analysis</h3> <section id="CD009764-sec-0048"> <h4 class="title">Selection of studies</h4> <p>For this update, two review authors (SH and RN) independently screened the abstracts of studies identified by the search as to whether or not they met our inclusion criteria. We obtained the full texts of publications for those that were considered definite or possible for inclusion. These were then reviewed independently by two review authors (SH and RN) to assess eligibility. We resolved any disagreement by discussion and consensus followed by an independent opinion from the third investigator (PP). </p> </section> <section id="CD009764-sec-0049"> <h4 class="title">Data extraction and management</h4> <p>Both review authors independently extracted the data from the eligible studies.</p> <p>We extracted the following data.</p> <p> <ul id="CD009764-list-0004"> <li> <p>Methods: study design, duration of follow‐up.</p> </li> <li> <p>Participants: age, gender, smoking status, study setting, inclusion and exclusion criteria. </p> </li> <li> <p>Intervention: drug name, dose, duration of treatment, control or standard therapy.</p> </li> <li> <p>Information on outcome measures.</p> </li> </ul> </p> <p>Where appropriate, we have combined the data from studies using <a href="./references#CD009764-bbs2-0088" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3.5. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2008. ">RevMan 5 2008</a>. </p> </section> <section id="CD009764-sec-0050"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two investigators independently assessed risk of bias for each study using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009764-bbs2-0076" title="HigginsJPT , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). Any disagreement was resolved by discussion. We assessed the risk of bias according to the following domains. </p> <p> <ol id="CD009764-list-0005"> <li> <p>Random sequence generation.</p> </li> <li> <p>Allocation concealment.</p> </li> <li> <p>Blinding of participants and personnel.</p> </li> <li> <p>Blinding of outcome assessment.</p> </li> <li> <p>Incomplete outcome data.</p> </li> <li> <p>Selective outcome reporting.</p> </li> <li> <p>Other bias.</p> </li> </ol> </p> <p>We graded each potential source of bias as high, low, or unclear risk.</p> </section> <section id="CD009764-sec-0051"> <h4 class="title">Measures of treatment effect</h4> <p>Results for continuous variables were expressed using a random‐effects model mean difference (MD) with 95% confidence interval (CI). Results for pooled outcomes with dichotomous variables were expressed using a random‐effects model odds ratio (OR) with 95% CI. We regarded a P value of less than 0.05 as statistically significant. We combined rate data (e.g. number of exacerbations per participant per year) using generic inverse variance (GIV) and expressed the outcome as a rate ratio. </p> <p>For ease of communication and clarity, the number needed to treat for an additional beneficial outcome (NNTB) was derived from the OR and mean control group event rate using <a href="./references#CD009764-bbs2-0095" title="Visual Rx. www.nntonline.net/visualrx/(accessed October 2013). ">Visual Rx</a>. </p> </section> <section id="CD009764-sec-0052"> <h4 class="title">Unit of analysis issues</h4> <p>We did not find any crossover trials or cluster‐randomised trials that met our inclusion criteria. However, if we had encountered them, we planned to evaluate the cluster‐randomised trials for trial quality and, if the design and analysis were of poor quality, exclude them. We planned to analyse any eligible cluster‐randomised trials with the help of a statistician. </p> </section> <section id="CD009764-sec-0053"> <h4 class="title">Dealing with missing data</h4> <p>We contacted the investigators from <a href="./references#CD009764-bbs2-0006" title="MygindLH , PedersenC , VestboJ , ChristensenJJ , Frimodt‐MollerN , KristiansenIS , et al. A randomised, placebo‐controlled 3 years study of prophylactic azithromycin in 575 patients with chronic obstructive pulmonary disease. European Respiratory Society 20th Annual Congress; 2010 Sep 18‐22; Barcelona. 2010. ">Mygind 2010</a> in writing in order to verify key study characteristics and to obtain missing numerical outcome data. We were unable to get more details. </p> </section> <section id="CD009764-sec-0054"> <h4 class="title">Assessment of heterogeneity</h4> <p>From the forest plot, we tested for heterogeneity where the CIs did not overlap with each other. We used the I<sup>2</sup> statistic to measure heterogeneity among the studies in each analysis. Where we identified heterogeneity (I<sup>2</sup> ≥ 40%), we explored this using a prespecified subgroup analysis. We used the following overlapping cut‐off to define heterogeneity (<a href="./references#CD009764-bbs2-0076" title="HigginsJPT , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). </p> <p> <ul id="CD009764-list-0006"> <li> <p>0% to 40%: might not be important;</p> </li> <li> <p>30% to 60%: may represent moderate heterogeneity;</p> </li> <li> <p>50% to 90%: may represent substantial heterogeneity;</p> </li> <li> <p>75% to 100%: considerable heterogeneity</p> </li> </ul> </p> </section> <section id="CD009764-sec-0055"> <h4 class="title">Assessment of reporting biases</h4> <p>Where we suspected reporting bias, we attempted to contact the study authors to ask them to provide the missing outcome data. Where this was not possible, and the missing data were thought to introduce serious bias, the impact of including such studies in the overall assessment of results was explored by a sensitivity analysis<b>. </b> </p> </section> <section id="CD009764-sec-0056"> <h4 class="title">Data synthesis</h4> <p>For the 2018 update, we subgrouped all meta‐analyses by regimen, grouping interventions into continuous (i.e. daily) antibiotic use, intermittent (e.g. two or three times per week) antibiotic use and pulsed (e.g. daily for five days every four weeks) antibiotic use. We performed meta‐analysis only where the study populations were sufficiently similar for pooling to make sense. </p> <p>We created a 'Summary of findings' table using the methods and recommendations described in Section 8.5 and Chapter 12 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009764-bbs2-0076" title="HigginsJPT , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>) and GRADEpro software for the following outcomes. </p> <p> <ol id="CD009764-list-0007"> <li> <p>Number of exacerbations, using an accepted definition.</p> </li> <li> <p>Days of disability (defined as days where the participant was unable to undertake normal activities). </p> </li> <li> <p>Frequency and duration of hospital admissions.</p> </li> <li> <p>Health‐related quality of life, using an accepted measure such as SGRQ or CRQ.</p> </li> <li> <p>Death.</p> </li> <li> <p>Drug resistance.</p> </li> <li> <p>Other adverse effects of treatment.</p> </li> </ol> </p> </section> <section id="CD009764-sec-0057"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to carry out the following subgroup analyses for the primary outcome (number of exacerbations). </p> <p> <ol id="CD009764-list-0008"> <li> <p>Severity of COPD according to FEV1 and the GOLD criteria.</p> </li> <li> <p>Type of antibiotic.</p> </li> <li> <p>Duration of antibiotic use ( ≥ 3 months to &lt; 6 months, ≥ 6 months to &lt; 12 months and ≥ 12 months). </p> </li> <li> <p>Year of conduct of study (2005 to 2009, 2010 to 2014 and 2014 to 2019)</p> </li> <li> <p>Whether the antibiotic was used primarily as an antimicrobial or as an anti‐inflammatory agent. </p> </li> <li> <p>Treatment regimen including dose, frequency, route of administration. </p> </li> <li> <p>History of exacerbations (studies in which participants were only included in they had experienced at least one exacerbation in the preceding year versus those in which exacerbation history was not an inclusion criteria). </p> </li> </ol> </p> </section> <section id="CD009764-sec-0058"> <h4 class="title">Sensitivity analysis</h4> <p>We conducted a sensitivity analysis on our primary outcome (people with one or more exacerbations) by removing studies judged to be at high or unclear risk of bias for the domains of sequence generation, allocation concealment, or blinding. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD009764-sec-0059" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD009764-sec-0059"></div> <section id="CD009764-sec-0060"> <h3 class="title">Description of studies</h3> <section id="CD009764-sec-0061"> <h4 class="title">Results of the search</h4> <p>We included seven studies in the 2013 version of this review. For the 2018 update, we identified 202 records through database searching and a further 76 additional records through other sources. We screened 265 records after removing duplicates. We excluded 226 records on the basis of the title and abstracts, leaving 39 full‐text articles which we assessed for eligibility. Of these, we excluded 10 studies (12 full‐text articles) and identified one as awaiting classification (<a href="./references#CD009764-sec-0125" title="">Characteristics of studies awaiting classification</a>). We identified four new ongoing studies, four new references to an included study (<a href="./references#CD009764-bbs2-0001" title="AlbertRK , ConnettJ , BaileyWC , CasaburiR , CooperJA , CrinerGJ , et al. Azithromycin for prevention of exacerbations of COPD. New England Journal of Medicine2011;365:689‐98. HanMK , TayobN , MurrayS , DransfieldMT , WashkoG , ScanlonPD , et al. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. American Journal of Respiratory and Critical Care Medicine2014;189(12):1503‐8. MartinezFJ , ConnettJ , VoelkerH , CrinerGJ , HanMK , MakeBJ , et al. Chronic azithromycin therapy decreases the risk of re‐hospitalization in patients with COPD. American Journal of Respiratory and Critical Care Medicine2013;187:A4383. O'ReillyPJ , JacksonPL , WellsJM , DransfieldMT , ScanlonPD , Blalock , JE . Sputum PGP is reduced by azithromycin treatment in patients with COPD and correlates with exacerbations. BMJ Open2013;3(12):e004140. WoodruffPG , ChatilaW , ConnettJE , CrinerGJ , CurtisJL , DransfieldMT , et al. Tumour necrosis factor receptor‐75 and risk of COPD exacerbation in the azithromycin trial. European Respiratory Journal2014;43:295–8. ">Albert 2011</a>) and one ongoing study was moved to the included studies section (<a href="./references#CD009764-bbs2-0015" title="DjaminRS , UzunS , ErmensAAM , KerstensR , HoogstedenHC , AertsJGJV , et al. Which predictors in COPD patients with the frequent exacerbator phenotype predict the treatment response to maintenance therapy with azithromycin?. European Respiratory Journal2016;48:PA3713. UzunS , DjaminRS , AertsJGJV , Van DerEerdenMM . Patients with COPD Gold C &amp; D: the effect of long‐term treatment with azithromycin on exacerbation risk assessed by the Gold Framework. American Journal of Respiratory and Critical Care Medicine2014;189:A5967. UzunS , DjaminRS , KluytmansJA , MulderPG , Van't VeerNE , ErmensAA , et al. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double‐blind,placebo‐controlled trial. Lancet Respiratory Medicine2014;2(5):361‐8. UzunS , DjaminRS , MulderPGH , KluytmansJAJW , PelleAJ , Van't VeerNE , et al. Effect of azithromycin maintenance treatment in patients with frequent exacerbations of COPD (columbus): a randomized, double‐blind, placebo‐controlled trial. American Journal of Respiratory and Critical Care Medicine2014;189:A2884. ">Uzun 2014</a>). We moved one study from the excluded studies section to be a subreference of an included study (<a href="./references#CD009764-bbs2-0002" title="BanerjeeD , HoneybourneD , KhairOA . The effect of oral Clarithromycin on bronchial airway inflammation in moderate‐to‐severe stable COPD: a randomised controlled trial. Treatments in Respiratory Medicine2004;3:59‐65. BanerjeeD , KhairO , HoneybourneD . The effect of oral clarithromycin on health status and sputum bacteriology in stable COPD. Respiratory Medicine2005;99:208‐15. ">Banerjee 2005</a>). </p> <p>We identified nine new studies that were eligible for inclusion in this systematic review, taking the total number of eligible studies to 16 (<a href="#CD009764-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD009764-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram: review update" data-id="CD009764-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_n/nCD009764-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram: review update</p> </div> </div> </div> </section> <section id="CD009764-sec-0062"> <h4 class="title">Included studies</h4> <p>We identified 16 studies as eligible for the systematic review (<a href="./references#CD009764-bbs2-0001" title="AlbertRK , ConnettJ , BaileyWC , CasaburiR , CooperJA , CrinerGJ , et al. Azithromycin for prevention of exacerbations of COPD. New England Journal of Medicine2011;365:689‐98. HanMK , TayobN , MurrayS , DransfieldMT , WashkoG , ScanlonPD , et al. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. American Journal of Respiratory and Critical Care Medicine2014;189(12):1503‐8. MartinezFJ , ConnettJ , VoelkerH , CrinerGJ , HanMK , MakeBJ , et al. Chronic azithromycin therapy decreases the risk of re‐hospitalization in patients with COPD. American Journal of Respiratory and Critical Care Medicine2013;187:A4383. O'ReillyPJ , JacksonPL , WellsJM , DransfieldMT , ScanlonPD , Blalock , JE . Sputum PGP is reduced by azithromycin treatment in patients with COPD and correlates with exacerbations. BMJ Open2013;3(12):e004140. WoodruffPG , ChatilaW , ConnettJE , CrinerGJ , CurtisJL , DransfieldMT , et al. Tumour necrosis factor receptor‐75 and risk of COPD exacerbation in the azithromycin trial. European Respiratory Journal2014;43:295–8. ">Albert 2011</a>; <a href="./references#CD009764-bbs2-0002" title="BanerjeeD , HoneybourneD , KhairOA . The effect of oral Clarithromycin on bronchial airway inflammation in moderate‐to‐severe stable COPD: a randomised controlled trial. Treatments in Respiratory Medicine2004;3:59‐65. BanerjeeD , KhairO , HoneybourneD . The effect of oral clarithromycin on health status and sputum bacteriology in stable COPD. Respiratory Medicine2005;99:208‐15. ">Banerjee 2005</a>; <a href="./references#CD009764-bbs2-0003" title="BerkhofFF , Doornewaard‐ten HertogNE , UilSM , KerstjensHAM , Van denBergJWK . Azithromycin and cough‐specific health status in patients with chronic obstructive pulmonary disease and chronic cough: a randomised controlled trial. Respiratory Research2013;14(1):125. BerkhofFF , TenHertogNE , UilSM , KerstjensHAM , Van DenBergJK , CACTUS study group. Randomized controlled trial of prophylactic azithromycin on cough‐specific health status in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2013;187:A2449. ">Berkhof 2013</a>; <a href="./references#CD009764-bbs2-0004" title="BrillS , JamesP , CuthbertsonL , CooksonW , MoffattM , WedzichaJ . Haemophilus dominance of the stable COPD microbiome is associated with greater bacterial load and inflammation and is modulated by prophylactic antibiotic therapy. European Respiratory Journal2015;46:OA4746. BrillS , LawM , AllinsonJ , El‐EmirE , McHughT , DonaldsonG , et al. Bacterial resistance induction with prophylactic antibiotics in COPD. European Respiratory Journal2014;44:P4731. BrillSE , LawM , El‐EmirE , AllinsonJP , JamesP , MaddoxV , et al. Effects of different antibiotic classes on airway bacteria in stable COPD using culture and molecular techniques: a randomised controlled trial. Thorax2015;70(10):930‐8. BrillSE , LawM , El‐EmirE , AllinsonP , NazarethI , DonaldsonGC , et al. Effect of antibiotics on airway bacteria in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2014;198:A2874. ">Brill 2015</a>; <a href="./references#CD009764-bbs2-0005" title="HeZY , OuLM , ZhangJQ , BaiJ , LiuGN , LiMH , et al. Effect of 6 months of erythromycin treatment on inflammatory cells in induced sputum and exacerbations in chronic obstructive pulmonary disease. Respiration2010;80:445‐52. ">He 2010</a>; <a href="./references#CD009764-bbs2-0006" title="MygindLH , PedersenC , VestboJ , ChristensenJJ , Frimodt‐MollerN , KristiansenIS , et al. A randomised, placebo‐controlled 3 years study of prophylactic azithromycin in 575 patients with chronic obstructive pulmonary disease. European Respiratory Society 20th Annual Congress; 2010 Sep 18‐22; Barcelona. 2010. ">Mygind 2010</a>; <a href="./references#CD009764-bbs2-0007" title="NCT00524095 . Bronchiectasis in chronic obstructive pulmonary disease (COPD) patients: role of prophylaxis. clinicaltrials.gov/ct2/show/NCT00524095 (first received 3 September 2007). ">NCT00524095</a>; <a href="./references#CD009764-bbs2-0008" title="BatistaCM . A bench to bedside investigation into defective innate immunity in chronic obstructive pulmonary disease. National Heart &amp; Lung Institute, Imperial College London, UK; 2018. NCT02628769 . A study to evaluate the anti‐inflammatory effects of solithromycin in chronic obstructive pulmonary disease. clinicaltrials.gov/ct2/show/NCT02628769 (first received 11 December 2015). ">NCT02628769</a>; <a href="./references#CD009764-bbs2-0009" title="SeemungalTA , WilkinsonTM , HurstJR , PereraWR , SapsfordRJ , WedzichaJA . Long‐term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. American Journal of Respiratory and Critical Care Medicine2008;178:1139‐47. ">Seemungal 2008</a>; <a href="./references#CD009764-bbs2-0010" title="SethiS , JonesPW , TheronMS , MiravitllesM , RubinsteinE , WedzichaJA , et al. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized control trial. Respiratory Research2010;11:10. ">Sethi 2010</a>; <a href="./references#CD009764-bbs2-0011" title="ShafuddinE , MillsGD , HolmesMD , PoolePJ , MullinsPR , BlackPN . A double‐blind, randomised, placebo‐controlled study of roxithromycin and doxycycline combination, roxithromycin alone, or matching placebo for 12 weeks in adults with frequent exacerbations of chronic obstructive pulmonary disease. Journal of Negative Results in Biomedicine2015;14:15. [DOI: 10.1186/s12952‐015‐0034‐8] ">Shafuddin 2015</a>; <a href="./references#CD009764-bbs2-0012" title="SimpsonJL , PowellH , BainesKJ , MilneD , CoxsonHO , HansbroPM , et al. The effect of azithromycin in adults with stable neutrophilic COPD: a double blind randomised, placebo controlled trial. PLOS One2014;9(8):e105609. ">Simpson 2014</a>; <a href="./references#CD009764-bbs2-0013" title="SuzukiT , YaniM , YamayaM , Satoh NakagawaT , SekizawaK , IshidaS , et al. Erythromycin and common cold in COPD. Chest2001;120:730‐3. ">Suzuki 2001</a>; <a href="./references#CD009764-bbs2-0014" title="TanC , HuangH , ZhangJ , HeZ , ZhongX , BaiJ . Effects of low‐dose and long‐term treatment with erythromycin on IL‐17 and IL‐23 in peripheral blood and induced sputum in patients with stable chronic obstructive pulmonary disease. Chest2016;149:387A. TanC , HuangH , ZhangJ , HeZ , ZhongX , BaiJ . Effects of low‐dose and long‐term treatment with erythromycin on interleukin‐17 and interleukin‐23 in peripheral blood and induced sputum in patients with stable chronic obstructive pulmonary disease. Mediators of Inflammation2016:4173962. [DOI: 10.1155/2016/4173962] ">Tan 2016</a>; <a href="./references#CD009764-bbs2-0015" title="DjaminRS , UzunS , ErmensAAM , KerstensR , HoogstedenHC , AertsJGJV , et al. Which predictors in COPD patients with the frequent exacerbator phenotype predict the treatment response to maintenance therapy with azithromycin?. European Respiratory Journal2016;48:PA3713. UzunS , DjaminRS , AertsJGJV , Van DerEerdenMM . Patients with COPD Gold C &amp; D: the effect of long‐term treatment with azithromycin on exacerbation risk assessed by the Gold Framework. American Journal of Respiratory and Critical Care Medicine2014;189:A5967. UzunS , DjaminRS , KluytmansJA , MulderPG , Van't VeerNE , ErmensAA , et al. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double‐blind,placebo‐controlled trial. Lancet Respiratory Medicine2014;2(5):361‐8. UzunS , DjaminRS , MulderPGH , KluytmansJAJW , PelleAJ , Van't VeerNE , et al. Effect of azithromycin maintenance treatment in patients with frequent exacerbations of COPD (columbus): a randomized, double‐blind, placebo‐controlled trial. American Journal of Respiratory and Critical Care Medicine2014;189:A2884. ">Uzun 2014</a>; <a href="./references#CD009764-bbs2-0016" title="WangP , YangJ , YangY , DingZ . Effect of azithromycin in combination with simvastatin in the treatment of chronic obstructive pulmonary disease complicated by pulmonary arterial hypertension. Pakistan Journal of Medicine Science2017;33(2):260‐4. ">Wang 2017</a>). The study durations varied from three to 36 months. For reasons not given, one study was terminated before the treatment phase (<a href="./references#CD009764-bbs2-0007" title="NCT00524095 . Bronchiectasis in chronic obstructive pulmonary disease (COPD) patients: role of prophylaxis. clinicaltrials.gov/ct2/show/NCT00524095 (first received 3 September 2007). ">NCT00524095</a>) and another was terminated after enrolment of five participants due to hepatotoxicity of the study drug, solithromycin (<a href="./references#CD009764-bbs2-0008" title="BatistaCM . A bench to bedside investigation into defective innate immunity in chronic obstructive pulmonary disease. National Heart &amp; Lung Institute, Imperial College London, UK; 2018. NCT02628769 . A study to evaluate the anti‐inflammatory effects of solithromycin in chronic obstructive pulmonary disease. clinicaltrials.gov/ct2/show/NCT02628769 (first received 11 December 2015). ">NCT02628769</a>). See <a href="./references#CD009764-sec-0123" title="">Characteristics of included studies</a> and <a href="#CD009764-tbl-0002">Table 1</a> for further details. </p> <div class="table" id="CD009764-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary of study characteristics</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Country</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>No. of patients</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Age (range unless otherwise stated)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>% predicted FEV1 (range ) unless otherwise stated</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Duration of treatment</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009764-bbs2-0001" title="AlbertRK , ConnettJ , BaileyWC , CasaburiR , CooperJA , CrinerGJ , et al. Azithromycin for prevention of exacerbations of COPD. New England Journal of Medicine2011;365:689‐98. HanMK , TayobN , MurrayS , DransfieldMT , WashkoG , ScanlonPD , et al. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. American Journal of Respiratory and Critical Care Medicine2014;189(12):1503‐8. MartinezFJ , ConnettJ , VoelkerH , CrinerGJ , HanMK , MakeBJ , et al. Chronic azithromycin therapy decreases the risk of re‐hospitalization in patients with COPD. American Journal of Respiratory and Critical Care Medicine2013;187:A4383. O'ReillyPJ , JacksonPL , WellsJM , DransfieldMT , ScanlonPD , Blalock , JE . Sputum PGP is reduced by azithromycin treatment in patients with COPD and correlates with exacerbations. BMJ Open2013;3(12):e004140. WoodruffPG , ChatilaW , ConnettJE , CrinerGJ , CurtisJL , DransfieldMT , et al. Tumour necrosis factor receptor‐75 and risk of COPD exacerbation in the azithromycin trial. European Respiratory Journal2014;43:295–8. ">Albert 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>United States of America</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65 ‐ 66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39 ‐ 40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Azithromycin 250 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009764-bbs2-0002" title="BanerjeeD , HoneybourneD , KhairOA . The effect of oral Clarithromycin on bronchial airway inflammation in moderate‐to‐severe stable COPD: a randomised controlled trial. Treatments in Respiratory Medicine2004;3:59‐65. BanerjeeD , KhairO , HoneybourneD . The effect of oral clarithromycin on health status and sputum bacteriology in stable COPD. Respiratory Medicine2005;99:208‐15. ">Banerjee 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>United Kingdom</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65.1 ‐ 68.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42.5 ‐ 43.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clarithromycin ‐ long‐acting Klaricid XL 500 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009764-bbs2-0003" title="BerkhofFF , Doornewaard‐ten HertogNE , UilSM , KerstjensHAM , Van denBergJWK . Azithromycin and cough‐specific health status in patients with chronic obstructive pulmonary disease and chronic cough: a randomised controlled trial. Respiratory Research2013;14(1):125. BerkhofFF , TenHertogNE , UilSM , KerstjensHAM , Van DenBergJK , CACTUS study group. Randomized controlled trial of prophylactic azithromycin on cough‐specific health status in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2013;187:A2449. ">Berkhof 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Netherlands</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67 ‐ 68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47.4 ‐ 49.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Azithromycin 250 mg 3 times a week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><a href="./references#CD009764-bbs2-0004" title="BrillS , JamesP , CuthbertsonL , CooksonW , MoffattM , WedzichaJ . Haemophilus dominance of the stable COPD microbiome is associated with greater bacterial load and inflammation and is modulated by prophylactic antibiotic therapy. European Respiratory Journal2015;46:OA4746. BrillS , LawM , AllinsonJ , El‐EmirE , McHughT , DonaldsonG , et al. Bacterial resistance induction with prophylactic antibiotics in COPD. European Respiratory Journal2014;44:P4731. BrillSE , LawM , El‐EmirE , AllinsonJP , JamesP , MaddoxV , et al. Effects of different antibiotic classes on airway bacteria in stable COPD using culture and molecular techniques: a randomised controlled trial. Thorax2015;70(10):930‐8. BrillSE , LawM , El‐EmirE , AllinsonP , NazarethI , DonaldsonGC , et al. Effect of antibiotics on airway bacteria in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2014;198:A2874. ">Brill 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>United Kingdom</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>67.9 ‐ 70.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>44 ‐ 53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moxifloxacin 400 mg/day for 5 days every 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>13 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Doxycycline 100 mg daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Azithromycin 250 mg 3 times a week</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009764-bbs2-0005" title="HeZY , OuLM , ZhangJQ , BaiJ , LiuGN , LiMH , et al. Effect of 6 months of erythromycin treatment on inflammatory cells in induced sputum and exacerbations in chronic obstructive pulmonary disease. Respiration2010;80:445‐52. ">He 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68.8 ‐ 69.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42.1 ‐ 44.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Erythromycin 125 mg 3 times a day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009764-bbs2-0006" title="MygindLH , PedersenC , VestboJ , ChristensenJJ , Frimodt‐MollerN , KristiansenIS , et al. A randomised, placebo‐controlled 3 years study of prophylactic azithromycin in 575 patients with chronic obstructive pulmonary disease. European Respiratory Society 20th Annual Congress; 2010 Sep 18‐22; Barcelona. 2010. ">Mygind 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denmark</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>575</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71 (median)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38.4 (median)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Azithromycin 500 mg 3 days a month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD009764-bbs2-0007" title="NCT00524095 . Bronchiectasis in chronic obstructive pulmonary disease (COPD) patients: role of prophylaxis. clinicaltrials.gov/ct2/show/NCT00524095 (first received 3 September 2007). ">NCT00524095</a> (terminated; details given represent proposal) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>210</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>45 ‐ 85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Azithromycin 500 mg 3 times a week for 6 months, then fluticasone 500 μg twice a day for 6 months </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>1 year</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fluticasone 500 μg twice a day for 6 months, then azithromycin 500 mg 3 times a week for 6 months </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009764-bbs2-0008" title="BatistaCM . A bench to bedside investigation into defective innate immunity in chronic obstructive pulmonary disease. National Heart &amp; Lung Institute, Imperial College London, UK; 2018. NCT02628769 . A study to evaluate the anti‐inflammatory effects of solithromycin in chronic obstructive pulmonary disease. clinicaltrials.gov/ct2/show/NCT02628769 (first received 11 December 2015). ">NCT02628769</a> (terminated; details given represent proposal) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>United Kingdom</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Solithromycin 400 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28 days</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009764-bbs2-0009" title="SeemungalTA , WilkinsonTM , HurstJR , PereraWR , SapsfordRJ , WedzichaJA . Long‐term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. American Journal of Respiratory and Critical Care Medicine2008;178:1139‐47. ">Seemungal 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>United Kingdom</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66 ‐ 68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49.25 ‐ 50.55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Erythromycin 250 mg twice a day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009764-bbs2-0010" title="SethiS , JonesPW , TheronMS , MiravitllesM , RubinsteinE , WedzichaJA , et al. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized control trial. Respiratory Research2010;11:10. ">Sethi 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>International</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1157</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66.1 ‐ 66.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40.6 ‐ 42.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moxifloxacin 400 mg daily for 5 days every 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD009764-bbs2-0011" title="ShafuddinE , MillsGD , HolmesMD , PoolePJ , MullinsPR , BlackPN . A double‐blind, randomised, placebo‐controlled study of roxithromycin and doxycycline combination, roxithromycin alone, or matching placebo for 12 weeks in adults with frequent exacerbations of chronic obstructive pulmonary disease. Journal of Negative Results in Biomedicine2015;14:15. [DOI: 10.1186/s12952‐015‐0034‐8] ">Shafuddin 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Australia &amp; New Zealand</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>292</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>65.8 ‐ 67.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>32.53 ‐ 35.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Roxithromycin 300 mg daily and Doxycycline 100 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>12 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Roxithromycin 300 mg daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009764-bbs2-0012" title="SimpsonJL , PowellH , BainesKJ , MilneD , CoxsonHO , HansbroPM , et al. The effect of azithromycin in adults with stable neutrophilic COPD: a double blind randomised, placebo controlled trial. PLOS One2014;9(8):e105609. ">Simpson 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69.9 ‐ 71.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51.1 ‐ 56.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Azithromycin 250 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009764-bbs2-0013" title="SuzukiT , YaniM , YamayaM , Satoh NakagawaT , SekizawaK , IshidaS , et al. Erythromycin and common cold in COPD. Chest2001;120:730‐3. ">Suzuki 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Japan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69.1 ‐ 71.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.3 ‐ 1.47 L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Erythromycin 200 ‐ 400 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Riboflavin 10 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD009764-bbs2-0014" title="TanC , HuangH , ZhangJ , HeZ , ZhongX , BaiJ . Effects of low‐dose and long‐term treatment with erythromycin on IL‐17 and IL‐23 in peripheral blood and induced sputum in patients with stable chronic obstructive pulmonary disease. Chest2016;149:387A. TanC , HuangH , ZhangJ , HeZ , ZhongX , BaiJ . Effects of low‐dose and long‐term treatment with erythromycin on interleukin‐17 and interleukin‐23 in peripheral blood and induced sputum in patients with stable chronic obstructive pulmonary disease. Mediators of Inflammation2016:4173962. [DOI: 10.1155/2016/4173962] ">Tan 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>67.3 ‐ 69.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>42.1 ‐ 46.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Erythromycin 125 mg 3 times a day for 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>12 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Erythromcyin 125 mg 3 times a day for 6 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009764-bbs2-0015" title="DjaminRS , UzunS , ErmensAAM , KerstensR , HoogstedenHC , AertsJGJV , et al. Which predictors in COPD patients with the frequent exacerbator phenotype predict the treatment response to maintenance therapy with azithromycin?. European Respiratory Journal2016;48:PA3713. UzunS , DjaminRS , AertsJGJV , Van DerEerdenMM . Patients with COPD Gold C &amp; D: the effect of long‐term treatment with azithromycin on exacerbation risk assessed by the Gold Framework. American Journal of Respiratory and Critical Care Medicine2014;189:A5967. UzunS , DjaminRS , KluytmansJA , MulderPG , Van't VeerNE , ErmensAA , et al. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double‐blind,placebo‐controlled trial. Lancet Respiratory Medicine2014;2(5):361‐8. UzunS , DjaminRS , MulderPGH , KluytmansJAJW , PelleAJ , Van't VeerNE , et al. Effect of azithromycin maintenance treatment in patients with frequent exacerbations of COPD (columbus): a randomized, double‐blind, placebo‐controlled trial. American Journal of Respiratory and Critical Care Medicine2014;189:A2884. ">Uzun 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Netherlands</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64.7 ‐ 64.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44.2 ‐ 45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Azithromycin 500 mg three times a week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009764-bbs2-0016" title="WangP , YangJ , YangY , DingZ . Effect of azithromycin in combination with simvastatin in the treatment of chronic obstructive pulmonary disease complicated by pulmonary arterial hypertension. Pakistan Journal of Medicine Science2017;33(2):260‐4. ">Wang 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70.54 ‐ 72.43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Azithromycin 250 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Simvastatin 20 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 months</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>FEV1: forced expiratory volume in one second.</p> </div> </div> <p>From this point forward, we will describe only the 14 completed studies, involving 3932 participants. </p> <p>Nine studies involving 1925 participants investigated continuous macrolide antibiotics administered on at least a daily basis. These included azithromycin (<a href="./references#CD009764-bbs2-0001" title="AlbertRK , ConnettJ , BaileyWC , CasaburiR , CooperJA , CrinerGJ , et al. Azithromycin for prevention of exacerbations of COPD. New England Journal of Medicine2011;365:689‐98. HanMK , TayobN , MurrayS , DransfieldMT , WashkoG , ScanlonPD , et al. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. American Journal of Respiratory and Critical Care Medicine2014;189(12):1503‐8. MartinezFJ , ConnettJ , VoelkerH , CrinerGJ , HanMK , MakeBJ , et al. Chronic azithromycin therapy decreases the risk of re‐hospitalization in patients with COPD. American Journal of Respiratory and Critical Care Medicine2013;187:A4383. O'ReillyPJ , JacksonPL , WellsJM , DransfieldMT , ScanlonPD , Blalock , JE . Sputum PGP is reduced by azithromycin treatment in patients with COPD and correlates with exacerbations. BMJ Open2013;3(12):e004140. WoodruffPG , ChatilaW , ConnettJE , CrinerGJ , CurtisJL , DransfieldMT , et al. Tumour necrosis factor receptor‐75 and risk of COPD exacerbation in the azithromycin trial. European Respiratory Journal2014;43:295–8. ">Albert 2011</a>; <a href="./references#CD009764-bbs2-0012" title="SimpsonJL , PowellH , BainesKJ , MilneD , CoxsonHO , HansbroPM , et al. The effect of azithromycin in adults with stable neutrophilic COPD: a double blind randomised, placebo controlled trial. PLOS One2014;9(8):e105609. ">Simpson 2014</a>; <a href="./references#CD009764-bbs2-0016" title="WangP , YangJ , YangY , DingZ . Effect of azithromycin in combination with simvastatin in the treatment of chronic obstructive pulmonary disease complicated by pulmonary arterial hypertension. Pakistan Journal of Medicine Science2017;33(2):260‐4. ">Wang 2017</a>), erythromycin (<a href="./references#CD009764-bbs2-0005" title="HeZY , OuLM , ZhangJQ , BaiJ , LiuGN , LiMH , et al. Effect of 6 months of erythromycin treatment on inflammatory cells in induced sputum and exacerbations in chronic obstructive pulmonary disease. Respiration2010;80:445‐52. ">He 2010</a>; <a href="./references#CD009764-bbs2-0009" title="SeemungalTA , WilkinsonTM , HurstJR , PereraWR , SapsfordRJ , WedzichaJA . Long‐term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. American Journal of Respiratory and Critical Care Medicine2008;178:1139‐47. ">Seemungal 2008</a>; <a href="./references#CD009764-bbs2-0013" title="SuzukiT , YaniM , YamayaM , Satoh NakagawaT , SekizawaK , IshidaS , et al. Erythromycin and common cold in COPD. Chest2001;120:730‐3. ">Suzuki 2001</a>; <a href="./references#CD009764-bbs2-0014" title="TanC , HuangH , ZhangJ , HeZ , ZhongX , BaiJ . Effects of low‐dose and long‐term treatment with erythromycin on IL‐17 and IL‐23 in peripheral blood and induced sputum in patients with stable chronic obstructive pulmonary disease. Chest2016;149:387A. TanC , HuangH , ZhangJ , HeZ , ZhongX , BaiJ . Effects of low‐dose and long‐term treatment with erythromycin on interleukin‐17 and interleukin‐23 in peripheral blood and induced sputum in patients with stable chronic obstructive pulmonary disease. Mediators of Inflammation2016:4173962. [DOI: 10.1155/2016/4173962] ">Tan 2016</a>), roxithromycin (<a href="./references#CD009764-bbs2-0011" title="ShafuddinE , MillsGD , HolmesMD , PoolePJ , MullinsPR , BlackPN . A double‐blind, randomised, placebo‐controlled study of roxithromycin and doxycycline combination, roxithromycin alone, or matching placebo for 12 weeks in adults with frequent exacerbations of chronic obstructive pulmonary disease. Journal of Negative Results in Biomedicine2015;14:15. [DOI: 10.1186/s12952‐015‐0034‐8] ">Shafuddin 2015</a>), and clarithromycin (<a href="./references#CD009764-bbs2-0002" title="BanerjeeD , HoneybourneD , KhairOA . The effect of oral Clarithromycin on bronchial airway inflammation in moderate‐to‐severe stable COPD: a randomised controlled trial. Treatments in Respiratory Medicine2004;3:59‐65. BanerjeeD , KhairO , HoneybourneD . The effect of oral clarithromycin on health status and sputum bacteriology in stable COPD. Respiratory Medicine2005;99:208‐15. ">Banerjee 2005</a>). <a href="./references#CD009764-bbs2-0011" title="ShafuddinE , MillsGD , HolmesMD , PoolePJ , MullinsPR , BlackPN . A double‐blind, randomised, placebo‐controlled study of roxithromycin and doxycycline combination, roxithromycin alone, or matching placebo for 12 weeks in adults with frequent exacerbations of chronic obstructive pulmonary disease. Journal of Negative Results in Biomedicine2015;14:15. [DOI: 10.1186/s12952‐015‐0034‐8] ">Shafuddin 2015</a> compared the combination of a macrolide and tetracycline (roxithromycin and doxycycline) with roxithromycin alone, and included a placebo arm. </p> <p>Two studies involving 176 participants investigated intermittent antibiotics which were administered three times a week for 12 weeks and 12 months respectively (<a href="./references#CD009764-bbs2-0003" title="BerkhofFF , Doornewaard‐ten HertogNE , UilSM , KerstjensHAM , Van denBergJWK . Azithromycin and cough‐specific health status in patients with chronic obstructive pulmonary disease and chronic cough: a randomised controlled trial. Respiratory Research2013;14(1):125. BerkhofFF , TenHertogNE , UilSM , KerstjensHAM , Van DenBergJK , CACTUS study group. Randomized controlled trial of prophylactic azithromycin on cough‐specific health status in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2013;187:A2449. ">Berkhof 2013</a>; <a href="./references#CD009764-bbs2-0015" title="DjaminRS , UzunS , ErmensAAM , KerstensR , HoogstedenHC , AertsJGJV , et al. Which predictors in COPD patients with the frequent exacerbator phenotype predict the treatment response to maintenance therapy with azithromycin?. European Respiratory Journal2016;48:PA3713. UzunS , DjaminRS , AertsJGJV , Van DerEerdenMM . Patients with COPD Gold C &amp; D: the effect of long‐term treatment with azithromycin on exacerbation risk assessed by the Gold Framework. American Journal of Respiratory and Critical Care Medicine2014;189:A5967. UzunS , DjaminRS , KluytmansJA , MulderPG , Van't VeerNE , ErmensAA , et al. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double‐blind,placebo‐controlled trial. Lancet Respiratory Medicine2014;2(5):361‐8. UzunS , DjaminRS , MulderPGH , KluytmansJAJW , PelleAJ , Van't VeerNE , et al. Effect of azithromycin maintenance treatment in patients with frequent exacerbations of COPD (columbus): a randomized, double‐blind, placebo‐controlled trial. American Journal of Respiratory and Critical Care Medicine2014;189:A2884. ">Uzun 2014</a>). </p> <p>Two studies involving 1732 participants investigated pulsed antibiotic prophylaxis (<a href="./references#CD009764-bbs2-0006" title="MygindLH , PedersenC , VestboJ , ChristensenJJ , Frimodt‐MollerN , KristiansenIS , et al. A randomised, placebo‐controlled 3 years study of prophylactic azithromycin in 575 patients with chronic obstructive pulmonary disease. European Respiratory Society 20th Annual Congress; 2010 Sep 18‐22; Barcelona. 2010. ">Mygind 2010</a>; <a href="./references#CD009764-bbs2-0010" title="SethiS , JonesPW , TheronMS , MiravitllesM , RubinsteinE , WedzichaJA , et al. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized control trial. Respiratory Research2010;11:10. ">Sethi 2010</a>). In <a href="./references#CD009764-bbs2-0006" title="MygindLH , PedersenC , VestboJ , ChristensenJJ , Frimodt‐MollerN , KristiansenIS , et al. A randomised, placebo‐controlled 3 years study of prophylactic azithromycin in 575 patients with chronic obstructive pulmonary disease. European Respiratory Society 20th Annual Congress; 2010 Sep 18‐22; Barcelona. 2010. ">Mygind 2010</a>, azithromycin was given for three days every month for 36 months and in <a href="./references#CD009764-bbs2-0010" title="SethiS , JonesPW , TheronMS , MiravitllesM , RubinsteinE , WedzichaJA , et al. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized control trial. Respiratory Research2010;11:10. ">Sethi 2010</a>, moxifloxacin was given for five days every eight weeks for a total of six antibiotic courses. </p> <p>One study that involved 99 participants compared three treatment arms with placebo for a duration of 13 weeks. One arm involved a continuous regimen (doxycycline 100 mg daily), one arm involved an intermittent regimen (azithromycin 250 mg for 3 times a week) and one arm involved a pulsed regimen (moxifloxacin daily for five days every four weeks) (<a href="./references#CD009764-bbs2-0004" title="BrillS , JamesP , CuthbertsonL , CooksonW , MoffattM , WedzichaJ . Haemophilus dominance of the stable COPD microbiome is associated with greater bacterial load and inflammation and is modulated by prophylactic antibiotic therapy. European Respiratory Journal2015;46:OA4746. BrillS , LawM , AllinsonJ , El‐EmirE , McHughT , DonaldsonG , et al. Bacterial resistance induction with prophylactic antibiotics in COPD. European Respiratory Journal2014;44:P4731. BrillSE , LawM , El‐EmirE , AllinsonJP , JamesP , MaddoxV , et al. Effects of different antibiotic classes on airway bacteria in stable COPD using culture and molecular techniques: a randomised controlled trial. Thorax2015;70(10):930‐8. BrillSE , LawM , El‐EmirE , AllinsonP , NazarethI , DonaldsonGC , et al. Effect of antibiotics on airway bacteria in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2014;198:A2874. ">Brill 2015</a>). As such, <a href="./references#CD009764-bbs2-0004" title="BrillS , JamesP , CuthbertsonL , CooksonW , MoffattM , WedzichaJ . Haemophilus dominance of the stable COPD microbiome is associated with greater bacterial load and inflammation and is modulated by prophylactic antibiotic therapy. European Respiratory Journal2015;46:OA4746. BrillS , LawM , AllinsonJ , El‐EmirE , McHughT , DonaldsonG , et al. Bacterial resistance induction with prophylactic antibiotics in COPD. European Respiratory Journal2014;44:P4731. BrillSE , LawM , El‐EmirE , AllinsonJP , JamesP , MaddoxV , et al. Effects of different antibiotic classes on airway bacteria in stable COPD using culture and molecular techniques: a randomised controlled trial. Thorax2015;70(10):930‐8. BrillSE , LawM , El‐EmirE , AllinsonP , NazarethI , DonaldsonGC , et al. Effect of antibiotics on airway bacteria in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2014;198:A2874. ">Brill 2015</a> was included in the subgroup analyses for all three regimen groups, with the control group split three ways. </p> <p>All except one study (<a href="./references#CD009764-bbs2-0016" title="WangP , YangJ , YangY , DingZ . Effect of azithromycin in combination with simvastatin in the treatment of chronic obstructive pulmonary disease complicated by pulmonary arterial hypertension. Pakistan Journal of Medicine Science2017;33(2):260‐4. ">Wang 2017</a>) were randomised, placebo‐controlled, parallel group trials. Ten studies were double‐blinded. One was single‐blinded (<a href="./references#CD009764-bbs2-0004" title="BrillS , JamesP , CuthbertsonL , CooksonW , MoffattM , WedzichaJ . Haemophilus dominance of the stable COPD microbiome is associated with greater bacterial load and inflammation and is modulated by prophylactic antibiotic therapy. European Respiratory Journal2015;46:OA4746. BrillS , LawM , AllinsonJ , El‐EmirE , McHughT , DonaldsonG , et al. Bacterial resistance induction with prophylactic antibiotics in COPD. European Respiratory Journal2014;44:P4731. BrillSE , LawM , El‐EmirE , AllinsonJP , JamesP , MaddoxV , et al. Effects of different antibiotic classes on airway bacteria in stable COPD using culture and molecular techniques: a randomised controlled trial. Thorax2015;70(10):930‐8. BrillSE , LawM , El‐EmirE , AllinsonP , NazarethI , DonaldsonGC , et al. Effect of antibiotics on airway bacteria in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2014;198:A2874. ">Brill 2015</a>), one was not blinded (<a href="./references#CD009764-bbs2-0013" title="SuzukiT , YaniM , YamayaM , Satoh NakagawaT , SekizawaK , IshidaS , et al. Erythromycin and common cold in COPD. Chest2001;120:730‐3. ">Suzuki 2001</a>), and there were no comments regarding blinding methods in two of the studies (<a href="./references#CD009764-bbs2-0014" title="TanC , HuangH , ZhangJ , HeZ , ZhongX , BaiJ . Effects of low‐dose and long‐term treatment with erythromycin on IL‐17 and IL‐23 in peripheral blood and induced sputum in patients with stable chronic obstructive pulmonary disease. Chest2016;149:387A. TanC , HuangH , ZhangJ , HeZ , ZhongX , BaiJ . Effects of low‐dose and long‐term treatment with erythromycin on interleukin‐17 and interleukin‐23 in peripheral blood and induced sputum in patients with stable chronic obstructive pulmonary disease. Mediators of Inflammation2016:4173962. [DOI: 10.1155/2016/4173962] ">Tan 2016</a>; <a href="./references#CD009764-bbs2-0016" title="WangP , YangJ , YangY , DingZ . Effect of azithromycin in combination with simvastatin in the treatment of chronic obstructive pulmonary disease complicated by pulmonary arterial hypertension. Pakistan Journal of Medicine Science2017;33(2):260‐4. ">Wang 2017</a>). All studies were published in journals except <a href="./references#CD009764-bbs2-0006" title="MygindLH , PedersenC , VestboJ , ChristensenJJ , Frimodt‐MollerN , KristiansenIS , et al. A randomised, placebo‐controlled 3 years study of prophylactic azithromycin in 575 patients with chronic obstructive pulmonary disease. European Respiratory Society 20th Annual Congress; 2010 Sep 18‐22; Barcelona. 2010. ">Mygind 2010</a>, which was an oral presentation at the European Respiratory Society Conference in 2010. The studies were published or presented between 2001 and 2017. </p> <p>All studies, except <a href="./references#CD009764-bbs2-0014" title="TanC , HuangH , ZhangJ , HeZ , ZhongX , BaiJ . Effects of low‐dose and long‐term treatment with erythromycin on IL‐17 and IL‐23 in peripheral blood and induced sputum in patients with stable chronic obstructive pulmonary disease. Chest2016;149:387A. TanC , HuangH , ZhangJ , HeZ , ZhongX , BaiJ . Effects of low‐dose and long‐term treatment with erythromycin on interleukin‐17 and interleukin‐23 in peripheral blood and induced sputum in patients with stable chronic obstructive pulmonary disease. Mediators of Inflammation2016:4173962. [DOI: 10.1155/2016/4173962] ">Tan 2016</a> and <a href="./references#CD009764-bbs2-0016" title="WangP , YangJ , YangY , DingZ . Effect of azithromycin in combination with simvastatin in the treatment of chronic obstructive pulmonary disease complicated by pulmonary arterial hypertension. Pakistan Journal of Medicine Science2017;33(2):260‐4. ">Wang 2017</a>, listed exacerbation frequency and/or health‐related quality of life as primary, co‐primary or secondary outcomes. Twelve studies were analysed using intention‐to‐treat analysis. For two studies, it was unclear if intention‐to‐treat analysis was used (<a href="./references#CD009764-bbs2-0014" title="TanC , HuangH , ZhangJ , HeZ , ZhongX , BaiJ . Effects of low‐dose and long‐term treatment with erythromycin on IL‐17 and IL‐23 in peripheral blood and induced sputum in patients with stable chronic obstructive pulmonary disease. Chest2016;149:387A. TanC , HuangH , ZhangJ , HeZ , ZhongX , BaiJ . Effects of low‐dose and long‐term treatment with erythromycin on interleukin‐17 and interleukin‐23 in peripheral blood and induced sputum in patients with stable chronic obstructive pulmonary disease. Mediators of Inflammation2016:4173962. [DOI: 10.1155/2016/4173962] ">Tan 2016</a>; <a href="./references#CD009764-bbs2-0016" title="WangP , YangJ , YangY , DingZ . Effect of azithromycin in combination with simvastatin in the treatment of chronic obstructive pulmonary disease complicated by pulmonary arterial hypertension. Pakistan Journal of Medicine Science2017;33(2):260‐4. ">Wang 2017</a>). <a href="./references#CD009764-bbs2-0010" title="SethiS , JonesPW , TheronMS , MiravitllesM , RubinsteinE , WedzichaJA , et al. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized control trial. Respiratory Research2010;11:10. ">Sethi 2010</a> reported both a per protocol analysis as well as an intention‐to‐treat analysis, but, for the review, we have included only the intention‐to‐treat analysis results. </p> <p>Of note, the <a href="./references#CD009764-bbs2-0011" title="ShafuddinE , MillsGD , HolmesMD , PoolePJ , MullinsPR , BlackPN . A double‐blind, randomised, placebo‐controlled study of roxithromycin and doxycycline combination, roxithromycin alone, or matching placebo for 12 weeks in adults with frequent exacerbations of chronic obstructive pulmonary disease. Journal of Negative Results in Biomedicine2015;14:15. [DOI: 10.1186/s12952‐015‐0034‐8] ">Shafuddin 2015</a> study was originally designed "to test the hypothesis that <i>Chlamydia pneumoniae</i> (now <i>Chlamydophilia pneumoniae</i> ) was a pathogenic factor in the aetiology of COPD and that eradication of <i>C. pneumoniae</i> infections could reduce exacerbation rates". In view of this original hypothesis, the study design was such that all included participants tested positive for <i>C. pneumoniae</i> , and the antibiotic regimens were chosen with the aim of eradicating <i>C. pneumoniae</i> infection specifically. This included a combined treatment arm of roxithromycin and doxycycline, which was thought to be more successful at eradicating <i>C. pneumoniae</i> compared to roxithromycin alone. In their background text, the authors explained that "this hypothesis is now considered unsubstantiated and is no longer believed to be clinically relevant". However, they have used their collected data to examine the effect of prophylactic antibiotic therapy on COPD exacerbations, reporting that their data may reasonably be applied to the general COPD population with frequent exacerbations, as differences between their included participants with <i>C. pneumoniae</i> are unlikely to have an effect on efficacy endpoints or the interpretation of results (<a href="./references#CD009764-bbs2-0011" title="ShafuddinE , MillsGD , HolmesMD , PoolePJ , MullinsPR , BlackPN . A double‐blind, randomised, placebo‐controlled study of roxithromycin and doxycycline combination, roxithromycin alone, or matching placebo for 12 weeks in adults with frequent exacerbations of chronic obstructive pulmonary disease. Journal of Negative Results in Biomedicine2015;14:15. [DOI: 10.1186/s12952‐015‐0034‐8] ">Shafuddin 2015</a>). </p> <section id="CD009764-sec-0063"> <h5 class="title">Study funding</h5> <p><a href="./references#CD009764-bbs2-0001" title="AlbertRK , ConnettJ , BaileyWC , CasaburiR , CooperJA , CrinerGJ , et al. Azithromycin for prevention of exacerbations of COPD. New England Journal of Medicine2011;365:689‐98. HanMK , TayobN , MurrayS , DransfieldMT , WashkoG , ScanlonPD , et al. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. American Journal of Respiratory and Critical Care Medicine2014;189(12):1503‐8. MartinezFJ , ConnettJ , VoelkerH , CrinerGJ , HanMK , MakeBJ , et al. Chronic azithromycin therapy decreases the risk of re‐hospitalization in patients with COPD. American Journal of Respiratory and Critical Care Medicine2013;187:A4383. O'ReillyPJ , JacksonPL , WellsJM , DransfieldMT , ScanlonPD , Blalock , JE . Sputum PGP is reduced by azithromycin treatment in patients with COPD and correlates with exacerbations. BMJ Open2013;3(12):e004140. WoodruffPG , ChatilaW , ConnettJE , CrinerGJ , CurtisJL , DransfieldMT , et al. Tumour necrosis factor receptor‐75 and risk of COPD exacerbation in the azithromycin trial. European Respiratory Journal2014;43:295–8. ">Albert 2011</a> was supported by grants from the National Institutes of Health, <a href="./references#CD009764-bbs2-0002" title="BanerjeeD , HoneybourneD , KhairOA . The effect of oral Clarithromycin on bronchial airway inflammation in moderate‐to‐severe stable COPD: a randomised controlled trial. Treatments in Respiratory Medicine2004;3:59‐65. BanerjeeD , KhairO , HoneybourneD . The effect of oral clarithromycin on health status and sputum bacteriology in stable COPD. Respiratory Medicine2005;99:208‐15. ">Banerjee 2005</a> received a grant from Abbott, <a href="./references#CD009764-bbs2-0003" title="BerkhofFF , Doornewaard‐ten HertogNE , UilSM , KerstjensHAM , Van denBergJWK . Azithromycin and cough‐specific health status in patients with chronic obstructive pulmonary disease and chronic cough: a randomised controlled trial. Respiratory Research2013;14(1):125. BerkhofFF , TenHertogNE , UilSM , KerstjensHAM , Van DenBergJK , CACTUS study group. Randomized controlled trial of prophylactic azithromycin on cough‐specific health status in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2013;187:A2449. ">Berkhof 2013</a> received financial support from Stichting Astma Bestrijding, <a href="./references#CD009764-bbs2-0004" title="BrillS , JamesP , CuthbertsonL , CooksonW , MoffattM , WedzichaJ . Haemophilus dominance of the stable COPD microbiome is associated with greater bacterial load and inflammation and is modulated by prophylactic antibiotic therapy. European Respiratory Journal2015;46:OA4746. BrillS , LawM , AllinsonJ , El‐EmirE , McHughT , DonaldsonG , et al. Bacterial resistance induction with prophylactic antibiotics in COPD. European Respiratory Journal2014;44:P4731. BrillSE , LawM , El‐EmirE , AllinsonJP , JamesP , MaddoxV , et al. Effects of different antibiotic classes on airway bacteria in stable COPD using culture and molecular techniques: a randomised controlled trial. Thorax2015;70(10):930‐8. BrillSE , LawM , El‐EmirE , AllinsonP , NazarethI , DonaldsonGC , et al. Effect of antibiotics on airway bacteria in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2014;198:A2874. ">Brill 2015</a> was funded by the National Institute for Health Research, <a href="./references#CD009764-bbs2-0005" title="HeZY , OuLM , ZhangJQ , BaiJ , LiuGN , LiMH , et al. Effect of 6 months of erythromycin treatment on inflammatory cells in induced sputum and exacerbations in chronic obstructive pulmonary disease. Respiration2010;80:445‐52. ">He 2010</a> was supported by grants from the National Nature Science Foundation of China, <a href="./references#CD009764-bbs2-0009" title="SeemungalTA , WilkinsonTM , HurstJR , PereraWR , SapsfordRJ , WedzichaJA . Long‐term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. American Journal of Respiratory and Critical Care Medicine2008;178:1139‐47. ">Seemungal 2008</a> was supported by the British Lung foundation, <a href="./references#CD009764-bbs2-0010" title="SethiS , JonesPW , TheronMS , MiravitllesM , RubinsteinE , WedzichaJA , et al. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized control trial. Respiratory Research2010;11:10. ">Sethi 2010</a> was supported by a research grant from Bayer HealthCare AB, <a href="./references#CD009764-bbs2-0011" title="ShafuddinE , MillsGD , HolmesMD , PoolePJ , MullinsPR , BlackPN . A double‐blind, randomised, placebo‐controlled study of roxithromycin and doxycycline combination, roxithromycin alone, or matching placebo for 12 weeks in adults with frequent exacerbations of chronic obstructive pulmonary disease. Journal of Negative Results in Biomedicine2015;14:15. [DOI: 10.1186/s12952‐015‐0034‐8] ">Shafuddin 2015</a> was supported by Sanofi‐Aventis Australia Pty Ltd, <a href="./references#CD009764-bbs2-0012" title="SimpsonJL , PowellH , BainesKJ , MilneD , CoxsonHO , HansbroPM , et al. The effect of azithromycin in adults with stable neutrophilic COPD: a double blind randomised, placebo controlled trial. PLOS One2014;9(8):e105609. ">Simpson 2014</a> was funded by the National Health and Medical Research Council of Australia, <a href="./references#CD009764-bbs2-0014" title="TanC , HuangH , ZhangJ , HeZ , ZhongX , BaiJ . Effects of low‐dose and long‐term treatment with erythromycin on IL‐17 and IL‐23 in peripheral blood and induced sputum in patients with stable chronic obstructive pulmonary disease. Chest2016;149:387A. TanC , HuangH , ZhangJ , HeZ , ZhongX , BaiJ . Effects of low‐dose and long‐term treatment with erythromycin on interleukin‐17 and interleukin‐23 in peripheral blood and induced sputum in patients with stable chronic obstructive pulmonary disease. Mediators of Inflammation2016:4173962. [DOI: 10.1155/2016/4173962] ">Tan 2016</a> was funded by the National Nature Science Foundation of China and the Guangxi Natural Science Foundation, and <a href="./references#CD009764-bbs2-0015" title="DjaminRS , UzunS , ErmensAAM , KerstensR , HoogstedenHC , AertsJGJV , et al. Which predictors in COPD patients with the frequent exacerbator phenotype predict the treatment response to maintenance therapy with azithromycin?. European Respiratory Journal2016;48:PA3713. UzunS , DjaminRS , AertsJGJV , Van DerEerdenMM . Patients with COPD Gold C &amp; D: the effect of long‐term treatment with azithromycin on exacerbation risk assessed by the Gold Framework. American Journal of Respiratory and Critical Care Medicine2014;189:A5967. UzunS , DjaminRS , KluytmansJA , MulderPG , Van't VeerNE , ErmensAA , et al. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double‐blind,placebo‐controlled trial. Lancet Respiratory Medicine2014;2(5):361‐8. UzunS , DjaminRS , MulderPGH , KluytmansJAJW , PelleAJ , Van't VeerNE , et al. Effect of azithromycin maintenance treatment in patients with frequent exacerbations of COPD (columbus): a randomized, double‐blind, placebo‐controlled trial. American Journal of Respiratory and Critical Care Medicine2014;189:A2884. ">Uzun 2014</a> was funded by a trust called SoLong, which is associated with the department of Respiratory Medicine of the Amphia Hospital in the Netherlands. From the material available to us, the funding for <a href="./references#CD009764-bbs2-0006" title="MygindLH , PedersenC , VestboJ , ChristensenJJ , Frimodt‐MollerN , KristiansenIS , et al. A randomised, placebo‐controlled 3 years study of prophylactic azithromycin in 575 patients with chronic obstructive pulmonary disease. European Respiratory Society 20th Annual Congress; 2010 Sep 18‐22; Barcelona. 2010. ">Mygind 2010</a> and <a href="./references#CD009764-bbs2-0013" title="SuzukiT , YaniM , YamayaM , Satoh NakagawaT , SekizawaK , IshidaS , et al. Erythromycin and common cold in COPD. Chest2001;120:730‐3. ">Suzuki 2001</a> was unclear. <a href="./references#CD009764-bbs2-0016" title="WangP , YangJ , YangY , DingZ . Effect of azithromycin in combination with simvastatin in the treatment of chronic obstructive pulmonary disease complicated by pulmonary arterial hypertension. Pakistan Journal of Medicine Science2017;33(2):260‐4. ">Wang 2017</a> reported that they had no grant support or financial disclosures. </p> </section> </section> <section id="CD009764-sec-0064"> <h4 class="title">Excluded studies</h4> <p>Excluded studies are listed in the <a href="./references#CD009764-sec-0124" title="">Characteristics of excluded studies</a> table, along with the reasons for exclusion. </p> </section> </section> <section id="CD009764-sec-0065"> <h3 class="title">Risk of bias in included studies</h3> <p>Judgements and reasons for the judgements can be found in <a href="./references#CD009764-sec-0123" title="">Characteristics of included studies</a> and an overview of our judgements can be found in <a href="#CD009764-fig-0002">Figure 2</a>. </p> <div class="figure" id="CD009764-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD009764-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_n/nCD009764-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD009764-sec-0066"> <h4 class="title">Allocation</h4> <p>Random sequence generation was well described in ten of the studies, which we judged to be at low risk of bias in this domain (<a href="./references#CD009764-bbs2-0001" title="AlbertRK , ConnettJ , BaileyWC , CasaburiR , CooperJA , CrinerGJ , et al. Azithromycin for prevention of exacerbations of COPD. New England Journal of Medicine2011;365:689‐98. HanMK , TayobN , MurrayS , DransfieldMT , WashkoG , ScanlonPD , et al. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. American Journal of Respiratory and Critical Care Medicine2014;189(12):1503‐8. MartinezFJ , ConnettJ , VoelkerH , CrinerGJ , HanMK , MakeBJ , et al. Chronic azithromycin therapy decreases the risk of re‐hospitalization in patients with COPD. American Journal of Respiratory and Critical Care Medicine2013;187:A4383. O'ReillyPJ , JacksonPL , WellsJM , DransfieldMT , ScanlonPD , Blalock , JE . Sputum PGP is reduced by azithromycin treatment in patients with COPD and correlates with exacerbations. BMJ Open2013;3(12):e004140. WoodruffPG , ChatilaW , ConnettJE , CrinerGJ , CurtisJL , DransfieldMT , et al. Tumour necrosis factor receptor‐75 and risk of COPD exacerbation in the azithromycin trial. European Respiratory Journal2014;43:295–8. ">Albert 2011</a>; <a href="./references#CD009764-bbs2-0002" title="BanerjeeD , HoneybourneD , KhairOA . The effect of oral Clarithromycin on bronchial airway inflammation in moderate‐to‐severe stable COPD: a randomised controlled trial. Treatments in Respiratory Medicine2004;3:59‐65. BanerjeeD , KhairO , HoneybourneD . The effect of oral clarithromycin on health status and sputum bacteriology in stable COPD. Respiratory Medicine2005;99:208‐15. ">Banerjee 2005</a>; <a href="./references#CD009764-bbs2-0003" title="BerkhofFF , Doornewaard‐ten HertogNE , UilSM , KerstjensHAM , Van denBergJWK . Azithromycin and cough‐specific health status in patients with chronic obstructive pulmonary disease and chronic cough: a randomised controlled trial. Respiratory Research2013;14(1):125. BerkhofFF , TenHertogNE , UilSM , KerstjensHAM , Van DenBergJK , CACTUS study group. Randomized controlled trial of prophylactic azithromycin on cough‐specific health status in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2013;187:A2449. ">Berkhof 2013</a>; <a href="./references#CD009764-bbs2-0004" title="BrillS , JamesP , CuthbertsonL , CooksonW , MoffattM , WedzichaJ . Haemophilus dominance of the stable COPD microbiome is associated with greater bacterial load and inflammation and is modulated by prophylactic antibiotic therapy. European Respiratory Journal2015;46:OA4746. BrillS , LawM , AllinsonJ , El‐EmirE , McHughT , DonaldsonG , et al. Bacterial resistance induction with prophylactic antibiotics in COPD. European Respiratory Journal2014;44:P4731. BrillSE , LawM , El‐EmirE , AllinsonJP , JamesP , MaddoxV , et al. Effects of different antibiotic classes on airway bacteria in stable COPD using culture and molecular techniques: a randomised controlled trial. Thorax2015;70(10):930‐8. BrillSE , LawM , El‐EmirE , AllinsonP , NazarethI , DonaldsonGC , et al. Effect of antibiotics on airway bacteria in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2014;198:A2874. ">Brill 2015</a>; <a href="./references#CD009764-bbs2-0009" title="SeemungalTA , WilkinsonTM , HurstJR , PereraWR , SapsfordRJ , WedzichaJA . Long‐term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. American Journal of Respiratory and Critical Care Medicine2008;178:1139‐47. ">Seemungal 2008</a>; <a href="./references#CD009764-bbs2-0011" title="ShafuddinE , MillsGD , HolmesMD , PoolePJ , MullinsPR , BlackPN . A double‐blind, randomised, placebo‐controlled study of roxithromycin and doxycycline combination, roxithromycin alone, or matching placebo for 12 weeks in adults with frequent exacerbations of chronic obstructive pulmonary disease. Journal of Negative Results in Biomedicine2015;14:15. [DOI: 10.1186/s12952‐015‐0034‐8] ">Shafuddin 2015</a>; <a href="./references#CD009764-bbs2-0012" title="SimpsonJL , PowellH , BainesKJ , MilneD , CoxsonHO , HansbroPM , et al. The effect of azithromycin in adults with stable neutrophilic COPD: a double blind randomised, placebo controlled trial. PLOS One2014;9(8):e105609. ">Simpson 2014</a>; <a href="./references#CD009764-bbs2-0013" title="SuzukiT , YaniM , YamayaM , Satoh NakagawaT , SekizawaK , IshidaS , et al. Erythromycin and common cold in COPD. Chest2001;120:730‐3. ">Suzuki 2001</a>; <a href="./references#CD009764-bbs2-0015" title="DjaminRS , UzunS , ErmensAAM , KerstensR , HoogstedenHC , AertsJGJV , et al. Which predictors in COPD patients with the frequent exacerbator phenotype predict the treatment response to maintenance therapy with azithromycin?. European Respiratory Journal2016;48:PA3713. UzunS , DjaminRS , AertsJGJV , Van DerEerdenMM . Patients with COPD Gold C &amp; D: the effect of long‐term treatment with azithromycin on exacerbation risk assessed by the Gold Framework. American Journal of Respiratory and Critical Care Medicine2014;189:A5967. UzunS , DjaminRS , KluytmansJA , MulderPG , Van't VeerNE , ErmensAA , et al. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double‐blind,placebo‐controlled trial. Lancet Respiratory Medicine2014;2(5):361‐8. UzunS , DjaminRS , MulderPGH , KluytmansJAJW , PelleAJ , Van't VeerNE , et al. Effect of azithromycin maintenance treatment in patients with frequent exacerbations of COPD (columbus): a randomized, double‐blind, placebo‐controlled trial. American Journal of Respiratory and Critical Care Medicine2014;189:A2884. ">Uzun 2014</a>; <a href="./references#CD009764-bbs2-0016" title="WangP , YangJ , YangY , DingZ . Effect of azithromycin in combination with simvastatin in the treatment of chronic obstructive pulmonary disease complicated by pulmonary arterial hypertension. Pakistan Journal of Medicine Science2017;33(2):260‐4. ">Wang 2017</a>). Four studies did not describe random sequence generation clearly and we judged them to be at unclear risk (<a href="./references#CD009764-bbs2-0005" title="HeZY , OuLM , ZhangJQ , BaiJ , LiuGN , LiMH , et al. Effect of 6 months of erythromycin treatment on inflammatory cells in induced sputum and exacerbations in chronic obstructive pulmonary disease. Respiration2010;80:445‐52. ">He 2010</a>; <a href="./references#CD009764-bbs2-0006" title="MygindLH , PedersenC , VestboJ , ChristensenJJ , Frimodt‐MollerN , KristiansenIS , et al. A randomised, placebo‐controlled 3 years study of prophylactic azithromycin in 575 patients with chronic obstructive pulmonary disease. European Respiratory Society 20th Annual Congress; 2010 Sep 18‐22; Barcelona. 2010. ">Mygind 2010</a>; <a href="./references#CD009764-bbs2-0010" title="SethiS , JonesPW , TheronMS , MiravitllesM , RubinsteinE , WedzichaJA , et al. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized control trial. Respiratory Research2010;11:10. ">Sethi 2010</a>; <a href="./references#CD009764-bbs2-0014" title="TanC , HuangH , ZhangJ , HeZ , ZhongX , BaiJ . Effects of low‐dose and long‐term treatment with erythromycin on IL‐17 and IL‐23 in peripheral blood and induced sputum in patients with stable chronic obstructive pulmonary disease. Chest2016;149:387A. TanC , HuangH , ZhangJ , HeZ , ZhongX , BaiJ . Effects of low‐dose and long‐term treatment with erythromycin on interleukin‐17 and interleukin‐23 in peripheral blood and induced sputum in patients with stable chronic obstructive pulmonary disease. Mediators of Inflammation2016:4173962. [DOI: 10.1155/2016/4173962] ">Tan 2016</a>). </p> <p>Allocation concealment was well described in eight studies, which we judged to be at low risk of bias in this domain (<a href="./references#CD009764-bbs2-0001" title="AlbertRK , ConnettJ , BaileyWC , CasaburiR , CooperJA , CrinerGJ , et al. Azithromycin for prevention of exacerbations of COPD. New England Journal of Medicine2011;365:689‐98. HanMK , TayobN , MurrayS , DransfieldMT , WashkoG , ScanlonPD , et al. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. American Journal of Respiratory and Critical Care Medicine2014;189(12):1503‐8. MartinezFJ , ConnettJ , VoelkerH , CrinerGJ , HanMK , MakeBJ , et al. Chronic azithromycin therapy decreases the risk of re‐hospitalization in patients with COPD. American Journal of Respiratory and Critical Care Medicine2013;187:A4383. O'ReillyPJ , JacksonPL , WellsJM , DransfieldMT , ScanlonPD , Blalock , JE . Sputum PGP is reduced by azithromycin treatment in patients with COPD and correlates with exacerbations. BMJ Open2013;3(12):e004140. WoodruffPG , ChatilaW , ConnettJE , CrinerGJ , CurtisJL , DransfieldMT , et al. Tumour necrosis factor receptor‐75 and risk of COPD exacerbation in the azithromycin trial. European Respiratory Journal2014;43:295–8. ">Albert 2011</a>; <a href="./references#CD009764-bbs2-0002" title="BanerjeeD , HoneybourneD , KhairOA . The effect of oral Clarithromycin on bronchial airway inflammation in moderate‐to‐severe stable COPD: a randomised controlled trial. Treatments in Respiratory Medicine2004;3:59‐65. BanerjeeD , KhairO , HoneybourneD . The effect of oral clarithromycin on health status and sputum bacteriology in stable COPD. Respiratory Medicine2005;99:208‐15. ">Banerjee 2005</a>; <a href="./references#CD009764-bbs2-0004" title="BrillS , JamesP , CuthbertsonL , CooksonW , MoffattM , WedzichaJ . Haemophilus dominance of the stable COPD microbiome is associated with greater bacterial load and inflammation and is modulated by prophylactic antibiotic therapy. European Respiratory Journal2015;46:OA4746. BrillS , LawM , AllinsonJ , El‐EmirE , McHughT , DonaldsonG , et al. Bacterial resistance induction with prophylactic antibiotics in COPD. European Respiratory Journal2014;44:P4731. BrillSE , LawM , El‐EmirE , AllinsonJP , JamesP , MaddoxV , et al. Effects of different antibiotic classes on airway bacteria in stable COPD using culture and molecular techniques: a randomised controlled trial. Thorax2015;70(10):930‐8. BrillSE , LawM , El‐EmirE , AllinsonP , NazarethI , DonaldsonGC , et al. Effect of antibiotics on airway bacteria in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2014;198:A2874. ">Brill 2015</a>; <a href="./references#CD009764-bbs2-0009" title="SeemungalTA , WilkinsonTM , HurstJR , PereraWR , SapsfordRJ , WedzichaJA . Long‐term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. American Journal of Respiratory and Critical Care Medicine2008;178:1139‐47. ">Seemungal 2008</a>; <a href="./references#CD009764-bbs2-0011" title="ShafuddinE , MillsGD , HolmesMD , PoolePJ , MullinsPR , BlackPN . A double‐blind, randomised, placebo‐controlled study of roxithromycin and doxycycline combination, roxithromycin alone, or matching placebo for 12 weeks in adults with frequent exacerbations of chronic obstructive pulmonary disease. Journal of Negative Results in Biomedicine2015;14:15. [DOI: 10.1186/s12952‐015‐0034‐8] ">Shafuddin 2015</a>; <a href="./references#CD009764-bbs2-0012" title="SimpsonJL , PowellH , BainesKJ , MilneD , CoxsonHO , HansbroPM , et al. The effect of azithromycin in adults with stable neutrophilic COPD: a double blind randomised, placebo controlled trial. PLOS One2014;9(8):e105609. ">Simpson 2014</a>; <a href="./references#CD009764-bbs2-0013" title="SuzukiT , YaniM , YamayaM , Satoh NakagawaT , SekizawaK , IshidaS , et al. Erythromycin and common cold in COPD. Chest2001;120:730‐3. ">Suzuki 2001</a>; <a href="./references#CD009764-bbs2-0015" title="DjaminRS , UzunS , ErmensAAM , KerstensR , HoogstedenHC , AertsJGJV , et al. Which predictors in COPD patients with the frequent exacerbator phenotype predict the treatment response to maintenance therapy with azithromycin?. European Respiratory Journal2016;48:PA3713. UzunS , DjaminRS , AertsJGJV , Van DerEerdenMM . Patients with COPD Gold C &amp; D: the effect of long‐term treatment with azithromycin on exacerbation risk assessed by the Gold Framework. American Journal of Respiratory and Critical Care Medicine2014;189:A5967. UzunS , DjaminRS , KluytmansJA , MulderPG , Van't VeerNE , ErmensAA , et al. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double‐blind,placebo‐controlled trial. Lancet Respiratory Medicine2014;2(5):361‐8. UzunS , DjaminRS , MulderPGH , KluytmansJAJW , PelleAJ , Van't VeerNE , et al. Effect of azithromycin maintenance treatment in patients with frequent exacerbations of COPD (columbus): a randomized, double‐blind, placebo‐controlled trial. American Journal of Respiratory and Critical Care Medicine2014;189:A2884. ">Uzun 2014</a>). Six studies did not describe allocation concealment clearly and we judged them to be at unclear risk in this domain (<a href="./references#CD009764-bbs2-0003" title="BerkhofFF , Doornewaard‐ten HertogNE , UilSM , KerstjensHAM , Van denBergJWK . Azithromycin and cough‐specific health status in patients with chronic obstructive pulmonary disease and chronic cough: a randomised controlled trial. Respiratory Research2013;14(1):125. BerkhofFF , TenHertogNE , UilSM , KerstjensHAM , Van DenBergJK , CACTUS study group. Randomized controlled trial of prophylactic azithromycin on cough‐specific health status in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2013;187:A2449. ">Berkhof 2013</a>; <a href="./references#CD009764-bbs2-0005" title="HeZY , OuLM , ZhangJQ , BaiJ , LiuGN , LiMH , et al. Effect of 6 months of erythromycin treatment on inflammatory cells in induced sputum and exacerbations in chronic obstructive pulmonary disease. Respiration2010;80:445‐52. ">He 2010</a>; <a href="./references#CD009764-bbs2-0006" title="MygindLH , PedersenC , VestboJ , ChristensenJJ , Frimodt‐MollerN , KristiansenIS , et al. A randomised, placebo‐controlled 3 years study of prophylactic azithromycin in 575 patients with chronic obstructive pulmonary disease. European Respiratory Society 20th Annual Congress; 2010 Sep 18‐22; Barcelona. 2010. ">Mygind 2010</a>; <a href="./references#CD009764-bbs2-0010" title="SethiS , JonesPW , TheronMS , MiravitllesM , RubinsteinE , WedzichaJA , et al. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized control trial. Respiratory Research2010;11:10. ">Sethi 2010</a>; <a href="./references#CD009764-bbs2-0014" title="TanC , HuangH , ZhangJ , HeZ , ZhongX , BaiJ . Effects of low‐dose and long‐term treatment with erythromycin on IL‐17 and IL‐23 in peripheral blood and induced sputum in patients with stable chronic obstructive pulmonary disease. Chest2016;149:387A. TanC , HuangH , ZhangJ , HeZ , ZhongX , BaiJ . Effects of low‐dose and long‐term treatment with erythromycin on interleukin‐17 and interleukin‐23 in peripheral blood and induced sputum in patients with stable chronic obstructive pulmonary disease. Mediators of Inflammation2016:4173962. [DOI: 10.1155/2016/4173962] ">Tan 2016</a>; <a href="./references#CD009764-bbs2-0016" title="WangP , YangJ , YangY , DingZ . Effect of azithromycin in combination with simvastatin in the treatment of chronic obstructive pulmonary disease complicated by pulmonary arterial hypertension. Pakistan Journal of Medicine Science2017;33(2):260‐4. ">Wang 2017</a>). </p> <p><a href="./references#CD009764-bbs2-0006" title="MygindLH , PedersenC , VestboJ , ChristensenJJ , Frimodt‐MollerN , KristiansenIS , et al. A randomised, placebo‐controlled 3 years study of prophylactic azithromycin in 575 patients with chronic obstructive pulmonary disease. European Respiratory Society 20th Annual Congress; 2010 Sep 18‐22; Barcelona. 2010. ">Mygind 2010</a> is a conference presentation, and, as such, we had access to limited data. We were not successful in obtaining further information from authors despite multiple attempts by email and post. </p> </section> <section id="CD009764-sec-0067"> <h4 class="title">Blinding</h4> <p>Blinding of the participants and personnel (performance bias) was described in ten of the included studies (<a href="./references#CD009764-bbs2-0001" title="AlbertRK , ConnettJ , BaileyWC , CasaburiR , CooperJA , CrinerGJ , et al. Azithromycin for prevention of exacerbations of COPD. New England Journal of Medicine2011;365:689‐98. HanMK , TayobN , MurrayS , DransfieldMT , WashkoG , ScanlonPD , et al. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. American Journal of Respiratory and Critical Care Medicine2014;189(12):1503‐8. MartinezFJ , ConnettJ , VoelkerH , CrinerGJ , HanMK , MakeBJ , et al. Chronic azithromycin therapy decreases the risk of re‐hospitalization in patients with COPD. American Journal of Respiratory and Critical Care Medicine2013;187:A4383. O'ReillyPJ , JacksonPL , WellsJM , DransfieldMT , ScanlonPD , Blalock , JE . Sputum PGP is reduced by azithromycin treatment in patients with COPD and correlates with exacerbations. BMJ Open2013;3(12):e004140. WoodruffPG , ChatilaW , ConnettJE , CrinerGJ , CurtisJL , DransfieldMT , et al. Tumour necrosis factor receptor‐75 and risk of COPD exacerbation in the azithromycin trial. European Respiratory Journal2014;43:295–8. ">Albert 2011</a>; <a href="./references#CD009764-bbs2-0002" title="BanerjeeD , HoneybourneD , KhairOA . The effect of oral Clarithromycin on bronchial airway inflammation in moderate‐to‐severe stable COPD: a randomised controlled trial. Treatments in Respiratory Medicine2004;3:59‐65. BanerjeeD , KhairO , HoneybourneD . The effect of oral clarithromycin on health status and sputum bacteriology in stable COPD. Respiratory Medicine2005;99:208‐15. ">Banerjee 2005</a>; <a href="./references#CD009764-bbs2-0003" title="BerkhofFF , Doornewaard‐ten HertogNE , UilSM , KerstjensHAM , Van denBergJWK . Azithromycin and cough‐specific health status in patients with chronic obstructive pulmonary disease and chronic cough: a randomised controlled trial. Respiratory Research2013;14(1):125. BerkhofFF , TenHertogNE , UilSM , KerstjensHAM , Van DenBergJK , CACTUS study group. Randomized controlled trial of prophylactic azithromycin on cough‐specific health status in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2013;187:A2449. ">Berkhof 2013</a>; <a href="./references#CD009764-bbs2-0005" title="HeZY , OuLM , ZhangJQ , BaiJ , LiuGN , LiMH , et al. Effect of 6 months of erythromycin treatment on inflammatory cells in induced sputum and exacerbations in chronic obstructive pulmonary disease. Respiration2010;80:445‐52. ">He 2010</a>; <a href="./references#CD009764-bbs2-0006" title="MygindLH , PedersenC , VestboJ , ChristensenJJ , Frimodt‐MollerN , KristiansenIS , et al. A randomised, placebo‐controlled 3 years study of prophylactic azithromycin in 575 patients with chronic obstructive pulmonary disease. European Respiratory Society 20th Annual Congress; 2010 Sep 18‐22; Barcelona. 2010. ">Mygind 2010</a>; <a href="./references#CD009764-bbs2-0009" title="SeemungalTA , WilkinsonTM , HurstJR , PereraWR , SapsfordRJ , WedzichaJA . Long‐term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. American Journal of Respiratory and Critical Care Medicine2008;178:1139‐47. ">Seemungal 2008</a>; <a href="./references#CD009764-bbs2-0010" title="SethiS , JonesPW , TheronMS , MiravitllesM , RubinsteinE , WedzichaJA , et al. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized control trial. Respiratory Research2010;11:10. ">Sethi 2010</a>; <a href="./references#CD009764-bbs2-0011" title="ShafuddinE , MillsGD , HolmesMD , PoolePJ , MullinsPR , BlackPN . A double‐blind, randomised, placebo‐controlled study of roxithromycin and doxycycline combination, roxithromycin alone, or matching placebo for 12 weeks in adults with frequent exacerbations of chronic obstructive pulmonary disease. Journal of Negative Results in Biomedicine2015;14:15. [DOI: 10.1186/s12952‐015‐0034‐8] ">Shafuddin 2015</a>; <a href="./references#CD009764-bbs2-0012" title="SimpsonJL , PowellH , BainesKJ , MilneD , CoxsonHO , HansbroPM , et al. The effect of azithromycin in adults with stable neutrophilic COPD: a double blind randomised, placebo controlled trial. PLOS One2014;9(8):e105609. ">Simpson 2014</a>; <a href="./references#CD009764-bbs2-0015" title="DjaminRS , UzunS , ErmensAAM , KerstensR , HoogstedenHC , AertsJGJV , et al. Which predictors in COPD patients with the frequent exacerbator phenotype predict the treatment response to maintenance therapy with azithromycin?. European Respiratory Journal2016;48:PA3713. UzunS , DjaminRS , AertsJGJV , Van DerEerdenMM . Patients with COPD Gold C &amp; D: the effect of long‐term treatment with azithromycin on exacerbation risk assessed by the Gold Framework. American Journal of Respiratory and Critical Care Medicine2014;189:A5967. UzunS , DjaminRS , KluytmansJA , MulderPG , Van't VeerNE , ErmensAA , et al. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double‐blind,placebo‐controlled trial. Lancet Respiratory Medicine2014;2(5):361‐8. UzunS , DjaminRS , MulderPGH , KluytmansJAJW , PelleAJ , Van't VeerNE , et al. Effect of azithromycin maintenance treatment in patients with frequent exacerbations of COPD (columbus): a randomized, double‐blind, placebo‐controlled trial. American Journal of Respiratory and Critical Care Medicine2014;189:A2884. ">Uzun 2014</a>), which we rated as low risk. <a href="./references#CD009764-bbs2-0013" title="SuzukiT , YaniM , YamayaM , Satoh NakagawaT , SekizawaK , IshidaS , et al. Erythromycin and common cold in COPD. Chest2001;120:730‐3. ">Suzuki 2001</a> was not blinded and therefore judged to be at high risk of bias. <a href="./references#CD009764-bbs2-0004" title="BrillS , JamesP , CuthbertsonL , CooksonW , MoffattM , WedzichaJ . Haemophilus dominance of the stable COPD microbiome is associated with greater bacterial load and inflammation and is modulated by prophylactic antibiotic therapy. European Respiratory Journal2015;46:OA4746. BrillS , LawM , AllinsonJ , El‐EmirE , McHughT , DonaldsonG , et al. Bacterial resistance induction with prophylactic antibiotics in COPD. European Respiratory Journal2014;44:P4731. BrillSE , LawM , El‐EmirE , AllinsonJP , JamesP , MaddoxV , et al. Effects of different antibiotic classes on airway bacteria in stable COPD using culture and molecular techniques: a randomised controlled trial. Thorax2015;70(10):930‐8. BrillSE , LawM , El‐EmirE , AllinsonP , NazarethI , DonaldsonGC , et al. Effect of antibiotics on airway bacteria in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2014;198:A2874. ">Brill 2015</a> was a single‐blinded study with only the participants being blinded to treatment allocation, so we judged this to be at unclear risk of bias. Blinding of participants and personnel was not described in <a href="./references#CD009764-bbs2-0014" title="TanC , HuangH , ZhangJ , HeZ , ZhongX , BaiJ . Effects of low‐dose and long‐term treatment with erythromycin on IL‐17 and IL‐23 in peripheral blood and induced sputum in patients with stable chronic obstructive pulmonary disease. Chest2016;149:387A. TanC , HuangH , ZhangJ , HeZ , ZhongX , BaiJ . Effects of low‐dose and long‐term treatment with erythromycin on interleukin‐17 and interleukin‐23 in peripheral blood and induced sputum in patients with stable chronic obstructive pulmonary disease. Mediators of Inflammation2016:4173962. [DOI: 10.1155/2016/4173962] ">Tan 2016</a> or <a href="./references#CD009764-bbs2-0016" title="WangP , YangJ , YangY , DingZ . Effect of azithromycin in combination with simvastatin in the treatment of chronic obstructive pulmonary disease complicated by pulmonary arterial hypertension. Pakistan Journal of Medicine Science2017;33(2):260‐4. ">Wang 2017</a> and despite multiple attempts by email to obtain further information from the corresponding authors, no responses have been received. We therefore judged these studies to be at high risk of bias. </p> <p>Blinding of the outcome assessment (detection bias) was well described in six of the included studies (<a href="./references#CD009764-bbs2-0001" title="AlbertRK , ConnettJ , BaileyWC , CasaburiR , CooperJA , CrinerGJ , et al. Azithromycin for prevention of exacerbations of COPD. New England Journal of Medicine2011;365:689‐98. HanMK , TayobN , MurrayS , DransfieldMT , WashkoG , ScanlonPD , et al. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. American Journal of Respiratory and Critical Care Medicine2014;189(12):1503‐8. MartinezFJ , ConnettJ , VoelkerH , CrinerGJ , HanMK , MakeBJ , et al. Chronic azithromycin therapy decreases the risk of re‐hospitalization in patients with COPD. American Journal of Respiratory and Critical Care Medicine2013;187:A4383. O'ReillyPJ , JacksonPL , WellsJM , DransfieldMT , ScanlonPD , Blalock , JE . Sputum PGP is reduced by azithromycin treatment in patients with COPD and correlates with exacerbations. BMJ Open2013;3(12):e004140. WoodruffPG , ChatilaW , ConnettJE , CrinerGJ , CurtisJL , DransfieldMT , et al. Tumour necrosis factor receptor‐75 and risk of COPD exacerbation in the azithromycin trial. European Respiratory Journal2014;43:295–8. ">Albert 2011</a>; <a href="./references#CD009764-bbs2-0003" title="BerkhofFF , Doornewaard‐ten HertogNE , UilSM , KerstjensHAM , Van denBergJWK . Azithromycin and cough‐specific health status in patients with chronic obstructive pulmonary disease and chronic cough: a randomised controlled trial. Respiratory Research2013;14(1):125. BerkhofFF , TenHertogNE , UilSM , KerstjensHAM , Van DenBergJK , CACTUS study group. Randomized controlled trial of prophylactic azithromycin on cough‐specific health status in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2013;187:A2449. ">Berkhof 2013</a>; <a href="./references#CD009764-bbs2-0009" title="SeemungalTA , WilkinsonTM , HurstJR , PereraWR , SapsfordRJ , WedzichaJA . Long‐term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. American Journal of Respiratory and Critical Care Medicine2008;178:1139‐47. ">Seemungal 2008</a>; <a href="./references#CD009764-bbs2-0011" title="ShafuddinE , MillsGD , HolmesMD , PoolePJ , MullinsPR , BlackPN . A double‐blind, randomised, placebo‐controlled study of roxithromycin and doxycycline combination, roxithromycin alone, or matching placebo for 12 weeks in adults with frequent exacerbations of chronic obstructive pulmonary disease. Journal of Negative Results in Biomedicine2015;14:15. [DOI: 10.1186/s12952‐015‐0034‐8] ">Shafuddin 2015</a>; <a href="./references#CD009764-bbs2-0012" title="SimpsonJL , PowellH , BainesKJ , MilneD , CoxsonHO , HansbroPM , et al. The effect of azithromycin in adults with stable neutrophilic COPD: a double blind randomised, placebo controlled trial. PLOS One2014;9(8):e105609. ">Simpson 2014</a>; <a href="./references#CD009764-bbs2-0015" title="DjaminRS , UzunS , ErmensAAM , KerstensR , HoogstedenHC , AertsJGJV , et al. Which predictors in COPD patients with the frequent exacerbator phenotype predict the treatment response to maintenance therapy with azithromycin?. European Respiratory Journal2016;48:PA3713. UzunS , DjaminRS , AertsJGJV , Van DerEerdenMM . Patients with COPD Gold C &amp; D: the effect of long‐term treatment with azithromycin on exacerbation risk assessed by the Gold Framework. American Journal of Respiratory and Critical Care Medicine2014;189:A5967. UzunS , DjaminRS , KluytmansJA , MulderPG , Van't VeerNE , ErmensAA , et al. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double‐blind,placebo‐controlled trial. Lancet Respiratory Medicine2014;2(5):361‐8. UzunS , DjaminRS , MulderPGH , KluytmansJAJW , PelleAJ , Van't VeerNE , et al. Effect of azithromycin maintenance treatment in patients with frequent exacerbations of COPD (columbus): a randomized, double‐blind, placebo‐controlled trial. American Journal of Respiratory and Critical Care Medicine2014;189:A2884. ">Uzun 2014</a>), while four were judged to be at a high risk of bias (<a href="./references#CD009764-bbs2-0004" title="BrillS , JamesP , CuthbertsonL , CooksonW , MoffattM , WedzichaJ . Haemophilus dominance of the stable COPD microbiome is associated with greater bacterial load and inflammation and is modulated by prophylactic antibiotic therapy. European Respiratory Journal2015;46:OA4746. BrillS , LawM , AllinsonJ , El‐EmirE , McHughT , DonaldsonG , et al. Bacterial resistance induction with prophylactic antibiotics in COPD. European Respiratory Journal2014;44:P4731. BrillSE , LawM , El‐EmirE , AllinsonJP , JamesP , MaddoxV , et al. Effects of different antibiotic classes on airway bacteria in stable COPD using culture and molecular techniques: a randomised controlled trial. Thorax2015;70(10):930‐8. BrillSE , LawM , El‐EmirE , AllinsonP , NazarethI , DonaldsonGC , et al. Effect of antibiotics on airway bacteria in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2014;198:A2874. ">Brill 2015</a>; <a href="./references#CD009764-bbs2-0013" title="SuzukiT , YaniM , YamayaM , Satoh NakagawaT , SekizawaK , IshidaS , et al. Erythromycin and common cold in COPD. Chest2001;120:730‐3. ">Suzuki 2001</a>; <a href="./references#CD009764-bbs2-0014" title="TanC , HuangH , ZhangJ , HeZ , ZhongX , BaiJ . Effects of low‐dose and long‐term treatment with erythromycin on IL‐17 and IL‐23 in peripheral blood and induced sputum in patients with stable chronic obstructive pulmonary disease. Chest2016;149:387A. TanC , HuangH , ZhangJ , HeZ , ZhongX , BaiJ . Effects of low‐dose and long‐term treatment with erythromycin on interleukin‐17 and interleukin‐23 in peripheral blood and induced sputum in patients with stable chronic obstructive pulmonary disease. Mediators of Inflammation2016:4173962. [DOI: 10.1155/2016/4173962] ">Tan 2016</a>; <a href="./references#CD009764-bbs2-0016" title="WangP , YangJ , YangY , DingZ . Effect of azithromycin in combination with simvastatin in the treatment of chronic obstructive pulmonary disease complicated by pulmonary arterial hypertension. Pakistan Journal of Medicine Science2017;33(2):260‐4. ">Wang 2017</a>), and the remaining four were unclear. </p> </section> <section id="CD009764-sec-0068"> <h4 class="title">Incomplete outcome data</h4> <p>Outcomes of the study participants were well described using either a CONSORT diagram (<a href="./references#CD009764-bbs2-0001" title="AlbertRK , ConnettJ , BaileyWC , CasaburiR , CooperJA , CrinerGJ , et al. Azithromycin for prevention of exacerbations of COPD. New England Journal of Medicine2011;365:689‐98. HanMK , TayobN , MurrayS , DransfieldMT , WashkoG , ScanlonPD , et al. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. American Journal of Respiratory and Critical Care Medicine2014;189(12):1503‐8. MartinezFJ , ConnettJ , VoelkerH , CrinerGJ , HanMK , MakeBJ , et al. Chronic azithromycin therapy decreases the risk of re‐hospitalization in patients with COPD. American Journal of Respiratory and Critical Care Medicine2013;187:A4383. O'ReillyPJ , JacksonPL , WellsJM , DransfieldMT , ScanlonPD , Blalock , JE . Sputum PGP is reduced by azithromycin treatment in patients with COPD and correlates with exacerbations. BMJ Open2013;3(12):e004140. WoodruffPG , ChatilaW , ConnettJE , CrinerGJ , CurtisJL , DransfieldMT , et al. Tumour necrosis factor receptor‐75 and risk of COPD exacerbation in the azithromycin trial. European Respiratory Journal2014;43:295–8. ">Albert 2011</a>; <a href="./references#CD009764-bbs2-0003" title="BerkhofFF , Doornewaard‐ten HertogNE , UilSM , KerstjensHAM , Van denBergJWK . Azithromycin and cough‐specific health status in patients with chronic obstructive pulmonary disease and chronic cough: a randomised controlled trial. Respiratory Research2013;14(1):125. BerkhofFF , TenHertogNE , UilSM , KerstjensHAM , Van DenBergJK , CACTUS study group. Randomized controlled trial of prophylactic azithromycin on cough‐specific health status in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2013;187:A2449. ">Berkhof 2013</a>; <a href="./references#CD009764-bbs2-0004" title="BrillS , JamesP , CuthbertsonL , CooksonW , MoffattM , WedzichaJ . Haemophilus dominance of the stable COPD microbiome is associated with greater bacterial load and inflammation and is modulated by prophylactic antibiotic therapy. European Respiratory Journal2015;46:OA4746. BrillS , LawM , AllinsonJ , El‐EmirE , McHughT , DonaldsonG , et al. Bacterial resistance induction with prophylactic antibiotics in COPD. European Respiratory Journal2014;44:P4731. BrillSE , LawM , El‐EmirE , AllinsonJP , JamesP , MaddoxV , et al. Effects of different antibiotic classes on airway bacteria in stable COPD using culture and molecular techniques: a randomised controlled trial. Thorax2015;70(10):930‐8. BrillSE , LawM , El‐EmirE , AllinsonP , NazarethI , DonaldsonGC , et al. Effect of antibiotics on airway bacteria in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2014;198:A2874. ">Brill 2015</a>; <a href="./references#CD009764-bbs2-0005" title="HeZY , OuLM , ZhangJQ , BaiJ , LiuGN , LiMH , et al. Effect of 6 months of erythromycin treatment on inflammatory cells in induced sputum and exacerbations in chronic obstructive pulmonary disease. Respiration2010;80:445‐52. ">He 2010</a>; <a href="./references#CD009764-bbs2-0009" title="SeemungalTA , WilkinsonTM , HurstJR , PereraWR , SapsfordRJ , WedzichaJA . Long‐term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. American Journal of Respiratory and Critical Care Medicine2008;178:1139‐47. ">Seemungal 2008</a>; <a href="./references#CD009764-bbs2-0010" title="SethiS , JonesPW , TheronMS , MiravitllesM , RubinsteinE , WedzichaJA , et al. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized control trial. Respiratory Research2010;11:10. ">Sethi 2010</a>; <a href="./references#CD009764-bbs2-0011" title="ShafuddinE , MillsGD , HolmesMD , PoolePJ , MullinsPR , BlackPN . A double‐blind, randomised, placebo‐controlled study of roxithromycin and doxycycline combination, roxithromycin alone, or matching placebo for 12 weeks in adults with frequent exacerbations of chronic obstructive pulmonary disease. Journal of Negative Results in Biomedicine2015;14:15. [DOI: 10.1186/s12952‐015‐0034‐8] ">Shafuddin 2015</a>; <a href="./references#CD009764-bbs2-0012" title="SimpsonJL , PowellH , BainesKJ , MilneD , CoxsonHO , HansbroPM , et al. The effect of azithromycin in adults with stable neutrophilic COPD: a double blind randomised, placebo controlled trial. PLOS One2014;9(8):e105609. ">Simpson 2014</a>; <a href="./references#CD009764-bbs2-0015" title="DjaminRS , UzunS , ErmensAAM , KerstensR , HoogstedenHC , AertsJGJV , et al. Which predictors in COPD patients with the frequent exacerbator phenotype predict the treatment response to maintenance therapy with azithromycin?. European Respiratory Journal2016;48:PA3713. UzunS , DjaminRS , AertsJGJV , Van DerEerdenMM . Patients with COPD Gold C &amp; D: the effect of long‐term treatment with azithromycin on exacerbation risk assessed by the Gold Framework. American Journal of Respiratory and Critical Care Medicine2014;189:A5967. UzunS , DjaminRS , KluytmansJA , MulderPG , Van't VeerNE , ErmensAA , et al. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double‐blind,placebo‐controlled trial. Lancet Respiratory Medicine2014;2(5):361‐8. UzunS , DjaminRS , MulderPGH , KluytmansJAJW , PelleAJ , Van't VeerNE , et al. Effect of azithromycin maintenance treatment in patients with frequent exacerbations of COPD (columbus): a randomized, double‐blind, placebo‐controlled trial. American Journal of Respiratory and Critical Care Medicine2014;189:A2884. ">Uzun 2014</a>) or by a dedicated paragraph or table (<a href="./references#CD009764-bbs2-0002" title="BanerjeeD , HoneybourneD , KhairOA . The effect of oral Clarithromycin on bronchial airway inflammation in moderate‐to‐severe stable COPD: a randomised controlled trial. Treatments in Respiratory Medicine2004;3:59‐65. BanerjeeD , KhairO , HoneybourneD . The effect of oral clarithromycin on health status and sputum bacteriology in stable COPD. Respiratory Medicine2005;99:208‐15. ">Banerjee 2005</a>; <a href="./references#CD009764-bbs2-0013" title="SuzukiT , YaniM , YamayaM , Satoh NakagawaT , SekizawaK , IshidaS , et al. Erythromycin and common cold in COPD. Chest2001;120:730‐3. ">Suzuki 2001</a>; <a href="./references#CD009764-bbs2-0014" title="TanC , HuangH , ZhangJ , HeZ , ZhongX , BaiJ . Effects of low‐dose and long‐term treatment with erythromycin on IL‐17 and IL‐23 in peripheral blood and induced sputum in patients with stable chronic obstructive pulmonary disease. Chest2016;149:387A. TanC , HuangH , ZhangJ , HeZ , ZhongX , BaiJ . Effects of low‐dose and long‐term treatment with erythromycin on interleukin‐17 and interleukin‐23 in peripheral blood and induced sputum in patients with stable chronic obstructive pulmonary disease. Mediators of Inflammation2016:4173962. [DOI: 10.1155/2016/4173962] ">Tan 2016</a>). Overall, withdrawal rates were similar between both studies and treatments and we judged these studies to be at low risk of attrition bias, with the exception of four studies (<a href="./references#CD009764-bbs2-0001" title="AlbertRK , ConnettJ , BaileyWC , CasaburiR , CooperJA , CrinerGJ , et al. Azithromycin for prevention of exacerbations of COPD. New England Journal of Medicine2011;365:689‐98. HanMK , TayobN , MurrayS , DransfieldMT , WashkoG , ScanlonPD , et al. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. American Journal of Respiratory and Critical Care Medicine2014;189(12):1503‐8. MartinezFJ , ConnettJ , VoelkerH , CrinerGJ , HanMK , MakeBJ , et al. Chronic azithromycin therapy decreases the risk of re‐hospitalization in patients with COPD. American Journal of Respiratory and Critical Care Medicine2013;187:A4383. O'ReillyPJ , JacksonPL , WellsJM , DransfieldMT , ScanlonPD , Blalock , JE . Sputum PGP is reduced by azithromycin treatment in patients with COPD and correlates with exacerbations. BMJ Open2013;3(12):e004140. WoodruffPG , ChatilaW , ConnettJE , CrinerGJ , CurtisJL , DransfieldMT , et al. Tumour necrosis factor receptor‐75 and risk of COPD exacerbation in the azithromycin trial. European Respiratory Journal2014;43:295–8. ">Albert 2011</a>; <a href="./references#CD009764-bbs2-0010" title="SethiS , JonesPW , TheronMS , MiravitllesM , RubinsteinE , WedzichaJA , et al. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized control trial. Respiratory Research2010;11:10. ">Sethi 2010</a>; <a href="./references#CD009764-bbs2-0011" title="ShafuddinE , MillsGD , HolmesMD , PoolePJ , MullinsPR , BlackPN . A double‐blind, randomised, placebo‐controlled study of roxithromycin and doxycycline combination, roxithromycin alone, or matching placebo for 12 weeks in adults with frequent exacerbations of chronic obstructive pulmonary disease. Journal of Negative Results in Biomedicine2015;14:15. [DOI: 10.1186/s12952‐015‐0034‐8] ">Shafuddin 2015</a>; <a href="./references#CD009764-bbs2-0014" title="TanC , HuangH , ZhangJ , HeZ , ZhongX , BaiJ . Effects of low‐dose and long‐term treatment with erythromycin on IL‐17 and IL‐23 in peripheral blood and induced sputum in patients with stable chronic obstructive pulmonary disease. Chest2016;149:387A. TanC , HuangH , ZhangJ , HeZ , ZhongX , BaiJ . Effects of low‐dose and long‐term treatment with erythromycin on interleukin‐17 and interleukin‐23 in peripheral blood and induced sputum in patients with stable chronic obstructive pulmonary disease. Mediators of Inflammation2016:4173962. [DOI: 10.1155/2016/4173962] ">Tan 2016</a>). </p> <p>In both <a href="./references#CD009764-bbs2-0001" title="AlbertRK , ConnettJ , BaileyWC , CasaburiR , CooperJA , CrinerGJ , et al. Azithromycin for prevention of exacerbations of COPD. New England Journal of Medicine2011;365:689‐98. HanMK , TayobN , MurrayS , DransfieldMT , WashkoG , ScanlonPD , et al. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. American Journal of Respiratory and Critical Care Medicine2014;189(12):1503‐8. MartinezFJ , ConnettJ , VoelkerH , CrinerGJ , HanMK , MakeBJ , et al. Chronic azithromycin therapy decreases the risk of re‐hospitalization in patients with COPD. American Journal of Respiratory and Critical Care Medicine2013;187:A4383. O'ReillyPJ , JacksonPL , WellsJM , DransfieldMT , ScanlonPD , Blalock , JE . Sputum PGP is reduced by azithromycin treatment in patients with COPD and correlates with exacerbations. BMJ Open2013;3(12):e004140. WoodruffPG , ChatilaW , ConnettJE , CrinerGJ , CurtisJL , DransfieldMT , et al. Tumour necrosis factor receptor‐75 and risk of COPD exacerbation in the azithromycin trial. European Respiratory Journal2014;43:295–8. ">Albert 2011</a> and <a href="./references#CD009764-bbs2-0010" title="SethiS , JonesPW , TheronMS , MiravitllesM , RubinsteinE , WedzichaJA , et al. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized control trial. Respiratory Research2010;11:10. ">Sethi 2010</a>, we noted the reason for missing health‐related quality of life (HRQoL) data was not given, and we therefore rated the studies at unclear risk. We also judged <a href="./references#CD009764-bbs2-0011" title="ShafuddinE , MillsGD , HolmesMD , PoolePJ , MullinsPR , BlackPN . A double‐blind, randomised, placebo‐controlled study of roxithromycin and doxycycline combination, roxithromycin alone, or matching placebo for 12 weeks in adults with frequent exacerbations of chronic obstructive pulmonary disease. Journal of Negative Results in Biomedicine2015;14:15. [DOI: 10.1186/s12952‐015‐0034‐8] ">Shafuddin 2015</a> to be at unclear risk because more participants dropped out of the combined antibiotic treatment arm compared to the single antibiotic and placebo arms (21 versus 13 versus 10), although all randomised participants were included in the intention‐to‐treat analysis. We judged <a href="./references#CD009764-bbs2-0014" title="TanC , HuangH , ZhangJ , HeZ , ZhongX , BaiJ . Effects of low‐dose and long‐term treatment with erythromycin on IL‐17 and IL‐23 in peripheral blood and induced sputum in patients with stable chronic obstructive pulmonary disease. Chest2016;149:387A. TanC , HuangH , ZhangJ , HeZ , ZhongX , BaiJ . Effects of low‐dose and long‐term treatment with erythromycin on interleukin‐17 and interleukin‐23 in peripheral blood and induced sputum in patients with stable chronic obstructive pulmonary disease. Mediators of Inflammation2016:4173962. [DOI: 10.1155/2016/4173962] ">Tan 2016</a> to be at unclear risk because the authors did not describe how many participants were analysed at each time point. </p> <p><a href="./references#CD009764-bbs2-0006" title="MygindLH , PedersenC , VestboJ , ChristensenJJ , Frimodt‐MollerN , KristiansenIS , et al. A randomised, placebo‐controlled 3 years study of prophylactic azithromycin in 575 patients with chronic obstructive pulmonary disease. European Respiratory Society 20th Annual Congress; 2010 Sep 18‐22; Barcelona. 2010. ">Mygind 2010</a> was a conference presentation of unpublished data and thus we had limited information on which to judge the attrition bias and we therefore rated the study to be at unclear risk. <a href="./references#CD009764-bbs2-0016" title="WangP , YangJ , YangY , DingZ . Effect of azithromycin in combination with simvastatin in the treatment of chronic obstructive pulmonary disease complicated by pulmonary arterial hypertension. Pakistan Journal of Medicine Science2017;33(2):260‐4. ">Wang 2017</a> also did not include any information on the outcomes of study participants and we judged it to be at unclear risk. </p> </section> <section id="CD009764-sec-0069"> <h4 class="title">Selective reporting</h4> <p>Twelve of the included studies reported all prespecified primary and secondary outcomes and these were judged to be at low risk of bias. For <a href="./references#CD009764-bbs2-0014" title="TanC , HuangH , ZhangJ , HeZ , ZhongX , BaiJ . Effects of low‐dose and long‐term treatment with erythromycin on IL‐17 and IL‐23 in peripheral blood and induced sputum in patients with stable chronic obstructive pulmonary disease. Chest2016;149:387A. TanC , HuangH , ZhangJ , HeZ , ZhongX , BaiJ . Effects of low‐dose and long‐term treatment with erythromycin on interleukin‐17 and interleukin‐23 in peripheral blood and induced sputum in patients with stable chronic obstructive pulmonary disease. Mediators of Inflammation2016:4173962. [DOI: 10.1155/2016/4173962] ">Tan 2016</a>, we were unable to identify a prospective trial registration or protocol so it was not clear if outcomes of interest for this review may have been collected but not reported (e.g. serious adverse events, exacerbations, and quality of life). We identified one study as being at high risk for selective reporting bias (<a href="./references#CD009764-bbs2-0016" title="WangP , YangJ , YangY , DingZ . Effect of azithromycin in combination with simvastatin in the treatment of chronic obstructive pulmonary disease complicated by pulmonary arterial hypertension. Pakistan Journal of Medicine Science2017;33(2):260‐4. ">Wang 2017</a>). See <a href="./references#CD009764-sec-0123" title="">Characteristics of included studies</a> to view bias tables for more details. </p> </section> <section id="CD009764-sec-0070"> <h4 class="title">Other potential sources of bias</h4> <p>No other potential sources of bias were identified.</p> </section> </section> <section id="CD009764-sec-0071"> <h3 class="title" id="CD009764-sec-0071">Effects of interventions</h3> <p>See: <a href="./full#CD009764-tbl-0001"><b>Summary of findings for the main comparison</b> Antibiotics versus placebo for COPD</a> </p> <p>An overview of the results together with a summary of the our confidence in the evidence per outcome is presented in <a href="./full#CD009764-tbl-0001">summary of findings Table for the main comparison</a>. </p> <section id="CD009764-sec-0072"> <h4 class="title">Primary outcome: number of participants with one or more exacerbations</h4> <p>We included eight studies in the meta‐analysis of the number of participants experiencing one or more exacerbations of COPD (<a href="./references#CD009764-bbs2-0001" title="AlbertRK , ConnettJ , BaileyWC , CasaburiR , CooperJA , CrinerGJ , et al. Azithromycin for prevention of exacerbations of COPD. New England Journal of Medicine2011;365:689‐98. HanMK , TayobN , MurrayS , DransfieldMT , WashkoG , ScanlonPD , et al. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. American Journal of Respiratory and Critical Care Medicine2014;189(12):1503‐8. MartinezFJ , ConnettJ , VoelkerH , CrinerGJ , HanMK , MakeBJ , et al. Chronic azithromycin therapy decreases the risk of re‐hospitalization in patients with COPD. American Journal of Respiratory and Critical Care Medicine2013;187:A4383. O'ReillyPJ , JacksonPL , WellsJM , DransfieldMT , ScanlonPD , Blalock , JE . Sputum PGP is reduced by azithromycin treatment in patients with COPD and correlates with exacerbations. BMJ Open2013;3(12):e004140. WoodruffPG , ChatilaW , ConnettJE , CrinerGJ , CurtisJL , DransfieldMT , et al. Tumour necrosis factor receptor‐75 and risk of COPD exacerbation in the azithromycin trial. European Respiratory Journal2014;43:295–8. ">Albert 2011</a>; <a href="./references#CD009764-bbs2-0003" title="BerkhofFF , Doornewaard‐ten HertogNE , UilSM , KerstjensHAM , Van denBergJWK . Azithromycin and cough‐specific health status in patients with chronic obstructive pulmonary disease and chronic cough: a randomised controlled trial. Respiratory Research2013;14(1):125. BerkhofFF , TenHertogNE , UilSM , KerstjensHAM , Van DenBergJK , CACTUS study group. Randomized controlled trial of prophylactic azithromycin on cough‐specific health status in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2013;187:A2449. ">Berkhof 2013</a>; <a href="./references#CD009764-bbs2-0004" title="BrillS , JamesP , CuthbertsonL , CooksonW , MoffattM , WedzichaJ . Haemophilus dominance of the stable COPD microbiome is associated with greater bacterial load and inflammation and is modulated by prophylactic antibiotic therapy. European Respiratory Journal2015;46:OA4746. BrillS , LawM , AllinsonJ , El‐EmirE , McHughT , DonaldsonG , et al. Bacterial resistance induction with prophylactic antibiotics in COPD. European Respiratory Journal2014;44:P4731. BrillSE , LawM , El‐EmirE , AllinsonJP , JamesP , MaddoxV , et al. Effects of different antibiotic classes on airway bacteria in stable COPD using culture and molecular techniques: a randomised controlled trial. Thorax2015;70(10):930‐8. BrillSE , LawM , El‐EmirE , AllinsonP , NazarethI , DonaldsonGC , et al. Effect of antibiotics on airway bacteria in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2014;198:A2874. ">Brill 2015</a>; <a href="./references#CD009764-bbs2-0005" title="HeZY , OuLM , ZhangJQ , BaiJ , LiuGN , LiMH , et al. Effect of 6 months of erythromycin treatment on inflammatory cells in induced sputum and exacerbations in chronic obstructive pulmonary disease. Respiration2010;80:445‐52. ">He 2010</a>; <a href="./references#CD009764-bbs2-0009" title="SeemungalTA , WilkinsonTM , HurstJR , PereraWR , SapsfordRJ , WedzichaJA . Long‐term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. American Journal of Respiratory and Critical Care Medicine2008;178:1139‐47. ">Seemungal 2008</a>; <a href="./references#CD009764-bbs2-0010" title="SethiS , JonesPW , TheronMS , MiravitllesM , RubinsteinE , WedzichaJA , et al. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized control trial. Respiratory Research2010;11:10. ">Sethi 2010</a>; <a href="./references#CD009764-bbs2-0012" title="SimpsonJL , PowellH , BainesKJ , MilneD , CoxsonHO , HansbroPM , et al. The effect of azithromycin in adults with stable neutrophilic COPD: a double blind randomised, placebo controlled trial. PLOS One2014;9(8):e105609. ">Simpson 2014</a>; <a href="./references#CD009764-bbs2-0015" title="DjaminRS , UzunS , ErmensAAM , KerstensR , HoogstedenHC , AertsJGJV , et al. Which predictors in COPD patients with the frequent exacerbator phenotype predict the treatment response to maintenance therapy with azithromycin?. European Respiratory Journal2016;48:PA3713. UzunS , DjaminRS , AertsJGJV , Van DerEerdenMM . Patients with COPD Gold C &amp; D: the effect of long‐term treatment with azithromycin on exacerbation risk assessed by the Gold Framework. American Journal of Respiratory and Critical Care Medicine2014;189:A5967. UzunS , DjaminRS , KluytmansJA , MulderPG , Van't VeerNE , ErmensAA , et al. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double‐blind,placebo‐controlled trial. Lancet Respiratory Medicine2014;2(5):361‐8. UzunS , DjaminRS , MulderPGH , KluytmansJAJW , PelleAJ , Van't VeerNE , et al. Effect of azithromycin maintenance treatment in patients with frequent exacerbations of COPD (columbus): a randomized, double‐blind, placebo‐controlled trial. American Journal of Respiratory and Critical Care Medicine2014;189:A2884. ">Uzun 2014</a>). <a href="./references#CD009764-bbs2-0013" title="SuzukiT , YaniM , YamayaM , Satoh NakagawaT , SekizawaK , IshidaS , et al. Erythromycin and common cold in COPD. Chest2001;120:730‐3. ">Suzuki 2001</a> was not included in the meta‐analysis as this study was not blinded. </p> <p>We found that prophylactic antibiotics reduce the overall odds of having one or more exacerbations over the treatment period compared to placebo (OR 0.57, 95% CI 0.42 to 0.78; participants = 2716; studies = 8; I<sup>2</sup> = 42%; moderate‐quality evidence, <a href="./references#CD009764-fig-0007" title="">Analysis 1.1</a>; <a href="#CD009764-fig-0003">Figure 3</a>). This equates to a 13.9 percentage‐point reduction in absolute risk. In the control group, 61 people out of 100 had one or more exacerbations compared to 47 (95% CI 39 to 55) out of 100 in the antibiotic group (<a href="#CD009764-fig-0004">Figure 4</a>). The number needed to treat for an additional beneficial outcome (NNTB) was 8 (95% CI 5 to 17). </p> <div class="figure" id="CD009764-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Antibiotics versus placebo, outcome: 1.1 Number of people with one or more exacerbations." data-id="CD009764-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_n/nCD009764-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Antibiotics versus placebo, outcome: 1.1 Number of people with one or more exacerbations. </p> </div> </div> </div> <div class="figure" id="CD009764-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="In the control group, 61 people out of 100 had one or more exacerbations over 12 weeks to 12 months, compared to 47 (95% CI 39 to 55) out of 100 for the antibiotic treatment group (Analysis 1.1)" data-id="CD009764-fig-0004" src="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_n/nCD009764-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>In the control group, 61 people out of 100 had one or more exacerbations over 12 weeks to 12 months, compared to 47 (95% CI 39 to 55) out of 100 for the antibiotic treatment group (<a href="./references#CD009764-fig-0007" title="">Analysis 1.1</a>) </p> </div> </div> </div> <p>The heterogeneity of the eight studies analysed for this outcome was moderate (I<sup>2</sup> = 42%), which has been explored using pre‐planned subgroup analyses. </p> <p>Of these studies, five (including one arm of <a href="./references#CD009764-bbs2-0004" title="BrillS , JamesP , CuthbertsonL , CooksonW , MoffattM , WedzichaJ . Haemophilus dominance of the stable COPD microbiome is associated with greater bacterial load and inflammation and is modulated by prophylactic antibiotic therapy. European Respiratory Journal2015;46:OA4746. BrillS , LawM , AllinsonJ , El‐EmirE , McHughT , DonaldsonG , et al. Bacterial resistance induction with prophylactic antibiotics in COPD. European Respiratory Journal2014;44:P4731. BrillSE , LawM , El‐EmirE , AllinsonJP , JamesP , MaddoxV , et al. Effects of different antibiotic classes on airway bacteria in stable COPD using culture and molecular techniques: a randomised controlled trial. Thorax2015;70(10):930‐8. BrillSE , LawM , El‐EmirE , AllinsonP , NazarethI , DonaldsonGC , et al. Effect of antibiotics on airway bacteria in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2014;198:A2874. ">Brill 2015</a>), were of continuous antibiotic prophylaxis. Compared to placebo, continuous antibiotics reduced the number of participants experiencing one or more exacerbations (OR 0.53, 95% CI 0.36 to 0.79; participants = 1325; studies = 5; I<sup>2</sup> = 19%; <a href="./references#CD009764-fig-0007" title="">Analysis 1.1</a>). This equated to a number needed to treat for an additional beneficial outcome of 7 (95% CI 5 to 19). </p> <p>Similarly, the analysis of three studies investigating intermittent antibiotic regimens (including one arm of <a href="./references#CD009764-bbs2-0004" title="BrillS , JamesP , CuthbertsonL , CooksonW , MoffattM , WedzichaJ . Haemophilus dominance of the stable COPD microbiome is associated with greater bacterial load and inflammation and is modulated by prophylactic antibiotic therapy. European Respiratory Journal2015;46:OA4746. BrillS , LawM , AllinsonJ , El‐EmirE , McHughT , DonaldsonG , et al. Bacterial resistance induction with prophylactic antibiotics in COPD. European Respiratory Journal2014;44:P4731. BrillSE , LawM , El‐EmirE , AllinsonJP , JamesP , MaddoxV , et al. Effects of different antibiotic classes on airway bacteria in stable COPD using culture and molecular techniques: a randomised controlled trial. Thorax2015;70(10):930‐8. BrillSE , LawM , El‐EmirE , AllinsonP , NazarethI , DonaldsonGC , et al. Effect of antibiotics on airway bacteria in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2014;198:A2874. ">Brill 2015</a>) suggested a benefit in favour of antibiotics compared to placebo in reducing the number of participants experiencing one or more exacerbations (OR 0.39, 95% CI 0.19 to 0.77; participants = 209; studies = 3; I<sup>2</sup> = 0%; <a href="./references#CD009764-fig-0007" title="">Analysis 1.1</a>).The number needed to treat to for an additional beneficial outcome was 5 (95% CI 3 to 17). </p> <p>Pulsed antibiotic regimens did not significantly reduce the number of people with at least one exacerbation (OR 0.85, 95% CI 0.68 to 1.07; participants = 1182; studies = 2; I<sup>2</sup> = 0% <a href="./references#CD009764-fig-0007" title="">Analysis 1.1</a>). </p> <p>The test for subgroup differences between continuous, intermittent, and pulsed regimens suggested a statistically significant difference between the groups (Chi² = 7.49, df = 2 (P = 0.02), I² = 73.3%). However, this was largely driven by the pulsed antibiotic subgroup, as when this subgroup was removed, the test for subgroup differences between the continuous and intermittent antibiotic groups was not significant (Chi² = 0.62, df = 1 (P = 0.43), I² = 0%). </p> <p>One study of 84 participants, that investigated continuous azithromycin versus placebo, reported the number of exacerbations of COPD that required hospitalisation (<a href="./references#CD009764-bbs2-0003" title="BerkhofFF , Doornewaard‐ten HertogNE , UilSM , KerstjensHAM , Van denBergJWK . Azithromycin and cough‐specific health status in patients with chronic obstructive pulmonary disease and chronic cough: a randomised controlled trial. Respiratory Research2013;14(1):125. BerkhofFF , TenHertogNE , UilSM , KerstjensHAM , Van DenBergJK , CACTUS study group. Randomized controlled trial of prophylactic azithromycin on cough‐specific health status in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2013;187:A2449. ">Berkhof 2013</a>). The number of events were too infrequent to draw any conclusion on the impact of prophylactic antibiotics in this situation. </p> </section> <section id="CD009764-sec-0073"> <h4 class="title">Primary outcome: rate of exacerbations per patient per year</h4> <p>The exacerbation rate was expressed as a rate ratio, which was calculated using the generic inverse variance (GIV) method in RevMan software. </p> <p>Five studies contributed data to this analysis, four investigating continuous regimens (<a href="./references#CD009764-bbs2-0001" title="AlbertRK , ConnettJ , BaileyWC , CasaburiR , CooperJA , CrinerGJ , et al. Azithromycin for prevention of exacerbations of COPD. New England Journal of Medicine2011;365:689‐98. HanMK , TayobN , MurrayS , DransfieldMT , WashkoG , ScanlonPD , et al. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. American Journal of Respiratory and Critical Care Medicine2014;189(12):1503‐8. MartinezFJ , ConnettJ , VoelkerH , CrinerGJ , HanMK , MakeBJ , et al. Chronic azithromycin therapy decreases the risk of re‐hospitalization in patients with COPD. American Journal of Respiratory and Critical Care Medicine2013;187:A4383. O'ReillyPJ , JacksonPL , WellsJM , DransfieldMT , ScanlonPD , Blalock , JE . Sputum PGP is reduced by azithromycin treatment in patients with COPD and correlates with exacerbations. BMJ Open2013;3(12):e004140. WoodruffPG , ChatilaW , ConnettJE , CrinerGJ , CurtisJL , DransfieldMT , et al. Tumour necrosis factor receptor‐75 and risk of COPD exacerbation in the azithromycin trial. European Respiratory Journal2014;43:295–8. ">Albert 2011</a>; <a href="./references#CD009764-bbs2-0005" title="HeZY , OuLM , ZhangJQ , BaiJ , LiuGN , LiMH , et al. Effect of 6 months of erythromycin treatment on inflammatory cells in induced sputum and exacerbations in chronic obstructive pulmonary disease. Respiration2010;80:445‐52. ">He 2010</a>; <a href="./references#CD009764-bbs2-0009" title="SeemungalTA , WilkinsonTM , HurstJR , PereraWR , SapsfordRJ , WedzichaJA . Long‐term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. American Journal of Respiratory and Critical Care Medicine2008;178:1139‐47. ">Seemungal 2008</a>; <a href="./references#CD009764-bbs2-0012" title="SimpsonJL , PowellH , BainesKJ , MilneD , CoxsonHO , HansbroPM , et al. The effect of azithromycin in adults with stable neutrophilic COPD: a double blind randomised, placebo controlled trial. PLOS One2014;9(8):e105609. ">Simpson 2014</a>) and one investigating an intermittent regimen (<a href="./references#CD009764-bbs2-0015" title="DjaminRS , UzunS , ErmensAAM , KerstensR , HoogstedenHC , AertsJGJV , et al. Which predictors in COPD patients with the frequent exacerbator phenotype predict the treatment response to maintenance therapy with azithromycin?. European Respiratory Journal2016;48:PA3713. UzunS , DjaminRS , AertsJGJV , Van DerEerdenMM . Patients with COPD Gold C &amp; D: the effect of long‐term treatment with azithromycin on exacerbation risk assessed by the Gold Framework. American Journal of Respiratory and Critical Care Medicine2014;189:A5967. UzunS , DjaminRS , KluytmansJA , MulderPG , Van't VeerNE , ErmensAA , et al. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double‐blind,placebo‐controlled trial. Lancet Respiratory Medicine2014;2(5):361‐8. UzunS , DjaminRS , MulderPGH , KluytmansJAJW , PelleAJ , Van't VeerNE , et al. Effect of azithromycin maintenance treatment in patients with frequent exacerbations of COPD (columbus): a randomized, double‐blind, placebo‐controlled trial. American Journal of Respiratory and Critical Care Medicine2014;189:A2884. ">Uzun 2014</a>). Compared to placebo, prophylactic antibiotics reduced the rate of exacerbations per patient per year (rate ratio 0.67, 95% CI 0.54 to 0.83; participants = 1384; studies = 5; moderate‐quality evidence; <a href="./references#CD009764-fig-0010" title="">Analysis 1.4</a>; <a href="#CD009764-fig-0005">Figure 5</a>). Considering the different regimens separately, use of continuous prophylactic antibiotics was also associated with a reduction (rate ratio 0.69, 95% CI 0.54 to 0.89; participants = 1292; studies = 4) as was use of intermittent antibiotics (rate ratio 0.58, 95% CI 0.42 to 0.80; participants = 92; studies = 1). There was a moderate level of heterogeneity among the included studies (I<sup>2</sup> = 52%). </p> <div class="figure" id="CD009764-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Antibiotics versus placebo, outcome: 1.4 Rate of exacerbation per patient per year." data-id="CD009764-fig-0005" src="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_n/nCD009764-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Antibiotics versus placebo, outcome: 1.4 Rate of exacerbation per patient per year. </p> </div> </div> </div> <p>A subgroup analysis performed in two studies (<a href="./references#CD009764-bbs2-0001" title="AlbertRK , ConnettJ , BaileyWC , CasaburiR , CooperJA , CrinerGJ , et al. Azithromycin for prevention of exacerbations of COPD. New England Journal of Medicine2011;365:689‐98. HanMK , TayobN , MurrayS , DransfieldMT , WashkoG , ScanlonPD , et al. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. American Journal of Respiratory and Critical Care Medicine2014;189(12):1503‐8. MartinezFJ , ConnettJ , VoelkerH , CrinerGJ , HanMK , MakeBJ , et al. Chronic azithromycin therapy decreases the risk of re‐hospitalization in patients with COPD. American Journal of Respiratory and Critical Care Medicine2013;187:A4383. O'ReillyPJ , JacksonPL , WellsJM , DransfieldMT , ScanlonPD , Blalock , JE . Sputum PGP is reduced by azithromycin treatment in patients with COPD and correlates with exacerbations. BMJ Open2013;3(12):e004140. WoodruffPG , ChatilaW , ConnettJE , CrinerGJ , CurtisJL , DransfieldMT , et al. Tumour necrosis factor receptor‐75 and risk of COPD exacerbation in the azithromycin trial. European Respiratory Journal2014;43:295–8. ">Albert 2011</a>; <a href="./references#CD009764-bbs2-0010" title="SethiS , JonesPW , TheronMS , MiravitllesM , RubinsteinE , WedzichaJA , et al. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized control trial. Respiratory Research2010;11:10. ">Sethi 2010</a>), according to the severity of COPD as defined by the GOLD criteria which were current at that time (2011), did not show a difference between the subgroups in the effect of antibiotics on exacerbation frequency (<a href="./references#CD009764-fig-0014" title="">Analysis 1.8</a>). </p> </section> <section id="CD009764-sec-0074"> <h4 class="title">Time to first exacerbation</h4> <p>The median time to first exacerbation was analysed using a Kaplan‐Meier survival curve and log‐rank test. We did not perform a meta‐analysis for this outcome and findings from individual studies are tabulated in <a href="./references#CD009764-fig-0011" title="">Analysis 1.5</a>. Data were available for six studies involving 2620 participants (<a href="./references#CD009764-bbs2-0001" title="AlbertRK , ConnettJ , BaileyWC , CasaburiR , CooperJA , CrinerGJ , et al. Azithromycin for prevention of exacerbations of COPD. New England Journal of Medicine2011;365:689‐98. HanMK , TayobN , MurrayS , DransfieldMT , WashkoG , ScanlonPD , et al. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. American Journal of Respiratory and Critical Care Medicine2014;189(12):1503‐8. MartinezFJ , ConnettJ , VoelkerH , CrinerGJ , HanMK , MakeBJ , et al. Chronic azithromycin therapy decreases the risk of re‐hospitalization in patients with COPD. American Journal of Respiratory and Critical Care Medicine2013;187:A4383. O'ReillyPJ , JacksonPL , WellsJM , DransfieldMT , ScanlonPD , Blalock , JE . Sputum PGP is reduced by azithromycin treatment in patients with COPD and correlates with exacerbations. BMJ Open2013;3(12):e004140. WoodruffPG , ChatilaW , ConnettJE , CrinerGJ , CurtisJL , DransfieldMT , et al. Tumour necrosis factor receptor‐75 and risk of COPD exacerbation in the azithromycin trial. European Respiratory Journal2014;43:295–8. ">Albert 2011</a>; <a href="./references#CD009764-bbs2-0003" title="BerkhofFF , Doornewaard‐ten HertogNE , UilSM , KerstjensHAM , Van denBergJWK . Azithromycin and cough‐specific health status in patients with chronic obstructive pulmonary disease and chronic cough: a randomised controlled trial. Respiratory Research2013;14(1):125. BerkhofFF , TenHertogNE , UilSM , KerstjensHAM , Van DenBergJK , CACTUS study group. Randomized controlled trial of prophylactic azithromycin on cough‐specific health status in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2013;187:A2449. ">Berkhof 2013</a>; <a href="./references#CD009764-bbs2-0005" title="HeZY , OuLM , ZhangJQ , BaiJ , LiuGN , LiMH , et al. Effect of 6 months of erythromycin treatment on inflammatory cells in induced sputum and exacerbations in chronic obstructive pulmonary disease. Respiration2010;80:445‐52. ">He 2010</a>; <a href="./references#CD009764-bbs2-0009" title="SeemungalTA , WilkinsonTM , HurstJR , PereraWR , SapsfordRJ , WedzichaJA . Long‐term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. American Journal of Respiratory and Critical Care Medicine2008;178:1139‐47. ">Seemungal 2008</a>; <a href="./references#CD009764-bbs2-0010" title="SethiS , JonesPW , TheronMS , MiravitllesM , RubinsteinE , WedzichaJA , et al. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized control trial. Respiratory Research2010;11:10. ">Sethi 2010</a>; <a href="./references#CD009764-bbs2-0015" title="DjaminRS , UzunS , ErmensAAM , KerstensR , HoogstedenHC , AertsJGJV , et al. Which predictors in COPD patients with the frequent exacerbator phenotype predict the treatment response to maintenance therapy with azithromycin?. European Respiratory Journal2016;48:PA3713. UzunS , DjaminRS , AertsJGJV , Van DerEerdenMM . Patients with COPD Gold C &amp; D: the effect of long‐term treatment with azithromycin on exacerbation risk assessed by the Gold Framework. American Journal of Respiratory and Critical Care Medicine2014;189:A5967. UzunS , DjaminRS , KluytmansJA , MulderPG , Van't VeerNE , ErmensAA , et al. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double‐blind,placebo‐controlled trial. Lancet Respiratory Medicine2014;2(5):361‐8. UzunS , DjaminRS , MulderPGH , KluytmansJAJW , PelleAJ , Van't VeerNE , et al. Effect of azithromycin maintenance treatment in patients with frequent exacerbations of COPD (columbus): a randomized, double‐blind, placebo‐controlled trial. American Journal of Respiratory and Critical Care Medicine2014;189:A2884. ">Uzun 2014</a>). </p> <p>Three studies used continuous prophylactic antibiotics, involving 1287 participants. Use of a continuous prophylactic antibiotic lengthened the time to first exacerbation in all three studies compared with placebo, and this was a statistically significant difference in all three. In <a href="./references#CD009764-bbs2-0001" title="AlbertRK , ConnettJ , BaileyWC , CasaburiR , CooperJA , CrinerGJ , et al. Azithromycin for prevention of exacerbations of COPD. New England Journal of Medicine2011;365:689‐98. HanMK , TayobN , MurrayS , DransfieldMT , WashkoG , ScanlonPD , et al. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. American Journal of Respiratory and Critical Care Medicine2014;189(12):1503‐8. MartinezFJ , ConnettJ , VoelkerH , CrinerGJ , HanMK , MakeBJ , et al. Chronic azithromycin therapy decreases the risk of re‐hospitalization in patients with COPD. American Journal of Respiratory and Critical Care Medicine2013;187:A4383. O'ReillyPJ , JacksonPL , WellsJM , DransfieldMT , ScanlonPD , Blalock , JE . Sputum PGP is reduced by azithromycin treatment in patients with COPD and correlates with exacerbations. BMJ Open2013;3(12):e004140. WoodruffPG , ChatilaW , ConnettJE , CrinerGJ , CurtisJL , DransfieldMT , et al. Tumour necrosis factor receptor‐75 and risk of COPD exacerbation in the azithromycin trial. European Respiratory Journal2014;43:295–8. ">Albert 2011</a>, this was 266 days (antibiotic) versus 174 days (placebo) (P &lt; 0.001); in <a href="./references#CD009764-bbs2-0005" title="HeZY , OuLM , ZhangJQ , BaiJ , LiuGN , LiMH , et al. Effect of 6 months of erythromycin treatment on inflammatory cells in induced sputum and exacerbations in chronic obstructive pulmonary disease. Respiration2010;80:445‐52. ">He 2010</a>,155 days versus 86 days (P = 0.032) and in <a href="./references#CD009764-bbs2-0009" title="SeemungalTA , WilkinsonTM , HurstJR , PereraWR , SapsfordRJ , WedzichaJA . Long‐term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. American Journal of Respiratory and Critical Care Medicine2008;178:1139‐47. ">Seemungal 2008</a>, 271 days versus 89 days (P = 0.02). </p> <p>Two studies, involving a total of 176 participants, investigated intermittent antibiotics and similarly found the time to first exacerbation was lengthened in both studies. In <a href="./references#CD009764-bbs2-0015" title="DjaminRS , UzunS , ErmensAAM , KerstensR , HoogstedenHC , AertsJGJV , et al. Which predictors in COPD patients with the frequent exacerbator phenotype predict the treatment response to maintenance therapy with azithromycin?. European Respiratory Journal2016;48:PA3713. UzunS , DjaminRS , AertsJGJV , Van DerEerdenMM . Patients with COPD Gold C &amp; D: the effect of long‐term treatment with azithromycin on exacerbation risk assessed by the Gold Framework. American Journal of Respiratory and Critical Care Medicine2014;189:A5967. UzunS , DjaminRS , KluytmansJA , MulderPG , Van't VeerNE , ErmensAA , et al. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double‐blind,placebo‐controlled trial. Lancet Respiratory Medicine2014;2(5):361‐8. UzunS , DjaminRS , MulderPGH , KluytmansJAJW , PelleAJ , Van't VeerNE , et al. Effect of azithromycin maintenance treatment in patients with frequent exacerbations of COPD (columbus): a randomized, double‐blind, placebo‐controlled trial. American Journal of Respiratory and Critical Care Medicine2014;189:A2884. ">Uzun 2014</a>, this was 130 days versus 59 days (P = 0.001). In <a href="./references#CD009764-bbs2-0003" title="BerkhofFF , Doornewaard‐ten HertogNE , UilSM , KerstjensHAM , Van denBergJWK . Azithromycin and cough‐specific health status in patients with chronic obstructive pulmonary disease and chronic cough: a randomised controlled trial. Respiratory Research2013;14(1):125. BerkhofFF , TenHertogNE , UilSM , KerstjensHAM , Van DenBergJK , CACTUS study group. Randomized controlled trial of prophylactic azithromycin on cough‐specific health status in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2013;187:A2449. ">Berkhof 2013</a>, the 20th percentile time to first exacerbation was 105 days (antibiotic) versus 66 days (placebo), but this was not statistically significantly different (P = 0.13). </p> <p>The median time to the first exacerbation in <a href="./references#CD009764-bbs2-0010" title="SethiS , JonesPW , TheronMS , MiravitllesM , RubinsteinE , WedzichaJA , et al. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized control trial. Respiratory Research2010;11:10. ">Sethi 2010</a> was increased by the use of pulsed antibiotics, but the difference was not statistically significant: 364 days versus 336 days (P = 0.062). </p> <p>One study, <a href="./references#CD009764-bbs2-0011" title="ShafuddinE , MillsGD , HolmesMD , PoolePJ , MullinsPR , BlackPN . A double‐blind, randomised, placebo‐controlled study of roxithromycin and doxycycline combination, roxithromycin alone, or matching placebo for 12 weeks in adults with frequent exacerbations of chronic obstructive pulmonary disease. Journal of Negative Results in Biomedicine2015;14:15. [DOI: 10.1186/s12952‐015‐0034‐8] ">Shafuddin 2015</a>, that involved 292 participants allocated to receive either continuous roxithromycin and doxycyline, continuous roxithromycin alone or placebo, reported the mean time (in days) to first exacerbation of COPD. Their results were inconclusive for this outcome and there was no significant difference between the treatment arms (MD ‐17 days, 95% CI ‐46 to 13; participants = 266; I<sup>2</sup> = 0%) </p> <p>In <a href="./references#CD009764-bbs2-0001" title="AlbertRK , ConnettJ , BaileyWC , CasaburiR , CooperJA , CrinerGJ , et al. Azithromycin for prevention of exacerbations of COPD. New England Journal of Medicine2011;365:689‐98. HanMK , TayobN , MurrayS , DransfieldMT , WashkoG , ScanlonPD , et al. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. American Journal of Respiratory and Critical Care Medicine2014;189(12):1503‐8. MartinezFJ , ConnettJ , VoelkerH , CrinerGJ , HanMK , MakeBJ , et al. Chronic azithromycin therapy decreases the risk of re‐hospitalization in patients with COPD. American Journal of Respiratory and Critical Care Medicine2013;187:A4383. O'ReillyPJ , JacksonPL , WellsJM , DransfieldMT , ScanlonPD , Blalock , JE . Sputum PGP is reduced by azithromycin treatment in patients with COPD and correlates with exacerbations. BMJ Open2013;3(12):e004140. WoodruffPG , ChatilaW , ConnettJE , CrinerGJ , CurtisJL , DransfieldMT , et al. Tumour necrosis factor receptor‐75 and risk of COPD exacerbation in the azithromycin trial. European Respiratory Journal2014;43:295–8. ">Albert 2011</a>, which used continuous azithromycin, a predefined subgroup analysis in 22 subgroups found that prophylactic antibiotics were associated with greater treatment effects in terms of lengthening time to first exacerbation in participants who had given up smoking (test for interaction P = 0.012), were not on steroid inhaler treatment at enrolment (P = 0.032), or older than 65 years (P = 0.012). </p> </section> <section id="CD009764-sec-0075"> <h4 class="title">Primary outcome: health‐related quality of life</h4> <p>Health‐related quality of life was explored in nine studies (<a href="./references#CD009764-bbs2-0001" title="AlbertRK , ConnettJ , BaileyWC , CasaburiR , CooperJA , CrinerGJ , et al. Azithromycin for prevention of exacerbations of COPD. New England Journal of Medicine2011;365:689‐98. HanMK , TayobN , MurrayS , DransfieldMT , WashkoG , ScanlonPD , et al. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. American Journal of Respiratory and Critical Care Medicine2014;189(12):1503‐8. MartinezFJ , ConnettJ , VoelkerH , CrinerGJ , HanMK , MakeBJ , et al. Chronic azithromycin therapy decreases the risk of re‐hospitalization in patients with COPD. American Journal of Respiratory and Critical Care Medicine2013;187:A4383. O'ReillyPJ , JacksonPL , WellsJM , DransfieldMT , ScanlonPD , Blalock , JE . Sputum PGP is reduced by azithromycin treatment in patients with COPD and correlates with exacerbations. BMJ Open2013;3(12):e004140. WoodruffPG , ChatilaW , ConnettJE , CrinerGJ , CurtisJL , DransfieldMT , et al. Tumour necrosis factor receptor‐75 and risk of COPD exacerbation in the azithromycin trial. European Respiratory Journal2014;43:295–8. ">Albert 2011</a>; <a href="./references#CD009764-bbs2-0002" title="BanerjeeD , HoneybourneD , KhairOA . The effect of oral Clarithromycin on bronchial airway inflammation in moderate‐to‐severe stable COPD: a randomised controlled trial. Treatments in Respiratory Medicine2004;3:59‐65. BanerjeeD , KhairO , HoneybourneD . The effect of oral clarithromycin on health status and sputum bacteriology in stable COPD. Respiratory Medicine2005;99:208‐15. ">Banerjee 2005</a>; <a href="./references#CD009764-bbs2-0003" title="BerkhofFF , Doornewaard‐ten HertogNE , UilSM , KerstjensHAM , Van denBergJWK . Azithromycin and cough‐specific health status in patients with chronic obstructive pulmonary disease and chronic cough: a randomised controlled trial. Respiratory Research2013;14(1):125. BerkhofFF , TenHertogNE , UilSM , KerstjensHAM , Van DenBergJK , CACTUS study group. Randomized controlled trial of prophylactic azithromycin on cough‐specific health status in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2013;187:A2449. ">Berkhof 2013</a>; <a href="./references#CD009764-bbs2-0004" title="BrillS , JamesP , CuthbertsonL , CooksonW , MoffattM , WedzichaJ . Haemophilus dominance of the stable COPD microbiome is associated with greater bacterial load and inflammation and is modulated by prophylactic antibiotic therapy. European Respiratory Journal2015;46:OA4746. BrillS , LawM , AllinsonJ , El‐EmirE , McHughT , DonaldsonG , et al. Bacterial resistance induction with prophylactic antibiotics in COPD. European Respiratory Journal2014;44:P4731. BrillSE , LawM , El‐EmirE , AllinsonJP , JamesP , MaddoxV , et al. Effects of different antibiotic classes on airway bacteria in stable COPD using culture and molecular techniques: a randomised controlled trial. Thorax2015;70(10):930‐8. BrillSE , LawM , El‐EmirE , AllinsonP , NazarethI , DonaldsonGC , et al. Effect of antibiotics on airway bacteria in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2014;198:A2874. ">Brill 2015</a>; <a href="./references#CD009764-bbs2-0005" title="HeZY , OuLM , ZhangJQ , BaiJ , LiuGN , LiMH , et al. Effect of 6 months of erythromycin treatment on inflammatory cells in induced sputum and exacerbations in chronic obstructive pulmonary disease. Respiration2010;80:445‐52. ">He 2010</a>; <a href="./references#CD009764-bbs2-0006" title="MygindLH , PedersenC , VestboJ , ChristensenJJ , Frimodt‐MollerN , KristiansenIS , et al. A randomised, placebo‐controlled 3 years study of prophylactic azithromycin in 575 patients with chronic obstructive pulmonary disease. European Respiratory Society 20th Annual Congress; 2010 Sep 18‐22; Barcelona. 2010. ">Mygind 2010</a>; <a href="./references#CD009764-bbs2-0010" title="SethiS , JonesPW , TheronMS , MiravitllesM , RubinsteinE , WedzichaJA , et al. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized control trial. Respiratory Research2010;11:10. ">Sethi 2010</a>; <a href="./references#CD009764-bbs2-0012" title="SimpsonJL , PowellH , BainesKJ , MilneD , CoxsonHO , HansbroPM , et al. The effect of azithromycin in adults with stable neutrophilic COPD: a double blind randomised, placebo controlled trial. PLOS One2014;9(8):e105609. ">Simpson 2014</a>; <a href="./references#CD009764-bbs2-0015" title="DjaminRS , UzunS , ErmensAAM , KerstensR , HoogstedenHC , AertsJGJV , et al. Which predictors in COPD patients with the frequent exacerbator phenotype predict the treatment response to maintenance therapy with azithromycin?. European Respiratory Journal2016;48:PA3713. UzunS , DjaminRS , AertsJGJV , Van DerEerdenMM . Patients with COPD Gold C &amp; D: the effect of long‐term treatment with azithromycin on exacerbation risk assessed by the Gold Framework. American Journal of Respiratory and Critical Care Medicine2014;189:A5967. UzunS , DjaminRS , KluytmansJA , MulderPG , Van't VeerNE , ErmensAA , et al. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double‐blind,placebo‐controlled trial. Lancet Respiratory Medicine2014;2(5):361‐8. UzunS , DjaminRS , MulderPGH , KluytmansJAJW , PelleAJ , Van't VeerNE , et al. Effect of azithromycin maintenance treatment in patients with frequent exacerbations of COPD (columbus): a randomized, double‐blind, placebo‐controlled trial. American Journal of Respiratory and Critical Care Medicine2014;189:A2884. ">Uzun 2014</a>). The quality of life assessment tools used in these studies included the St George's Respiratory Questionnaire (SGRQ) (<a href="./references#CD009764-bbs2-0078" title="JonesP . St George's Respiratory Questionnaire Manual Version 2.3. www.healthstatus.sgul.ac.uk/SGRQ_download/SGRQ%20Manual%20June%202009.pdf (accessed prior to 20 July 2018). ">Jones 2009</a>), the Leicester Cough Questionnaire (LCQ) (<a href="./references#CD009764-bbs2-0070" title="BirringSS , PrudonB , CarrAJ , SinghSJ , MorganMDL , PavordID . Development of a symptom specific health status measure for patients with chronic cough: Leicester Cough Questionnaire (LCQ). Thorax2003;58(4):339‐43. ">Birring 2003</a>), the Short Form Health Survey‐36 (SF‐36), the Short Form Health Survey‐12 (SF‐12), the Chronic Respiratory Disease Questionnaire (CRQ) and the Clinical COPD Questionnaire (CCQ). We were not able to include data from <a href="./references#CD009764-bbs2-0002" title="BanerjeeD , HoneybourneD , KhairOA . The effect of oral Clarithromycin on bronchial airway inflammation in moderate‐to‐severe stable COPD: a randomised controlled trial. Treatments in Respiratory Medicine2004;3:59‐65. BanerjeeD , KhairO , HoneybourneD . The effect of oral clarithromycin on health status and sputum bacteriology in stable COPD. Respiratory Medicine2005;99:208‐15. ">Banerjee 2005</a> and <a href="./references#CD009764-bbs2-0006" title="MygindLH , PedersenC , VestboJ , ChristensenJJ , Frimodt‐MollerN , KristiansenIS , et al. A randomised, placebo‐controlled 3 years study of prophylactic azithromycin in 575 patients with chronic obstructive pulmonary disease. European Respiratory Society 20th Annual Congress; 2010 Sep 18‐22; Barcelona. 2010. ">Mygind 2010</a> in the meta‐analyses. </p> <p>Seven studies assessed quality of life using the SGRQ. The meta‐analysis demonstrated a benefit of prophylactic antibiotics compared to placebo (MD ‐1.94, 95% CI ‐3.13 to ‐0.75; participants = 2237; studies = 7; high‐quality evidence; <a href="./references#CD009764-fig-0015" title="">Analysis 1.9</a>; <a href="#CD009764-fig-0006">Figure 6</a>). However, the mean difference did not reach the level of clinical significance according to the conventional cut‐off of at least a four‐unit reduction (<a href="./references#CD009764-bbs2-0078" title="JonesP . St George's Respiratory Questionnaire Manual Version 2.3. www.healthstatus.sgul.ac.uk/SGRQ_download/SGRQ%20Manual%20June%202009.pdf (accessed prior to 20 July 2018). ">Jones 2009</a>). </p> <div class="figure" id="CD009764-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Antibiotics versus placebo, outcome: 1.9 HRQoL, SGRQ (total score)." data-id="CD009764-fig-0006" src="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_n/nCD009764-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Antibiotics versus placebo, outcome: 1.9 HRQoL, SGRQ (total score). </p> </div> </div> </div> <p>When we grouped the studies by antibiotic regimen, we noted a similar improvement with continuous prophylactic antibiotic use (MD ‐1.96, 95% CI ‐3.45 to ‐0.47; participants = 991; studies = 4). While the pooled mean difference did not exceed the MCID of four units, it should be noted that <a href="./references#CD009764-bbs2-0001" title="AlbertRK , ConnettJ , BaileyWC , CasaburiR , CooperJA , CrinerGJ , et al. Azithromycin for prevention of exacerbations of COPD. New England Journal of Medicine2011;365:689‐98. HanMK , TayobN , MurrayS , DransfieldMT , WashkoG , ScanlonPD , et al. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. American Journal of Respiratory and Critical Care Medicine2014;189(12):1503‐8. MartinezFJ , ConnettJ , VoelkerH , CrinerGJ , HanMK , MakeBJ , et al. Chronic azithromycin therapy decreases the risk of re‐hospitalization in patients with COPD. American Journal of Respiratory and Critical Care Medicine2013;187:A4383. O'ReillyPJ , JacksonPL , WellsJM , DransfieldMT , ScanlonPD , Blalock , JE . Sputum PGP is reduced by azithromycin treatment in patients with COPD and correlates with exacerbations. BMJ Open2013;3(12):e004140. WoodruffPG , ChatilaW , ConnettJE , CrinerGJ , CurtisJL , DransfieldMT , et al. Tumour necrosis factor receptor‐75 and risk of COPD exacerbation in the azithromycin trial. European Respiratory Journal2014;43:295–8. ">Albert 2011</a> (1142 participants) reported a responder analysis, which demonstrated that more participants in the continuous azithromycin group (43%) than the placebo group (36%) had at least a four‐unit reduction in the SGRQ (P = 0.03). We found a larger benefit with intermittent antibiotic use (MD ‐4.59, 95% CI ‐8.83 to ‐0.36; participants = 184; studies = 3). There was no statistically or clinically significant improvement in SGRQ total scores with pulsed antibiotics (MD ‐1.22, 95% CI ‐3.00 to 0.55; participants = 1062; studies = 2; <a href="./references#CD009764-fig-0015" title="">Analysis 1.9</a>). However, the formal test for subgroup difference did not identify a significant difference between continuous, intermittent, and pulsed antibiotics. </p> <p>The SGRQ comprises three subcomponents; symptom score, impact score, and activity score. Four studies presented data for these subcomponents which were analysed separately (<a href="./references#CD009764-bbs2-0001" title="AlbertRK , ConnettJ , BaileyWC , CasaburiR , CooperJA , CrinerGJ , et al. Azithromycin for prevention of exacerbations of COPD. New England Journal of Medicine2011;365:689‐98. HanMK , TayobN , MurrayS , DransfieldMT , WashkoG , ScanlonPD , et al. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. American Journal of Respiratory and Critical Care Medicine2014;189(12):1503‐8. MartinezFJ , ConnettJ , VoelkerH , CrinerGJ , HanMK , MakeBJ , et al. Chronic azithromycin therapy decreases the risk of re‐hospitalization in patients with COPD. American Journal of Respiratory and Critical Care Medicine2013;187:A4383. O'ReillyPJ , JacksonPL , WellsJM , DransfieldMT , ScanlonPD , Blalock , JE . Sputum PGP is reduced by azithromycin treatment in patients with COPD and correlates with exacerbations. BMJ Open2013;3(12):e004140. WoodruffPG , ChatilaW , ConnettJE , CrinerGJ , CurtisJL , DransfieldMT , et al. Tumour necrosis factor receptor‐75 and risk of COPD exacerbation in the azithromycin trial. European Respiratory Journal2014;43:295–8. ">Albert 2011</a>; <a href="./references#CD009764-bbs2-0003" title="BerkhofFF , Doornewaard‐ten HertogNE , UilSM , KerstjensHAM , Van denBergJWK . Azithromycin and cough‐specific health status in patients with chronic obstructive pulmonary disease and chronic cough: a randomised controlled trial. Respiratory Research2013;14(1):125. BerkhofFF , TenHertogNE , UilSM , KerstjensHAM , Van DenBergJK , CACTUS study group. Randomized controlled trial of prophylactic azithromycin on cough‐specific health status in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2013;187:A2449. ">Berkhof 2013</a>: <a href="./references#CD009764-bbs2-0010" title="SethiS , JonesPW , TheronMS , MiravitllesM , RubinsteinE , WedzichaJA , et al. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized control trial. Respiratory Research2010;11:10. ">Sethi 2010</a>; <a href="./references#CD009764-bbs2-0015" title="DjaminRS , UzunS , ErmensAAM , KerstensR , HoogstedenHC , AertsJGJV , et al. Which predictors in COPD patients with the frequent exacerbator phenotype predict the treatment response to maintenance therapy with azithromycin?. European Respiratory Journal2016;48:PA3713. UzunS , DjaminRS , AertsJGJV , Van DerEerdenMM . Patients with COPD Gold C &amp; D: the effect of long‐term treatment with azithromycin on exacerbation risk assessed by the Gold Framework. American Journal of Respiratory and Critical Care Medicine2014;189:A5967. UzunS , DjaminRS , KluytmansJA , MulderPG , Van't VeerNE , ErmensAA , et al. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double‐blind,placebo‐controlled trial. Lancet Respiratory Medicine2014;2(5):361‐8. UzunS , DjaminRS , MulderPGH , KluytmansJAJW , PelleAJ , Van't VeerNE , et al. Effect of azithromycin maintenance treatment in patients with frequent exacerbations of COPD (columbus): a randomized, double‐blind, placebo‐controlled trial. American Journal of Respiratory and Critical Care Medicine2014;189:A2884. ">Uzun 2014</a>). All three domains improved with antibiotics compared to placebo, although the improvement in the activity score was more uncertain (symptom score: MD ‐4.07, 95% CI ‐5.72 to ‐2.41; impact score: MD ‐2.56, 95% CI ‐5.02 to ‐0.10; activity score: MD ‐0.99, 95% CI ‐2.62 to 0.65; <a href="./references#CD009764-fig-0016" title="">Analysis 1.10</a>). In terms of clinically significant improvements with antibiotic use versus placebo in the subgroup analysis, the symptom score showed the greatest difference, with three studies having greater than a four‐unit mean difference (<a href="./references#CD009764-bbs2-0003" title="BerkhofFF , Doornewaard‐ten HertogNE , UilSM , KerstjensHAM , Van denBergJWK . Azithromycin and cough‐specific health status in patients with chronic obstructive pulmonary disease and chronic cough: a randomised controlled trial. Respiratory Research2013;14(1):125. BerkhofFF , TenHertogNE , UilSM , KerstjensHAM , Van DenBergJK , CACTUS study group. Randomized controlled trial of prophylactic azithromycin on cough‐specific health status in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2013;187:A2449. ">Berkhof 2013</a> 9.3 units, <a href="./references#CD009764-bbs2-0015" title="DjaminRS , UzunS , ErmensAAM , KerstensR , HoogstedenHC , AertsJGJV , et al. Which predictors in COPD patients with the frequent exacerbator phenotype predict the treatment response to maintenance therapy with azithromycin?. European Respiratory Journal2016;48:PA3713. UzunS , DjaminRS , AertsJGJV , Van DerEerdenMM . Patients with COPD Gold C &amp; D: the effect of long‐term treatment with azithromycin on exacerbation risk assessed by the Gold Framework. American Journal of Respiratory and Critical Care Medicine2014;189:A5967. UzunS , DjaminRS , KluytmansJA , MulderPG , Van't VeerNE , ErmensAA , et al. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double‐blind,placebo‐controlled trial. Lancet Respiratory Medicine2014;2(5):361‐8. UzunS , DjaminRS , MulderPGH , KluytmansJAJW , PelleAJ , Van't VeerNE , et al. Effect of azithromycin maintenance treatment in patients with frequent exacerbations of COPD (columbus): a randomized, double‐blind, placebo‐controlled trial. American Journal of Respiratory and Critical Care Medicine2014;189:A2884. ">Uzun 2014</a> 5.7 units and <a href="./references#CD009764-bbs2-0010" title="SethiS , JonesPW , TheronMS , MiravitllesM , RubinsteinE , WedzichaJA , et al. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized control trial. Respiratory Research2010;11:10. ">Sethi 2010</a> 4.4 units). </p> <p>The authors of <a href="./references#CD009764-bbs2-0002" title="BanerjeeD , HoneybourneD , KhairOA . The effect of oral Clarithromycin on bronchial airway inflammation in moderate‐to‐severe stable COPD: a randomised controlled trial. Treatments in Respiratory Medicine2004;3:59‐65. BanerjeeD , KhairO , HoneybourneD . The effect of oral clarithromycin on health status and sputum bacteriology in stable COPD. Respiratory Medicine2005;99:208‐15. ">Banerjee 2005</a>, <a href="./references#CD009764-bbs2-0006" title="MygindLH , PedersenC , VestboJ , ChristensenJJ , Frimodt‐MollerN , KristiansenIS , et al. A randomised, placebo‐controlled 3 years study of prophylactic azithromycin in 575 patients with chronic obstructive pulmonary disease. European Respiratory Society 20th Annual Congress; 2010 Sep 18‐22; Barcelona. 2010. ">Mygind 2010</a> and <a href="./references#CD009764-bbs2-0012" title="SimpsonJL , PowellH , BainesKJ , MilneD , CoxsonHO , HansbroPM , et al. The effect of azithromycin in adults with stable neutrophilic COPD: a double blind randomised, placebo controlled trial. PLOS One2014;9(8):e105609. ">Simpson 2014</a> reported no statistically significant difference in the total SGRQ scores. However, <a href="./references#CD009764-bbs2-0002" title="BanerjeeD , HoneybourneD , KhairOA . The effect of oral Clarithromycin on bronchial airway inflammation in moderate‐to‐severe stable COPD: a randomised controlled trial. Treatments in Respiratory Medicine2004;3:59‐65. BanerjeeD , KhairO , HoneybourneD . The effect of oral clarithromycin on health status and sputum bacteriology in stable COPD. Respiratory Medicine2005;99:208‐15. ">Banerjee 2005</a> did report a significant improvement only in the symptom domain score in the participants treated with continuous prophylactic clarithromycin over a three‐month period (MD ‐10.2; 95% CI ‐18.7 to ‐1.6). </p> <p>In addition to the SGRQ, <a href="./references#CD009764-bbs2-0003" title="BerkhofFF , Doornewaard‐ten HertogNE , UilSM , KerstjensHAM , Van denBergJWK . Azithromycin and cough‐specific health status in patients with chronic obstructive pulmonary disease and chronic cough: a randomised controlled trial. Respiratory Research2013;14(1):125. BerkhofFF , TenHertogNE , UilSM , KerstjensHAM , Van DenBergJK , CACTUS study group. Randomized controlled trial of prophylactic azithromycin on cough‐specific health status in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2013;187:A2449. ">Berkhof 2013</a> used the LCQ and SF‐36 as quality of life assessment tools. The LCQ is a 19‐point questionnaire designed to assess cough‐related quality of life that is divided into three domains (physical, psychological, and social). The domain scores range from one to seven and therefore the total score range is three to 21; higher scores are indicative of a better quality of life. The authors of <a href="./references#CD009764-bbs2-0003" title="BerkhofFF , Doornewaard‐ten HertogNE , UilSM , KerstjensHAM , Van denBergJWK . Azithromycin and cough‐specific health status in patients with chronic obstructive pulmonary disease and chronic cough: a randomised controlled trial. Respiratory Research2013;14(1):125. BerkhofFF , TenHertogNE , UilSM , KerstjensHAM , Van DenBergJK , CACTUS study group. Randomized controlled trial of prophylactic azithromycin on cough‐specific health status in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2013;187:A2449. ">Berkhof 2013</a> reported an improvement in total LCQ score with intermittent azithromycin use (MD 1.30, 95% CI 0.32 to 2.28; <a href="./references#CD009764-fig-0017" title="">Analysis 1.11</a>). The only domain that did not show a clear improvement with the antibiotics was the social domain (MD 0.40, 95% CI ‐0.15 to 0.95; <a href="./references#CD009764-fig-0020" title="">Analysis 1.14</a>). </p> <p>Four studies used the SF‐36 (<a href="./references#CD009764-bbs2-0001" title="AlbertRK , ConnettJ , BaileyWC , CasaburiR , CooperJA , CrinerGJ , et al. Azithromycin for prevention of exacerbations of COPD. New England Journal of Medicine2011;365:689‐98. HanMK , TayobN , MurrayS , DransfieldMT , WashkoG , ScanlonPD , et al. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. American Journal of Respiratory and Critical Care Medicine2014;189(12):1503‐8. MartinezFJ , ConnettJ , VoelkerH , CrinerGJ , HanMK , MakeBJ , et al. Chronic azithromycin therapy decreases the risk of re‐hospitalization in patients with COPD. American Journal of Respiratory and Critical Care Medicine2013;187:A4383. O'ReillyPJ , JacksonPL , WellsJM , DransfieldMT , ScanlonPD , Blalock , JE . Sputum PGP is reduced by azithromycin treatment in patients with COPD and correlates with exacerbations. BMJ Open2013;3(12):e004140. WoodruffPG , ChatilaW , ConnettJE , CrinerGJ , CurtisJL , DransfieldMT , et al. Tumour necrosis factor receptor‐75 and risk of COPD exacerbation in the azithromycin trial. European Respiratory Journal2014;43:295–8. ">Albert 2011</a>; <a href="./references#CD009764-bbs2-0002" title="BanerjeeD , HoneybourneD , KhairOA . The effect of oral Clarithromycin on bronchial airway inflammation in moderate‐to‐severe stable COPD: a randomised controlled trial. Treatments in Respiratory Medicine2004;3:59‐65. BanerjeeD , KhairO , HoneybourneD . The effect of oral clarithromycin on health status and sputum bacteriology in stable COPD. Respiratory Medicine2005;99:208‐15. ">Banerjee 2005</a>; <a href="./references#CD009764-bbs2-0003" title="BerkhofFF , Doornewaard‐ten HertogNE , UilSM , KerstjensHAM , Van denBergJWK . Azithromycin and cough‐specific health status in patients with chronic obstructive pulmonary disease and chronic cough: a randomised controlled trial. Respiratory Research2013;14(1):125. BerkhofFF , TenHertogNE , UilSM , KerstjensHAM , Van DenBergJK , CACTUS study group. Randomized controlled trial of prophylactic azithromycin on cough‐specific health status in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2013;187:A2449. ">Berkhof 2013</a>; <a href="./references#CD009764-bbs2-0005" title="HeZY , OuLM , ZhangJQ , BaiJ , LiuGN , LiMH , et al. Effect of 6 months of erythromycin treatment on inflammatory cells in induced sputum and exacerbations in chronic obstructive pulmonary disease. Respiration2010;80:445‐52. ">He 2010</a>). The SF‐36 is a 36‐item nonspecific health‐related quality of life questionnaire. It is divided into eight domains that are each scored on a 100‐point scale where 100 is equivalent to no disability. The domains include general health, physical functioning, bodily pain, vitality, role emotional, social functioning, mental health, and role physical. Three of the four studies (<a href="./references#CD009764-bbs2-0001" title="AlbertRK , ConnettJ , BaileyWC , CasaburiR , CooperJA , CrinerGJ , et al. Azithromycin for prevention of exacerbations of COPD. New England Journal of Medicine2011;365:689‐98. HanMK , TayobN , MurrayS , DransfieldMT , WashkoG , ScanlonPD , et al. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. American Journal of Respiratory and Critical Care Medicine2014;189(12):1503‐8. MartinezFJ , ConnettJ , VoelkerH , CrinerGJ , HanMK , MakeBJ , et al. Chronic azithromycin therapy decreases the risk of re‐hospitalization in patients with COPD. American Journal of Respiratory and Critical Care Medicine2013;187:A4383. O'ReillyPJ , JacksonPL , WellsJM , DransfieldMT , ScanlonPD , Blalock , JE . Sputum PGP is reduced by azithromycin treatment in patients with COPD and correlates with exacerbations. BMJ Open2013;3(12):e004140. WoodruffPG , ChatilaW , ConnettJE , CrinerGJ , CurtisJL , DransfieldMT , et al. Tumour necrosis factor receptor‐75 and risk of COPD exacerbation in the azithromycin trial. European Respiratory Journal2014;43:295–8. ">Albert 2011</a>; <a href="./references#CD009764-bbs2-0003" title="BerkhofFF , Doornewaard‐ten HertogNE , UilSM , KerstjensHAM , Van denBergJWK . Azithromycin and cough‐specific health status in patients with chronic obstructive pulmonary disease and chronic cough: a randomised controlled trial. Respiratory Research2013;14(1):125. BerkhofFF , TenHertogNE , UilSM , KerstjensHAM , Van DenBergJK , CACTUS study group. Randomized controlled trial of prophylactic azithromycin on cough‐specific health status in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2013;187:A2449. ">Berkhof 2013</a>; <a href="./references#CD009764-bbs2-0005" title="HeZY , OuLM , ZhangJQ , BaiJ , LiuGN , LiMH , et al. Effect of 6 months of erythromycin treatment on inflammatory cells in induced sputum and exacerbations in chronic obstructive pulmonary disease. Respiration2010;80:445‐52. ">He 2010</a>) that used SF‐36 to assess quality of life, involving 1262 participants, presented data that we were able to extract for meta‐analysis. <a href="./references#CD009764-bbs2-0001" title="AlbertRK , ConnettJ , BaileyWC , CasaburiR , CooperJA , CrinerGJ , et al. Azithromycin for prevention of exacerbations of COPD. New England Journal of Medicine2011;365:689‐98. HanMK , TayobN , MurrayS , DransfieldMT , WashkoG , ScanlonPD , et al. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. American Journal of Respiratory and Critical Care Medicine2014;189(12):1503‐8. MartinezFJ , ConnettJ , VoelkerH , CrinerGJ , HanMK , MakeBJ , et al. Chronic azithromycin therapy decreases the risk of re‐hospitalization in patients with COPD. American Journal of Respiratory and Critical Care Medicine2013;187:A4383. O'ReillyPJ , JacksonPL , WellsJM , DransfieldMT , ScanlonPD , Blalock , JE . Sputum PGP is reduced by azithromycin treatment in patients with COPD and correlates with exacerbations. BMJ Open2013;3(12):e004140. WoodruffPG , ChatilaW , ConnettJE , CrinerGJ , CurtisJL , DransfieldMT , et al. Tumour necrosis factor receptor‐75 and risk of COPD exacerbation in the azithromycin trial. European Respiratory Journal2014;43:295–8. ">Albert 2011</a> used continuous azithromycin for 12 months, <a href="./references#CD009764-bbs2-0003" title="BerkhofFF , Doornewaard‐ten HertogNE , UilSM , KerstjensHAM , Van denBergJWK . Azithromycin and cough‐specific health status in patients with chronic obstructive pulmonary disease and chronic cough: a randomised controlled trial. Respiratory Research2013;14(1):125. BerkhofFF , TenHertogNE , UilSM , KerstjensHAM , Van DenBergJK , CACTUS study group. Randomized controlled trial of prophylactic azithromycin on cough‐specific health status in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2013;187:A2449. ">Berkhof 2013</a> used intermittent azithromycin for three months and <a href="./references#CD009764-bbs2-0005" title="HeZY , OuLM , ZhangJQ , BaiJ , LiuGN , LiMH , et al. Effect of 6 months of erythromycin treatment on inflammatory cells in induced sputum and exacerbations in chronic obstructive pulmonary disease. Respiration2010;80:445‐52. ">He 2010</a> used continuous erythromycin for six months. Given the spread of treatment duration and the different time points of data available for us to extract, we chose to extract data as close to six months as possible, which involved outcomes at six months for <a href="./references#CD009764-bbs2-0001" title="AlbertRK , ConnettJ , BaileyWC , CasaburiR , CooperJA , CrinerGJ , et al. Azithromycin for prevention of exacerbations of COPD. New England Journal of Medicine2011;365:689‐98. HanMK , TayobN , MurrayS , DransfieldMT , WashkoG , ScanlonPD , et al. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. American Journal of Respiratory and Critical Care Medicine2014;189(12):1503‐8. MartinezFJ , ConnettJ , VoelkerH , CrinerGJ , HanMK , MakeBJ , et al. Chronic azithromycin therapy decreases the risk of re‐hospitalization in patients with COPD. American Journal of Respiratory and Critical Care Medicine2013;187:A4383. O'ReillyPJ , JacksonPL , WellsJM , DransfieldMT , ScanlonPD , Blalock , JE . Sputum PGP is reduced by azithromycin treatment in patients with COPD and correlates with exacerbations. BMJ Open2013;3(12):e004140. WoodruffPG , ChatilaW , ConnettJE , CrinerGJ , CurtisJL , DransfieldMT , et al. Tumour necrosis factor receptor‐75 and risk of COPD exacerbation in the azithromycin trial. European Respiratory Journal2014;43:295–8. ">Albert 2011</a> and <a href="./references#CD009764-bbs2-0005" title="HeZY , OuLM , ZhangJQ , BaiJ , LiuGN , LiMH , et al. Effect of 6 months of erythromycin treatment on inflammatory cells in induced sputum and exacerbations in chronic obstructive pulmonary disease. Respiration2010;80:445‐52. ">He 2010</a>, and three months for <a href="./references#CD009764-bbs2-0003" title="BerkhofFF , Doornewaard‐ten HertogNE , UilSM , KerstjensHAM , Van denBergJWK . Azithromycin and cough‐specific health status in patients with chronic obstructive pulmonary disease and chronic cough: a randomised controlled trial. Respiratory Research2013;14(1):125. BerkhofFF , TenHertogNE , UilSM , KerstjensHAM , Van DenBergJK , CACTUS study group. Randomized controlled trial of prophylactic azithromycin on cough‐specific health status in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2013;187:A2449. ">Berkhof 2013</a>. Only the general health domain showed a clear benefit of antibiotics over placebo (MD 4.06, 95% CI 0.70 to 7.42; participants = 1071; studies = 3; I<sup>2</sup> = 18%; <a href="./references#CD009764-fig-0019" title="">Analysis 1.13</a>) but the confidence intervals for each domain effect estimate were highly overlapping. <a href="./references#CD009764-bbs2-0002" title="BanerjeeD , HoneybourneD , KhairOA . The effect of oral Clarithromycin on bronchial airway inflammation in moderate‐to‐severe stable COPD: a randomised controlled trial. Treatments in Respiratory Medicine2004;3:59‐65. BanerjeeD , KhairO , HoneybourneD . The effect of oral clarithromycin on health status and sputum bacteriology in stable COPD. Respiratory Medicine2005;99:208‐15. ">Banerjee 2005</a> also used the SF‐36 but the raw data were not available for extraction for inclusion in the meta‐analysis; however, in their text; they reported a significant improvement in the physical functioning score in the group that used prophylactic clarithromycin for three months (MD 12.9; 95% CI 3.1 to 22.6). </p> <p>One study used SF‐12 in addition to the SGRQ, and found no difference in the mental (MD 0.90, 95% CI ‐4.68 to 6.48) nor the physical (MD ‐0.40, 95% CI ‐5.10 to 4.30) health domains after 12 months of treatment with prophylactic antibiotics (intermittent azithromycin) (overall; MD 0.14, 95% CI ‐3.45 to 3.73; <a href="./references#CD009764-fig-0018" title="">Analysis 1.12</a>) (<a href="./references#CD009764-bbs2-0015" title="DjaminRS , UzunS , ErmensAAM , KerstensR , HoogstedenHC , AertsJGJV , et al. Which predictors in COPD patients with the frequent exacerbator phenotype predict the treatment response to maintenance therapy with azithromycin?. European Respiratory Journal2016;48:PA3713. UzunS , DjaminRS , AertsJGJV , Van DerEerdenMM . Patients with COPD Gold C &amp; D: the effect of long‐term treatment with azithromycin on exacerbation risk assessed by the Gold Framework. American Journal of Respiratory and Critical Care Medicine2014;189:A5967. UzunS , DjaminRS , KluytmansJA , MulderPG , Van't VeerNE , ErmensAA , et al. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double‐blind,placebo‐controlled trial. Lancet Respiratory Medicine2014;2(5):361‐8. UzunS , DjaminRS , MulderPGH , KluytmansJAJW , PelleAJ , Van't VeerNE , et al. Effect of azithromycin maintenance treatment in patients with frequent exacerbations of COPD (columbus): a randomized, double‐blind, placebo‐controlled trial. American Journal of Respiratory and Critical Care Medicine2014;189:A2884. ">Uzun 2014</a>) . They did, however, report "a significant difference in mean change in the mental component score at three months in favour of azithromycin (MD 6.6; CI 1.4 to 11.8; P = 0.013)" (<a href="./references#CD009764-bbs2-0015" title="DjaminRS , UzunS , ErmensAAM , KerstensR , HoogstedenHC , AertsJGJV , et al. Which predictors in COPD patients with the frequent exacerbator phenotype predict the treatment response to maintenance therapy with azithromycin?. European Respiratory Journal2016;48:PA3713. UzunS , DjaminRS , AertsJGJV , Van DerEerdenMM . Patients with COPD Gold C &amp; D: the effect of long‐term treatment with azithromycin on exacerbation risk assessed by the Gold Framework. American Journal of Respiratory and Critical Care Medicine2014;189:A5967. UzunS , DjaminRS , KluytmansJA , MulderPG , Van't VeerNE , ErmensAA , et al. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double‐blind,placebo‐controlled trial. Lancet Respiratory Medicine2014;2(5):361‐8. UzunS , DjaminRS , MulderPGH , KluytmansJAJW , PelleAJ , Van't VeerNE , et al. Effect of azithromycin maintenance treatment in patients with frequent exacerbations of COPD (columbus): a randomized, double‐blind, placebo‐controlled trial. American Journal of Respiratory and Critical Care Medicine2014;189:A2884. ">Uzun 2014</a>). </p> <p><a href="./references#CD009764-bbs2-0012" title="SimpsonJL , PowellH , BainesKJ , MilneD , CoxsonHO , HansbroPM , et al. The effect of azithromycin in adults with stable neutrophilic COPD: a double blind randomised, placebo controlled trial. PLOS One2014;9(8):e105609. ">Simpson 2014</a> similarly found no significant improvement in quality of life as assessed by the CCQ with continuous antibiotic (azithromycin) use at the end of their treatment period (MD 1.80, 95% CI ‐5.11 to 8.71; <a href="./references#CD009764-fig-0021" title="">Analysis 1.15</a>). Finally, <a href="./references#CD009764-bbs2-0011" title="ShafuddinE , MillsGD , HolmesMD , PoolePJ , MullinsPR , BlackPN . A double‐blind, randomised, placebo‐controlled study of roxithromycin and doxycycline combination, roxithromycin alone, or matching placebo for 12 weeks in adults with frequent exacerbations of chronic obstructive pulmonary disease. Journal of Negative Results in Biomedicine2015;14:15. [DOI: 10.1186/s12952‐015‐0034‐8] ">Shafuddin 2015</a> used the CRQ (which assesses four domains: dyspnoea, fatigue, emotional function, and mastery) and found no significant improvement in any of these domains with continuous antibiotic use (roxithromycin/doxycycline or doxycycline alone) (<a href="./references#CD009764-fig-0022" title="">Analysis 1.16</a>). </p> </section> <section id="CD009764-sec-0076"> <h4 class="title">Secondary outcome: frequency of hospitalisation</h4> <p>The frequency of hospitalisation was assessed using data from four studies involving 2958 participants (<a href="./references#CD009764-bbs2-0001" title="AlbertRK , ConnettJ , BaileyWC , CasaburiR , CooperJA , CrinerGJ , et al. Azithromycin for prevention of exacerbations of COPD. New England Journal of Medicine2011;365:689‐98. HanMK , TayobN , MurrayS , DransfieldMT , WashkoG , ScanlonPD , et al. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. American Journal of Respiratory and Critical Care Medicine2014;189(12):1503‐8. MartinezFJ , ConnettJ , VoelkerH , CrinerGJ , HanMK , MakeBJ , et al. Chronic azithromycin therapy decreases the risk of re‐hospitalization in patients with COPD. American Journal of Respiratory and Critical Care Medicine2013;187:A4383. O'ReillyPJ , JacksonPL , WellsJM , DransfieldMT , ScanlonPD , Blalock , JE . Sputum PGP is reduced by azithromycin treatment in patients with COPD and correlates with exacerbations. BMJ Open2013;3(12):e004140. WoodruffPG , ChatilaW , ConnettJE , CrinerGJ , CurtisJL , DransfieldMT , et al. Tumour necrosis factor receptor‐75 and risk of COPD exacerbation in the azithromycin trial. European Respiratory Journal2014;43:295–8. ">Albert 2011</a>; <a href="./references#CD009764-bbs2-0006" title="MygindLH , PedersenC , VestboJ , ChristensenJJ , Frimodt‐MollerN , KristiansenIS , et al. A randomised, placebo‐controlled 3 years study of prophylactic azithromycin in 575 patients with chronic obstructive pulmonary disease. European Respiratory Society 20th Annual Congress; 2010 Sep 18‐22; Barcelona. 2010. ">Mygind 2010</a>; <a href="./references#CD009764-bbs2-0010" title="SethiS , JonesPW , TheronMS , MiravitllesM , RubinsteinE , WedzichaJA , et al. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized control trial. Respiratory Research2010;11:10. ">Sethi 2010</a>; <a href="./references#CD009764-bbs2-0013" title="SuzukiT , YaniM , YamayaM , Satoh NakagawaT , SekizawaK , IshidaS , et al. Erythromycin and common cold in COPD. Chest2001;120:730‐3. ">Suzuki 2001</a>). In this update, none of the new studies presented data on the frequency of hospitalisation and as such, our data remained unchanged from the previous update (<a href="./references#CD009764-bbs2-0101" title="HerathS , PooleP . Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD). Cochrane Database of Systematic Reviews2013, Issue 11. [DOI: 10.1002/14651858.CD009764.pub2] ">Herath 2013</a>). </p> <p>The study by <a href="./references#CD009764-bbs2-0010" title="SethiS , JonesPW , TheronMS , MiravitllesM , RubinsteinE , WedzichaJA , et al. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized control trial. Respiratory Research2010;11:10. ">Sethi 2010</a>, involving pulsed moxifloxacin in 1157 participants, did not show any improvement in the hospitalisation frequency (131/569 treatment arm versus 136/580 placebo arm; P = 0.46; <a href="./references#CD009764-fig-0024" title="">Analysis 1.18</a>). </p> <p>The study by <a href="./references#CD009764-bbs2-0001" title="AlbertRK , ConnettJ , BaileyWC , CasaburiR , CooperJA , CrinerGJ , et al. Azithromycin for prevention of exacerbations of COPD. New England Journal of Medicine2011;365:689‐98. HanMK , TayobN , MurrayS , DransfieldMT , WashkoG , ScanlonPD , et al. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. American Journal of Respiratory and Critical Care Medicine2014;189(12):1503‐8. MartinezFJ , ConnettJ , VoelkerH , CrinerGJ , HanMK , MakeBJ , et al. Chronic azithromycin therapy decreases the risk of re‐hospitalization in patients with COPD. American Journal of Respiratory and Critical Care Medicine2013;187:A4383. O'ReillyPJ , JacksonPL , WellsJM , DransfieldMT , ScanlonPD , Blalock , JE . Sputum PGP is reduced by azithromycin treatment in patients with COPD and correlates with exacerbations. BMJ Open2013;3(12):e004140. WoodruffPG , ChatilaW , ConnettJE , CrinerGJ , CurtisJL , DransfieldMT , et al. Tumour necrosis factor receptor‐75 and risk of COPD exacerbation in the azithromycin trial. European Respiratory Journal2014;43:295–8. ">Albert 2011</a>, involving continuous azithromycin in 1142 participants, calculated the rate of exacerbations requiring hospitalisation per patient per year according to the severity of COPD by the GOLD criteria (<a href="./references#CD009764-fig-0024" title="">Analysis 1.18</a>). The rate ratio was 0.77 (GOLD stage 2), 0.89 (GOLD stage 3) and 0.72 (GOLD stage 4). There were not adequate data to calculate the statistical significance of this outcome but there did not appear to be a trend. </p> <p>The other two studies had inadequate data to calculate the mean event rate per year. Of these, one study involving 109 participants found a statistically significant reduction (P &lt; 0.001) in hospitalisation while using erythromycin 200 to 400 mg daily for a 12‐month period (<a href="./references#CD009764-bbs2-0013" title="SuzukiT , YaniM , YamayaM , Satoh NakagawaT , SekizawaK , IshidaS , et al. Erythromycin and common cold in COPD. Chest2001;120:730‐3. ">Suzuki 2001</a>). The other study (<a href="./references#CD009764-bbs2-0006" title="MygindLH , PedersenC , VestboJ , ChristensenJJ , Frimodt‐MollerN , KristiansenIS , et al. A randomised, placebo‐controlled 3 years study of prophylactic azithromycin in 575 patients with chronic obstructive pulmonary disease. European Respiratory Society 20th Annual Congress; 2010 Sep 18‐22; Barcelona. 2010. ">Mygind 2010</a>) did not show a statistically significant difference in the frequency of hospitalisations. </p> </section> <section id="CD009764-sec-0077"> <h4 class="title">Secondary outcome: duration of exacerbations</h4> <p>The duration of exacerbations was addressed by only two studies involving 684 participants (<a href="./references#CD009764-bbs2-0006" title="MygindLH , PedersenC , VestboJ , ChristensenJJ , Frimodt‐MollerN , KristiansenIS , et al. A randomised, placebo‐controlled 3 years study of prophylactic azithromycin in 575 patients with chronic obstructive pulmonary disease. European Respiratory Society 20th Annual Congress; 2010 Sep 18‐22; Barcelona. 2010. ">Mygind 2010</a>; <a href="./references#CD009764-bbs2-0009" title="SeemungalTA , WilkinsonTM , HurstJR , PereraWR , SapsfordRJ , WedzichaJA . Long‐term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. American Journal of Respiratory and Critical Care Medicine2008;178:1139‐47. ">Seemungal 2008</a>), again already included in the previous version of this review (<a href="./references#CD009764-bbs2-0101" title="HerathS , PooleP . Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD). Cochrane Database of Systematic Reviews2013, Issue 11. [DOI: 10.1002/14651858.CD009764.pub2] ">Herath 2013</a>). None of the new studies in this update presented data on the impact of prophylactic antibiotics on the duration of exacerbations. <a href="./references#CD009764-bbs2-0009" title="SeemungalTA , WilkinsonTM , HurstJR , PereraWR , SapsfordRJ , WedzichaJA . Long‐term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. American Journal of Respiratory and Critical Care Medicine2008;178:1139‐47. ">Seemungal 2008</a> showed that antibiotic use was associated with a lower median number of exacerbation days: 9 days (interquartile range (IQR) 6 to 13 days) compared to 13 days on placebo (IQR 6 to 24 days) (P = 0.036). Similar findings were reported by <a href="./references#CD009764-bbs2-0006" title="MygindLH , PedersenC , VestboJ , ChristensenJJ , Frimodt‐MollerN , KristiansenIS , et al. A randomised, placebo‐controlled 3 years study of prophylactic azithromycin in 575 patients with chronic obstructive pulmonary disease. European Respiratory Society 20th Annual Congress; 2010 Sep 18‐22; Barcelona. 2010. ">Mygind 2010</a>. This study had 575 participants and used pulsed azithromycin over a 36‐month period. The median number of exacerbation days (at home or in hospital) was 93 in the azithromycin group compared to 111 in the placebo group (P = 0.04). Prophylactic pulsed antibiotic use (<a href="./references#CD009764-bbs2-0006" title="MygindLH , PedersenC , VestboJ , ChristensenJJ , Frimodt‐MollerN , KristiansenIS , et al. A randomised, placebo‐controlled 3 years study of prophylactic azithromycin in 575 patients with chronic obstructive pulmonary disease. European Respiratory Society 20th Annual Congress; 2010 Sep 18‐22; Barcelona. 2010. ">Mygind 2010</a>) reduced the number of days with severe exacerbations managed at home: a median of 31 days versus 42.5 days for the placebo group (P = 0.01). A meta‐analysis was not carried out for this comparison due to paucity of data. </p> <p>Furthermore, <a href="./references#CD009764-bbs2-0006" title="MygindLH , PedersenC , VestboJ , ChristensenJJ , Frimodt‐MollerN , KristiansenIS , et al. A randomised, placebo‐controlled 3 years study of prophylactic azithromycin in 575 patients with chronic obstructive pulmonary disease. European Respiratory Society 20th Annual Congress; 2010 Sep 18‐22; Barcelona. 2010. ">Mygind 2010</a> reported data on hospitalisation due to COPD exacerbations. The study showed no difference in the number of hospitalisations between the treatment and placebo arms; however, there was a median reduction in hospital stay from 18 days in the placebo group to 15.5 days in the treatment group. No P value was stated for this comparison. </p> </section> <section id="CD009764-sec-0078"> <h4 class="title">Secondary outcome: days of disability</h4> <p>Only one study reported on the number of days the participant was unable to undertake normal activity (<a href="./references#CD009764-bbs2-0006" title="MygindLH , PedersenC , VestboJ , ChristensenJJ , Frimodt‐MollerN , KristiansenIS , et al. A randomised, placebo‐controlled 3 years study of prophylactic azithromycin in 575 patients with chronic obstructive pulmonary disease. European Respiratory Society 20th Annual Congress; 2010 Sep 18‐22; Barcelona. 2010. ">Mygind 2010</a>). The median number of days spent at home due to a mild exacerbation was no different between the treatment and placebo arms (42 days in each arm). However, there was a reduction in the median number of days spent at home due to a moderate to severe exacerbation from 42.5 days in the placebo group to 31 days in the azithromycin group (P = 0.01). </p> </section> <section id="CD009764-sec-0079"> <h4 class="title">Secondary outcome: change in lung function</h4> <p>Change in lung function was addressed in nine studies (<a href="./references#CD009764-bbs2-0003" title="BerkhofFF , Doornewaard‐ten HertogNE , UilSM , KerstjensHAM , Van denBergJWK . Azithromycin and cough‐specific health status in patients with chronic obstructive pulmonary disease and chronic cough: a randomised controlled trial. Respiratory Research2013;14(1):125. BerkhofFF , TenHertogNE , UilSM , KerstjensHAM , Van DenBergJK , CACTUS study group. Randomized controlled trial of prophylactic azithromycin on cough‐specific health status in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2013;187:A2449. ">Berkhof 2013</a>; <a href="./references#CD009764-bbs2-0004" title="BrillS , JamesP , CuthbertsonL , CooksonW , MoffattM , WedzichaJ . Haemophilus dominance of the stable COPD microbiome is associated with greater bacterial load and inflammation and is modulated by prophylactic antibiotic therapy. European Respiratory Journal2015;46:OA4746. BrillS , LawM , AllinsonJ , El‐EmirE , McHughT , DonaldsonG , et al. Bacterial resistance induction with prophylactic antibiotics in COPD. European Respiratory Journal2014;44:P4731. BrillSE , LawM , El‐EmirE , AllinsonJP , JamesP , MaddoxV , et al. Effects of different antibiotic classes on airway bacteria in stable COPD using culture and molecular techniques: a randomised controlled trial. Thorax2015;70(10):930‐8. BrillSE , LawM , El‐EmirE , AllinsonP , NazarethI , DonaldsonGC , et al. Effect of antibiotics on airway bacteria in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2014;198:A2874. ">Brill 2015</a>; <a href="./references#CD009764-bbs2-0006" title="MygindLH , PedersenC , VestboJ , ChristensenJJ , Frimodt‐MollerN , KristiansenIS , et al. A randomised, placebo‐controlled 3 years study of prophylactic azithromycin in 575 patients with chronic obstructive pulmonary disease. European Respiratory Society 20th Annual Congress; 2010 Sep 18‐22; Barcelona. 2010. ">Mygind 2010</a>; <a href="./references#CD009764-bbs2-0009" title="SeemungalTA , WilkinsonTM , HurstJR , PereraWR , SapsfordRJ , WedzichaJA . Long‐term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. American Journal of Respiratory and Critical Care Medicine2008;178:1139‐47. ">Seemungal 2008</a>; <a href="./references#CD009764-bbs2-0010" title="SethiS , JonesPW , TheronMS , MiravitllesM , RubinsteinE , WedzichaJA , et al. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized control trial. Respiratory Research2010;11:10. ">Sethi 2010</a>; <a href="./references#CD009764-bbs2-0011" title="ShafuddinE , MillsGD , HolmesMD , PoolePJ , MullinsPR , BlackPN . A double‐blind, randomised, placebo‐controlled study of roxithromycin and doxycycline combination, roxithromycin alone, or matching placebo for 12 weeks in adults with frequent exacerbations of chronic obstructive pulmonary disease. Journal of Negative Results in Biomedicine2015;14:15. [DOI: 10.1186/s12952‐015‐0034‐8] ">Shafuddin 2015</a>; <a href="./references#CD009764-bbs2-0012" title="SimpsonJL , PowellH , BainesKJ , MilneD , CoxsonHO , HansbroPM , et al. The effect of azithromycin in adults with stable neutrophilic COPD: a double blind randomised, placebo controlled trial. PLOS One2014;9(8):e105609. ">Simpson 2014</a>; <a href="./references#CD009764-bbs2-0014" title="TanC , HuangH , ZhangJ , HeZ , ZhongX , BaiJ . Effects of low‐dose and long‐term treatment with erythromycin on IL‐17 and IL‐23 in peripheral blood and induced sputum in patients with stable chronic obstructive pulmonary disease. Chest2016;149:387A. TanC , HuangH , ZhangJ , HeZ , ZhongX , BaiJ . Effects of low‐dose and long‐term treatment with erythromycin on interleukin‐17 and interleukin‐23 in peripheral blood and induced sputum in patients with stable chronic obstructive pulmonary disease. Mediators of Inflammation2016:4173962. [DOI: 10.1155/2016/4173962] ">Tan 2016</a>; <a href="./references#CD009764-bbs2-0015" title="DjaminRS , UzunS , ErmensAAM , KerstensR , HoogstedenHC , AertsJGJV , et al. Which predictors in COPD patients with the frequent exacerbator phenotype predict the treatment response to maintenance therapy with azithromycin?. European Respiratory Journal2016;48:PA3713. UzunS , DjaminRS , AertsJGJV , Van DerEerdenMM . Patients with COPD Gold C &amp; D: the effect of long‐term treatment with azithromycin on exacerbation risk assessed by the Gold Framework. American Journal of Respiratory and Critical Care Medicine2014;189:A5967. UzunS , DjaminRS , KluytmansJA , MulderPG , Van't VeerNE , ErmensAA , et al. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double‐blind,placebo‐controlled trial. Lancet Respiratory Medicine2014;2(5):361‐8. UzunS , DjaminRS , MulderPGH , KluytmansJAJW , PelleAJ , Van't VeerNE , et al. Effect of azithromycin maintenance treatment in patients with frequent exacerbations of COPD (columbus): a randomized, double‐blind, placebo‐controlled trial. American Journal of Respiratory and Critical Care Medicine2014;189:A2884. ">Uzun 2014</a>). Six analysed changes in FEV1 in a total of 658 participants. The meta‐analysis showed no significant difference in FEV1 (MD 20 mL, 95% CI ‐26 to 67; participants = 658; studies = 9; moderate‐quality evidence; <a href="./references#CD009764-fig-0026" title="">Analysis 1.20</a>) with prophylactic antibiotics (continuous, intermittent, or pulsed) compared to placebo. Similarly, there was no significant difference in FEV1 % predicted values (MD 0.33, 95% CI ‐1.56 to 2.22; participants = 1737; studies = 6; <a href="./references#CD009764-fig-0028" title="">Analysis 1.22</a>). However, there appeared to be an improvement in FVC with antibiotic use (combining available data for continuous and intermittent regimens) (MD 0.12 L, 95% CI 0.01 to 0.23; participants = 514; studies = 4; <a href="./references#CD009764-fig-0027" title="">Analysis 1.21</a>). We did not detect any statistically significant differences between the antibiotic regimen subgroups. </p> </section> <section id="CD009764-sec-0080"> <h4 class="title">Secondary outcome: functional capacity</h4> <p>Two studies (<a href="./references#CD009764-bbs2-0014" title="TanC , HuangH , ZhangJ , HeZ , ZhongX , BaiJ . Effects of low‐dose and long‐term treatment with erythromycin on IL‐17 and IL‐23 in peripheral blood and induced sputum in patients with stable chronic obstructive pulmonary disease. Chest2016;149:387A. TanC , HuangH , ZhangJ , HeZ , ZhongX , BaiJ . Effects of low‐dose and long‐term treatment with erythromycin on interleukin‐17 and interleukin‐23 in peripheral blood and induced sputum in patients with stable chronic obstructive pulmonary disease. Mediators of Inflammation2016:4173962. [DOI: 10.1155/2016/4173962] ">Tan 2016</a> and <a href="./references#CD009764-bbs2-0015" title="DjaminRS , UzunS , ErmensAAM , KerstensR , HoogstedenHC , AertsJGJV , et al. Which predictors in COPD patients with the frequent exacerbator phenotype predict the treatment response to maintenance therapy with azithromycin?. European Respiratory Journal2016;48:PA3713. UzunS , DjaminRS , AertsJGJV , Van DerEerdenMM . Patients with COPD Gold C &amp; D: the effect of long‐term treatment with azithromycin on exacerbation risk assessed by the Gold Framework. American Journal of Respiratory and Critical Care Medicine2014;189:A5967. UzunS , DjaminRS , KluytmansJA , MulderPG , Van't VeerNE , ErmensAA , et al. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double‐blind,placebo‐controlled trial. Lancet Respiratory Medicine2014;2(5):361‐8. UzunS , DjaminRS , MulderPGH , KluytmansJAJW , PelleAJ , Van't VeerNE , et al. Effect of azithromycin maintenance treatment in patients with frequent exacerbations of COPD (columbus): a randomized, double‐blind, placebo‐controlled trial. American Journal of Respiratory and Critical Care Medicine2014;189:A2884. ">Uzun 2014</a>) assessed functional exercise capacity. Both studies measured the six‐minute walk test (6MWT) at baseline, three, six, nine, and 12 months. The meta‐analysis demonstrated a significant difference in favour of antibiotics in improving performance at 12 months, but with a high level of heterogeneity (MD 68 m, 95% CI 16 to 119; participants = 126; studies = 2; I<sup>2</sup> = 64%; <a href="./references#CD009764-fig-0029" title="">Analysis 1.23</a>). <a href="./references#CD009764-bbs2-0014" title="TanC , HuangH , ZhangJ , HeZ , ZhongX , BaiJ . Effects of low‐dose and long‐term treatment with erythromycin on IL‐17 and IL‐23 in peripheral blood and induced sputum in patients with stable chronic obstructive pulmonary disease. Chest2016;149:387A. TanC , HuangH , ZhangJ , HeZ , ZhongX , BaiJ . Effects of low‐dose and long‐term treatment with erythromycin on interleukin‐17 and interleukin‐23 in peripheral blood and induced sputum in patients with stable chronic obstructive pulmonary disease. Mediators of Inflammation2016:4173962. [DOI: 10.1155/2016/4173962] ">Tan 2016</a>, an unblinded study considered to be at high risk of bias, investigated continuous antibiotics and had two treatment arms (group A: erythromycin 125 mg three times a day for 12 months and group B: erythromycin 125 mg three times a day for six months) and a placebo arm. Their data suggested an improvement in exercise capacity at six months with erythromycin use compared to placebo, with similar results seen for both treatment groups, as would be expected (group A: mean distance 388 m ± 62 , n = 17; group B: mean distance 389 m ± 61, n = 17; placebo mean distance 326 m ± 79, n = 15). <a href="./references#CD009764-bbs2-0015" title="DjaminRS , UzunS , ErmensAAM , KerstensR , HoogstedenHC , AertsJGJV , et al. Which predictors in COPD patients with the frequent exacerbator phenotype predict the treatment response to maintenance therapy with azithromycin?. European Respiratory Journal2016;48:PA3713. UzunS , DjaminRS , AertsJGJV , Van DerEerdenMM . Patients with COPD Gold C &amp; D: the effect of long‐term treatment with azithromycin on exacerbation risk assessed by the Gold Framework. American Journal of Respiratory and Critical Care Medicine2014;189:A5967. UzunS , DjaminRS , KluytmansJA , MulderPG , Van't VeerNE , ErmensAA , et al. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double‐blind,placebo‐controlled trial. Lancet Respiratory Medicine2014;2(5):361‐8. UzunS , DjaminRS , MulderPGH , KluytmansJAJW , PelleAJ , Van't VeerNE , et al. Effect of azithromycin maintenance treatment in patients with frequent exacerbations of COPD (columbus): a randomized, double‐blind, placebo‐controlled trial. American Journal of Respiratory and Critical Care Medicine2014;189:A2884. ">Uzun 2014</a> investigated the use of intermittent azithromycin and, when isolated from <a href="./references#CD009764-bbs2-0014" title="TanC , HuangH , ZhangJ , HeZ , ZhongX , BaiJ . Effects of low‐dose and long‐term treatment with erythromycin on IL‐17 and IL‐23 in peripheral blood and induced sputum in patients with stable chronic obstructive pulmonary disease. Chest2016;149:387A. TanC , HuangH , ZhangJ , HeZ , ZhongX , BaiJ . Effects of low‐dose and long‐term treatment with erythromycin on interleukin‐17 and interleukin‐23 in peripheral blood and induced sputum in patients with stable chronic obstructive pulmonary disease. Mediators of Inflammation2016:4173962. [DOI: 10.1155/2016/4173962] ">Tan 2016</a>, this study did not show an improvement in 6MWT results with antibiotic use (MD 36, 95% CI ‐16 to 88; participants = 77). </p> </section> <section id="CD009764-sec-0081"> <h4 class="title">Secondary outcome: death (all‐cause and respiratory aetiology)</h4> <p>Mortality data were reported in six studies involving 3309 participants and were combined in a meta‐analysis (<a href="./references#CD009764-bbs2-0001" title="AlbertRK , ConnettJ , BaileyWC , CasaburiR , CooperJA , CrinerGJ , et al. Azithromycin for prevention of exacerbations of COPD. New England Journal of Medicine2011;365:689‐98. HanMK , TayobN , MurrayS , DransfieldMT , WashkoG , ScanlonPD , et al. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. American Journal of Respiratory and Critical Care Medicine2014;189(12):1503‐8. MartinezFJ , ConnettJ , VoelkerH , CrinerGJ , HanMK , MakeBJ , et al. Chronic azithromycin therapy decreases the risk of re‐hospitalization in patients with COPD. American Journal of Respiratory and Critical Care Medicine2013;187:A4383. O'ReillyPJ , JacksonPL , WellsJM , DransfieldMT , ScanlonPD , Blalock , JE . Sputum PGP is reduced by azithromycin treatment in patients with COPD and correlates with exacerbations. BMJ Open2013;3(12):e004140. WoodruffPG , ChatilaW , ConnettJE , CrinerGJ , CurtisJL , DransfieldMT , et al. Tumour necrosis factor receptor‐75 and risk of COPD exacerbation in the azithromycin trial. European Respiratory Journal2014;43:295–8. ">Albert 2011</a>; <a href="./references#CD009764-bbs2-0003" title="BerkhofFF , Doornewaard‐ten HertogNE , UilSM , KerstjensHAM , Van denBergJWK . Azithromycin and cough‐specific health status in patients with chronic obstructive pulmonary disease and chronic cough: a randomised controlled trial. Respiratory Research2013;14(1):125. BerkhofFF , TenHertogNE , UilSM , KerstjensHAM , Van DenBergJK , CACTUS study group. Randomized controlled trial of prophylactic azithromycin on cough‐specific health status in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2013;187:A2449. ">Berkhof 2013</a>; <a href="./references#CD009764-bbs2-0006" title="MygindLH , PedersenC , VestboJ , ChristensenJJ , Frimodt‐MollerN , KristiansenIS , et al. A randomised, placebo‐controlled 3 years study of prophylactic azithromycin in 575 patients with chronic obstructive pulmonary disease. European Respiratory Society 20th Annual Congress; 2010 Sep 18‐22; Barcelona. 2010. ">Mygind 2010</a>; <a href="./references#CD009764-bbs2-0010" title="SethiS , JonesPW , TheronMS , MiravitllesM , RubinsteinE , WedzichaJA , et al. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized control trial. Respiratory Research2010;11:10. ">Sethi 2010</a>; <a href="./references#CD009764-bbs2-0011" title="ShafuddinE , MillsGD , HolmesMD , PoolePJ , MullinsPR , BlackPN . A double‐blind, randomised, placebo‐controlled study of roxithromycin and doxycycline combination, roxithromycin alone, or matching placebo for 12 weeks in adults with frequent exacerbations of chronic obstructive pulmonary disease. Journal of Negative Results in Biomedicine2015;14:15. [DOI: 10.1186/s12952‐015‐0034‐8] ">Shafuddin 2015</a>; <a href="./references#CD009764-bbs2-0015" title="DjaminRS , UzunS , ErmensAAM , KerstensR , HoogstedenHC , AertsJGJV , et al. Which predictors in COPD patients with the frequent exacerbator phenotype predict the treatment response to maintenance therapy with azithromycin?. European Respiratory Journal2016;48:PA3713. UzunS , DjaminRS , AertsJGJV , Van DerEerdenMM . Patients with COPD Gold C &amp; D: the effect of long‐term treatment with azithromycin on exacerbation risk assessed by the Gold Framework. American Journal of Respiratory and Critical Care Medicine2014;189:A5967. UzunS , DjaminRS , KluytmansJA , MulderPG , Van't VeerNE , ErmensAA , et al. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double‐blind,placebo‐controlled trial. Lancet Respiratory Medicine2014;2(5):361‐8. UzunS , DjaminRS , MulderPGH , KluytmansJAJW , PelleAJ , Van't VeerNE , et al. Effect of azithromycin maintenance treatment in patients with frequent exacerbations of COPD (columbus): a randomized, double‐blind, placebo‐controlled trial. American Journal of Respiratory and Critical Care Medicine2014;189:A2884. ">Uzun 2014</a>). There was no significant difference between the treatment and placebo arms in all‐cause mortality (OR 0.87, 95% CI 0.66 to 1.15; participants = 3309; studies = 6; I<sup>2</sup> = 0%; moderate‐quality evidence; <a href="./references#CD009764-fig-0030" title="">Analysis 1.24</a>), but confidence intervals were not sufficiently narrow to exclude a clinically important difference. Data on mortality secondary to a respiratory cause were available in the two larger studies (<a href="./references#CD009764-bbs2-0001" title="AlbertRK , ConnettJ , BaileyWC , CasaburiR , CooperJA , CrinerGJ , et al. Azithromycin for prevention of exacerbations of COPD. New England Journal of Medicine2011;365:689‐98. HanMK , TayobN , MurrayS , DransfieldMT , WashkoG , ScanlonPD , et al. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. American Journal of Respiratory and Critical Care Medicine2014;189(12):1503‐8. MartinezFJ , ConnettJ , VoelkerH , CrinerGJ , HanMK , MakeBJ , et al. Chronic azithromycin therapy decreases the risk of re‐hospitalization in patients with COPD. American Journal of Respiratory and Critical Care Medicine2013;187:A4383. O'ReillyPJ , JacksonPL , WellsJM , DransfieldMT , ScanlonPD , Blalock , JE . Sputum PGP is reduced by azithromycin treatment in patients with COPD and correlates with exacerbations. BMJ Open2013;3(12):e004140. WoodruffPG , ChatilaW , ConnettJE , CrinerGJ , CurtisJL , DransfieldMT , et al. Tumour necrosis factor receptor‐75 and risk of COPD exacerbation in the azithromycin trial. European Respiratory Journal2014;43:295–8. ">Albert 2011</a>; <a href="./references#CD009764-bbs2-0010" title="SethiS , JonesPW , TheronMS , MiravitllesM , RubinsteinE , WedzichaJA , et al. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized control trial. Respiratory Research2010;11:10. ">Sethi 2010</a>), which again showed no significant difference between groups (OR 1.17, 95% CI 0.63 to 2.19; <a href="./references#CD009764-fig-0031" title="">Analysis 1.25</a>), but the estimate was imprecise. </p> </section> <section id="CD009764-sec-0082"> <h4 class="title">Secondary outcome: serious adverse events</h4> <p>Adverse events were well explained in ten studies (<a href="./references#CD009764-bbs2-0001" title="AlbertRK , ConnettJ , BaileyWC , CasaburiR , CooperJA , CrinerGJ , et al. Azithromycin for prevention of exacerbations of COPD. New England Journal of Medicine2011;365:689‐98. HanMK , TayobN , MurrayS , DransfieldMT , WashkoG , ScanlonPD , et al. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. American Journal of Respiratory and Critical Care Medicine2014;189(12):1503‐8. MartinezFJ , ConnettJ , VoelkerH , CrinerGJ , HanMK , MakeBJ , et al. Chronic azithromycin therapy decreases the risk of re‐hospitalization in patients with COPD. American Journal of Respiratory and Critical Care Medicine2013;187:A4383. O'ReillyPJ , JacksonPL , WellsJM , DransfieldMT , ScanlonPD , Blalock , JE . Sputum PGP is reduced by azithromycin treatment in patients with COPD and correlates with exacerbations. BMJ Open2013;3(12):e004140. WoodruffPG , ChatilaW , ConnettJE , CrinerGJ , CurtisJL , DransfieldMT , et al. Tumour necrosis factor receptor‐75 and risk of COPD exacerbation in the azithromycin trial. European Respiratory Journal2014;43:295–8. ">Albert 2011</a>; <a href="./references#CD009764-bbs2-0003" title="BerkhofFF , Doornewaard‐ten HertogNE , UilSM , KerstjensHAM , Van denBergJWK . Azithromycin and cough‐specific health status in patients with chronic obstructive pulmonary disease and chronic cough: a randomised controlled trial. Respiratory Research2013;14(1):125. BerkhofFF , TenHertogNE , UilSM , KerstjensHAM , Van DenBergJK , CACTUS study group. Randomized controlled trial of prophylactic azithromycin on cough‐specific health status in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2013;187:A2449. ">Berkhof 2013</a>; <a href="./references#CD009764-bbs2-0004" title="BrillS , JamesP , CuthbertsonL , CooksonW , MoffattM , WedzichaJ . Haemophilus dominance of the stable COPD microbiome is associated with greater bacterial load and inflammation and is modulated by prophylactic antibiotic therapy. European Respiratory Journal2015;46:OA4746. BrillS , LawM , AllinsonJ , El‐EmirE , McHughT , DonaldsonG , et al. Bacterial resistance induction with prophylactic antibiotics in COPD. European Respiratory Journal2014;44:P4731. BrillSE , LawM , El‐EmirE , AllinsonJP , JamesP , MaddoxV , et al. Effects of different antibiotic classes on airway bacteria in stable COPD using culture and molecular techniques: a randomised controlled trial. Thorax2015;70(10):930‐8. BrillSE , LawM , El‐EmirE , AllinsonP , NazarethI , DonaldsonGC , et al. Effect of antibiotics on airway bacteria in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2014;198:A2874. ">Brill 2015</a>; <a href="./references#CD009764-bbs2-0005" title="HeZY , OuLM , ZhangJQ , BaiJ , LiuGN , LiMH , et al. Effect of 6 months of erythromycin treatment on inflammatory cells in induced sputum and exacerbations in chronic obstructive pulmonary disease. Respiration2010;80:445‐52. ">He 2010</a>; <a href="./references#CD009764-bbs2-0009" title="SeemungalTA , WilkinsonTM , HurstJR , PereraWR , SapsfordRJ , WedzichaJA . Long‐term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. American Journal of Respiratory and Critical Care Medicine2008;178:1139‐47. ">Seemungal 2008</a>; <a href="./references#CD009764-bbs2-0010" title="SethiS , JonesPW , TheronMS , MiravitllesM , RubinsteinE , WedzichaJA , et al. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized control trial. Respiratory Research2010;11:10. ">Sethi 2010</a>; <a href="./references#CD009764-bbs2-0012" title="SimpsonJL , PowellH , BainesKJ , MilneD , CoxsonHO , HansbroPM , et al. The effect of azithromycin in adults with stable neutrophilic COPD: a double blind randomised, placebo controlled trial. PLOS One2014;9(8):e105609. ">Simpson 2014</a>; <a href="./references#CD009764-bbs2-0011" title="ShafuddinE , MillsGD , HolmesMD , PoolePJ , MullinsPR , BlackPN . A double‐blind, randomised, placebo‐controlled study of roxithromycin and doxycycline combination, roxithromycin alone, or matching placebo for 12 weeks in adults with frequent exacerbations of chronic obstructive pulmonary disease. Journal of Negative Results in Biomedicine2015;14:15. [DOI: 10.1186/s12952‐015‐0034‐8] ">Shafuddin 2015</a>; <a href="./references#CD009764-bbs2-0014" title="TanC , HuangH , ZhangJ , HeZ , ZhongX , BaiJ . Effects of low‐dose and long‐term treatment with erythromycin on IL‐17 and IL‐23 in peripheral blood and induced sputum in patients with stable chronic obstructive pulmonary disease. Chest2016;149:387A. TanC , HuangH , ZhangJ , HeZ , ZhongX , BaiJ . Effects of low‐dose and long‐term treatment with erythromycin on interleukin‐17 and interleukin‐23 in peripheral blood and induced sputum in patients with stable chronic obstructive pulmonary disease. Mediators of Inflammation2016:4173962. [DOI: 10.1155/2016/4173962] ">Tan 2016</a>; <a href="./references#CD009764-bbs2-0015" title="DjaminRS , UzunS , ErmensAAM , KerstensR , HoogstedenHC , AertsJGJV , et al. Which predictors in COPD patients with the frequent exacerbator phenotype predict the treatment response to maintenance therapy with azithromycin?. European Respiratory Journal2016;48:PA3713. UzunS , DjaminRS , AertsJGJV , Van DerEerdenMM . Patients with COPD Gold C &amp; D: the effect of long‐term treatment with azithromycin on exacerbation risk assessed by the Gold Framework. American Journal of Respiratory and Critical Care Medicine2014;189:A5967. UzunS , DjaminRS , KluytmansJA , MulderPG , Van't VeerNE , ErmensAA , et al. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double‐blind,placebo‐controlled trial. Lancet Respiratory Medicine2014;2(5):361‐8. UzunS , DjaminRS , MulderPGH , KluytmansJAJW , PelleAJ , Van't VeerNE , et al. Effect of azithromycin maintenance treatment in patients with frequent exacerbations of COPD (columbus): a randomized, double‐blind, placebo‐controlled trial. American Journal of Respiratory and Critical Care Medicine2014;189:A2884. ">Uzun 2014</a>), but there was no uniform system for reporting them. </p> <p>There was a reduction in serious adverse events as defined by the trialists, with prophylactic antibiotics, but the confidence interval included no difference (OR 0.88, 95% CI 0.74 to 1.05; participants = 2978; studies = 9; I<sup>2</sup> = 0%; moderate‐quality evidence; <a href="./references#CD009764-fig-0032" title="">Analysis 1.26</a>). Similarly, there was no significant difference in the total number of any adverse event, as defined by the trialists, between antibiotic prophylaxis and placebo arms (OR 1.07, 95% CI 0.69 to 1.67; participants = 512; studies = 4; I<sup>2</sup> = 0%; moderate‐quality evidence; <a href="./references#CD009764-fig-0033" title="">Analysis 1.27</a>), but the confidence interval was wide. </p> <p>Looking at specific adverse events, there were no significant differences in the number of adverse events between the treatment and placebo arms related to the respiratory system (<a href="./references#CD009764-fig-0034" title="">Analysis 1.28</a>.1), gastrointestinal system (<a href="./references#CD009764-fig-0034" title="">Analysis 1.28</a>.2), QTc prolongation (<a href="./references#CD009764-fig-0034" title="">Analysis 1.28</a>.3), musculoskeletal system (<a href="./references#CD009764-fig-0034" title="">Analysis 1.28</a>.5), hypersensitivity (<a href="./references#CD009764-fig-0034" title="">Analysis 1.28</a>.6), nervous system (<a href="./references#CD009764-fig-0034" title="">Analysis 1.28</a>.7) or the cardiovascular system (<a href="./references#CD009764-fig-0034" title="">Analysis 1.28</a>.8), but all estimates lacked precision. </p> <p>The adverse event most frequently recorded across the studies (<a href="./references#CD009764-bbs2-0001" title="AlbertRK , ConnettJ , BaileyWC , CasaburiR , CooperJA , CrinerGJ , et al. Azithromycin for prevention of exacerbations of COPD. New England Journal of Medicine2011;365:689‐98. HanMK , TayobN , MurrayS , DransfieldMT , WashkoG , ScanlonPD , et al. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. American Journal of Respiratory and Critical Care Medicine2014;189(12):1503‐8. MartinezFJ , ConnettJ , VoelkerH , CrinerGJ , HanMK , MakeBJ , et al. Chronic azithromycin therapy decreases the risk of re‐hospitalization in patients with COPD. American Journal of Respiratory and Critical Care Medicine2013;187:A4383. O'ReillyPJ , JacksonPL , WellsJM , DransfieldMT , ScanlonPD , Blalock , JE . Sputum PGP is reduced by azithromycin treatment in patients with COPD and correlates with exacerbations. BMJ Open2013;3(12):e004140. WoodruffPG , ChatilaW , ConnettJE , CrinerGJ , CurtisJL , DransfieldMT , et al. Tumour necrosis factor receptor‐75 and risk of COPD exacerbation in the azithromycin trial. European Respiratory Journal2014;43:295–8. ">Albert 2011</a>; <a href="./references#CD009764-bbs2-0003" title="BerkhofFF , Doornewaard‐ten HertogNE , UilSM , KerstjensHAM , Van denBergJWK . Azithromycin and cough‐specific health status in patients with chronic obstructive pulmonary disease and chronic cough: a randomised controlled trial. Respiratory Research2013;14(1):125. BerkhofFF , TenHertogNE , UilSM , KerstjensHAM , Van DenBergJK , CACTUS study group. Randomized controlled trial of prophylactic azithromycin on cough‐specific health status in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2013;187:A2449. ">Berkhof 2013</a>; <a href="./references#CD009764-bbs2-0005" title="HeZY , OuLM , ZhangJQ , BaiJ , LiuGN , LiMH , et al. Effect of 6 months of erythromycin treatment on inflammatory cells in induced sputum and exacerbations in chronic obstructive pulmonary disease. Respiration2010;80:445‐52. ">He 2010</a>; <a href="./references#CD009764-bbs2-0009" title="SeemungalTA , WilkinsonTM , HurstJR , PereraWR , SapsfordRJ , WedzichaJA . Long‐term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. American Journal of Respiratory and Critical Care Medicine2008;178:1139‐47. ">Seemungal 2008</a>; <a href="./references#CD009764-bbs2-0010" title="SethiS , JonesPW , TheronMS , MiravitllesM , RubinsteinE , WedzichaJA , et al. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized control trial. Respiratory Research2010;11:10. ">Sethi 2010</a>; <a href="./references#CD009764-bbs2-0012" title="SimpsonJL , PowellH , BainesKJ , MilneD , CoxsonHO , HansbroPM , et al. The effect of azithromycin in adults with stable neutrophilic COPD: a double blind randomised, placebo controlled trial. PLOS One2014;9(8):e105609. ">Simpson 2014</a>) was gastrointestinal in origin (OR 1.16, 95% CI 0.43 to 3.11; participants = 2522; studies = 6; I<sup>2</sup> = 72%, <a href="./references#CD009764-fig-0034" title="">Analysis 1.28</a>). There was significant heterogeneity among these studies which suggested differences among the antibiotics and their adverse events for each study. </p> <p>Individual studies did show some differences which may have clinical relevance.</p> <p><a href="./references#CD009764-bbs2-0010" title="SethiS , JonesPW , TheronMS , MiravitllesM , RubinsteinE , WedzichaJA , et al. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized control trial. Respiratory Research2010;11:10. ">Sethi 2010</a> reported significantly higher numbers of adverse events in the treatment arm with moxifloxacin (P &lt; 0.001) secondary to increased gastrointestinal adverse events including diarrhoea, nausea, and vomiting (OR 7.17; 95% CI 2.49 to 20.63; <a href="./references#CD009764-fig-0034" title="">Analysis 1.28</a>), representing a number needed to treat for an additional harmful outcome (NNTH) of 25 (95% CI 98 to 9). The intervention group in this study received moxifloxacin 400 mg daily for 5 days, every 8 weeks for 48 weeks. A single case of diarrhoea was reported secondary to <i>Clostridium difficile</i> in the placebo group. <a href="./references#CD009764-bbs2-0010" title="SethiS , JonesPW , TheronMS , MiravitllesM , RubinsteinE , WedzichaJA , et al. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized control trial. Respiratory Research2010;11:10. ">Sethi 2010</a> stated that the adverse events were drug‐related. </p> <p><a href="./references#CD009764-bbs2-0001" title="AlbertRK , ConnettJ , BaileyWC , CasaburiR , CooperJA , CrinerGJ , et al. Azithromycin for prevention of exacerbations of COPD. New England Journal of Medicine2011;365:689‐98. HanMK , TayobN , MurrayS , DransfieldMT , WashkoG , ScanlonPD , et al. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. American Journal of Respiratory and Critical Care Medicine2014;189(12):1503‐8. MartinezFJ , ConnettJ , VoelkerH , CrinerGJ , HanMK , MakeBJ , et al. Chronic azithromycin therapy decreases the risk of re‐hospitalization in patients with COPD. American Journal of Respiratory and Critical Care Medicine2013;187:A4383. O'ReillyPJ , JacksonPL , WellsJM , DransfieldMT , ScanlonPD , Blalock , JE . Sputum PGP is reduced by azithromycin treatment in patients with COPD and correlates with exacerbations. BMJ Open2013;3(12):e004140. WoodruffPG , ChatilaW , ConnettJE , CrinerGJ , CurtisJL , DransfieldMT , et al. Tumour necrosis factor receptor‐75 and risk of COPD exacerbation in the azithromycin trial. European Respiratory Journal2014;43:295–8. ">Albert 2011</a> reported that azithromycin 250 mg daily for a 12‐month period was associated with a significant increase in hearing impairment (OR 1.39; 95% CI 1.05 to 1.85) representing a NNTH of 18 (95% CI 128 to 9). The authors reported that the majority of the drug discontinuations due to a drug‐related adverse events were due to hearing impairment (treatment group, N = 142 (25%) versus placebo group, N = 110 (20%) by three months). It should be noted that all participants in this study had baseline audiometry, with participants with hearing impairment below the 95% percentile excluded from the study. Since there were a large number of participants in both the treatment and placebo arms that had drug discontinuation secondary to hearing loss, the authors commented that this could be due to a measurement error. </p> <p>In <a href="./references#CD009764-bbs2-0001" title="AlbertRK , ConnettJ , BaileyWC , CasaburiR , CooperJA , CrinerGJ , et al. Azithromycin for prevention of exacerbations of COPD. New England Journal of Medicine2011;365:689‐98. HanMK , TayobN , MurrayS , DransfieldMT , WashkoG , ScanlonPD , et al. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. American Journal of Respiratory and Critical Care Medicine2014;189(12):1503‐8. MartinezFJ , ConnettJ , VoelkerH , CrinerGJ , HanMK , MakeBJ , et al. Chronic azithromycin therapy decreases the risk of re‐hospitalization in patients with COPD. American Journal of Respiratory and Critical Care Medicine2013;187:A4383. O'ReillyPJ , JacksonPL , WellsJM , DransfieldMT , ScanlonPD , Blalock , JE . Sputum PGP is reduced by azithromycin treatment in patients with COPD and correlates with exacerbations. BMJ Open2013;3(12):e004140. WoodruffPG , ChatilaW , ConnettJE , CrinerGJ , CurtisJL , DransfieldMT , et al. Tumour necrosis factor receptor‐75 and risk of COPD exacerbation in the azithromycin trial. European Respiratory Journal2014;43:295–8. ">Albert 2011</a>, while there were no statistically significant differences observed in cardiovascular disease or QTc prolongation, six participants in the treatment group had to discontinue the medication due to development of prolonged QTc compared to four participants in the placebo group (P = 0.55). This study excluded participants with tachycardia, long QTc, and participants taking medications that could prolong the QTc. </p> <p>In the non‐blinded study of <a href="./references#CD009764-bbs2-0013" title="SuzukiT , YaniM , YamayaM , Satoh NakagawaT , SekizawaK , IshidaS , et al. Erythromycin and common cold in COPD. Chest2001;120:730‐3. ">Suzuki 2001</a>, it was reported that participants in the treatment group did not have any apparent adverse effects from erythromycin therapy during the study period. </p> <p><a href="./references#CD009764-bbs2-0011" title="ShafuddinE , MillsGD , HolmesMD , PoolePJ , MullinsPR , BlackPN . A double‐blind, randomised, placebo‐controlled study of roxithromycin and doxycycline combination, roxithromycin alone, or matching placebo for 12 weeks in adults with frequent exacerbations of chronic obstructive pulmonary disease. Journal of Negative Results in Biomedicine2015;14:15. [DOI: 10.1186/s12952‐015‐0034‐8] ">Shafuddin 2015</a> reported one case of an abnormal electrocardiogram (ECG) deemed to be related to the combined roxithromycin/doxycyline medication. </p> <p><a href="./references#CD009764-bbs2-0004" title="BrillS , JamesP , CuthbertsonL , CooksonW , MoffattM , WedzichaJ . Haemophilus dominance of the stable COPD microbiome is associated with greater bacterial load and inflammation and is modulated by prophylactic antibiotic therapy. European Respiratory Journal2015;46:OA4746. BrillS , LawM , AllinsonJ , El‐EmirE , McHughT , DonaldsonG , et al. Bacterial resistance induction with prophylactic antibiotics in COPD. European Respiratory Journal2014;44:P4731. BrillSE , LawM , El‐EmirE , AllinsonJP , JamesP , MaddoxV , et al. Effects of different antibiotic classes on airway bacteria in stable COPD using culture and molecular techniques: a randomised controlled trial. Thorax2015;70(10):930‐8. BrillSE , LawM , El‐EmirE , AllinsonP , NazarethI , DonaldsonGC , et al. Effect of antibiotics on airway bacteria in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2014;198:A2874. ">Brill 2015</a> found that 40% of adverse events, although reported as minor, were in the moxifloxacin group, with half of those being gastrointestinal. In four cases, therapy was withdrawn in this group. </p> </section> <section id="CD009764-sec-0083"> <h4 class="title">Secondary outcome: antibiotic resistance</h4> <p>The development of antibiotic resistance was assessed in six studies involving 2610 participants (<a href="./references#CD009764-bbs2-0001" title="AlbertRK , ConnettJ , BaileyWC , CasaburiR , CooperJA , CrinerGJ , et al. Azithromycin for prevention of exacerbations of COPD. New England Journal of Medicine2011;365:689‐98. HanMK , TayobN , MurrayS , DransfieldMT , WashkoG , ScanlonPD , et al. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. American Journal of Respiratory and Critical Care Medicine2014;189(12):1503‐8. MartinezFJ , ConnettJ , VoelkerH , CrinerGJ , HanMK , MakeBJ , et al. Chronic azithromycin therapy decreases the risk of re‐hospitalization in patients with COPD. American Journal of Respiratory and Critical Care Medicine2013;187:A4383. O'ReillyPJ , JacksonPL , WellsJM , DransfieldMT , ScanlonPD , Blalock , JE . Sputum PGP is reduced by azithromycin treatment in patients with COPD and correlates with exacerbations. BMJ Open2013;3(12):e004140. WoodruffPG , ChatilaW , ConnettJE , CrinerGJ , CurtisJL , DransfieldMT , et al. Tumour necrosis factor receptor‐75 and risk of COPD exacerbation in the azithromycin trial. European Respiratory Journal2014;43:295–8. ">Albert 2011</a>; <a href="./references#CD009764-bbs2-0002" title="BanerjeeD , HoneybourneD , KhairOA . The effect of oral Clarithromycin on bronchial airway inflammation in moderate‐to‐severe stable COPD: a randomised controlled trial. Treatments in Respiratory Medicine2004;3:59‐65. BanerjeeD , KhairO , HoneybourneD . The effect of oral clarithromycin on health status and sputum bacteriology in stable COPD. Respiratory Medicine2005;99:208‐15. ">Banerjee 2005</a>; <a href="./references#CD009764-bbs2-0004" title="BrillS , JamesP , CuthbertsonL , CooksonW , MoffattM , WedzichaJ . Haemophilus dominance of the stable COPD microbiome is associated with greater bacterial load and inflammation and is modulated by prophylactic antibiotic therapy. European Respiratory Journal2015;46:OA4746. BrillS , LawM , AllinsonJ , El‐EmirE , McHughT , DonaldsonG , et al. Bacterial resistance induction with prophylactic antibiotics in COPD. European Respiratory Journal2014;44:P4731. BrillSE , LawM , El‐EmirE , AllinsonJP , JamesP , MaddoxV , et al. Effects of different antibiotic classes on airway bacteria in stable COPD using culture and molecular techniques: a randomised controlled trial. Thorax2015;70(10):930‐8. BrillSE , LawM , El‐EmirE , AllinsonP , NazarethI , DonaldsonGC , et al. Effect of antibiotics on airway bacteria in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2014;198:A2874. ">Brill 2015</a>; <a href="./references#CD009764-bbs2-0005" title="HeZY , OuLM , ZhangJQ , BaiJ , LiuGN , LiMH , et al. Effect of 6 months of erythromycin treatment on inflammatory cells in induced sputum and exacerbations in chronic obstructive pulmonary disease. Respiration2010;80:445‐52. ">He 2010</a>; <a href="./references#CD009764-bbs2-0009" title="SeemungalTA , WilkinsonTM , HurstJR , PereraWR , SapsfordRJ , WedzichaJA . Long‐term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. American Journal of Respiratory and Critical Care Medicine2008;178:1139‐47. ">Seemungal 2008</a>; <a href="./references#CD009764-bbs2-0010" title="SethiS , JonesPW , TheronMS , MiravitllesM , RubinsteinE , WedzichaJA , et al. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized control trial. Respiratory Research2010;11:10. ">Sethi 2010</a>). Because of the variety of ways in which resistance was evaluated and reported, it has proved impossible to combine these results in a meta‐analysis. </p> <p>In <a href="./references#CD009764-bbs2-0004" title="BrillS , JamesP , CuthbertsonL , CooksonW , MoffattM , WedzichaJ . Haemophilus dominance of the stable COPD microbiome is associated with greater bacterial load and inflammation and is modulated by prophylactic antibiotic therapy. European Respiratory Journal2015;46:OA4746. BrillS , LawM , AllinsonJ , El‐EmirE , McHughT , DonaldsonG , et al. Bacterial resistance induction with prophylactic antibiotics in COPD. European Respiratory Journal2014;44:P4731. BrillSE , LawM , El‐EmirE , AllinsonJP , JamesP , MaddoxV , et al. Effects of different antibiotic classes on airway bacteria in stable COPD using culture and molecular techniques: a randomised controlled trial. Thorax2015;70(10):930‐8. BrillSE , LawM , El‐EmirE , AllinsonP , NazarethI , DonaldsonGC , et al. Effect of antibiotics on airway bacteria in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2014;198:A2874. ">Brill 2015</a>, both sputum bacterial load and antibiotic resistance was assessed pre‐ and post‐ 13 weeks antibiotic treatment. Bacterial load was reduced by all three antibiotic treatments, and most substantially (by 62%) in the pulsed moxifloxacin arm, but there was not a statistically significant difference when compared to placebo in any of the three treatment arms. The most common isolate both pre and post‐treatment was non‐<i>Pneumoniae streptococcus</i> species. There were increases in the degree of antibiotic resistance of isolates in all three antibiotic arms after 13 weeks treatment. Compared to placebo, moxifloxacin was associated with a factor increase in mean inhibitory concentration (MIC) of 4.82 (95% CI 1.44 to 16.19, P = 0.01), doxycycline 3.74 (95% CI 1.46 to 9.58, P = 0.01) and azithromycin 6.23 (95% CI 1.66 to 23.35, P = 0.01). Furthermore, isolates from participants in the doxycycline group were more likely to be resistant to doxycycline than in the placebo group (OR 5.77, 95% CI 1.40 to 23.74, P = 0.02). ORs for the moxifloxacin and azithromycin were also greater than 2, but not statistically significant. </p> <p><a href="./references#CD009764-bbs2-0001" title="AlbertRK , ConnettJ , BaileyWC , CasaburiR , CooperJA , CrinerGJ , et al. Azithromycin for prevention of exacerbations of COPD. New England Journal of Medicine2011;365:689‐98. HanMK , TayobN , MurrayS , DransfieldMT , WashkoG , ScanlonPD , et al. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. American Journal of Respiratory and Critical Care Medicine2014;189(12):1503‐8. MartinezFJ , ConnettJ , VoelkerH , CrinerGJ , HanMK , MakeBJ , et al. Chronic azithromycin therapy decreases the risk of re‐hospitalization in patients with COPD. American Journal of Respiratory and Critical Care Medicine2013;187:A4383. O'ReillyPJ , JacksonPL , WellsJM , DransfieldMT , ScanlonPD , Blalock , JE . Sputum PGP is reduced by azithromycin treatment in patients with COPD and correlates with exacerbations. BMJ Open2013;3(12):e004140. WoodruffPG , ChatilaW , ConnettJE , CrinerGJ , CurtisJL , DransfieldMT , et al. Tumour necrosis factor receptor‐75 and risk of COPD exacerbation in the azithromycin trial. European Respiratory Journal2014;43:295–8. ">Albert 2011</a> used sputum from participants who could expectorate as well as nasopharyngeal swabs. They found only 15% of participants were able to expectorate at the end of the three‐month treatment period. The commonest organisms identified in the treatment versus placebo groups were: <i>Staphylococcus aureus</i> (N = 60 (10.7%) versus N = 71 (12.7%)); <i>Moraxella spp</i> (N=13 (2.3%) versus N = 6 (1%)); and <i>S. pneumoniae</i> (N = 6 (1.1%) versus N = 6 (1.1%)). The predominance of <i>S. aureus</i> in this COPD population was out of keeping with the usual pathogens anticipated and was thought to be due to the nasopharyngeal sampling. During the study period, the participants in the placebo group without bacterial colonisation (N = 172) became colonised at a significantly higher rate than those treated with 250 mg of daily azithromycin (N = 66) (P &lt; 0.001). However, in the group that became newly colonised throughout the study period, the resistance to macrolide was higher in the treatment group: 81% compared to 41% in the placebo group (P &lt; 0.001). </p> <p>In <a href="./references#CD009764-bbs2-0010" title="SethiS , JonesPW , TheronMS , MiravitllesM , RubinsteinE , WedzichaJA , et al. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized control trial. Respiratory Research2010;11:10. ">Sethi 2010</a>, which used pulsed moxifloxacin over a 48‐week period, the sampling for organisms was carried out using sputum sampling and rectal sampling. Only 24% of all participants could produce sputum. The commonest organisms isolated were: <i>H. influenzae</i> (8.3%), <i>Haemophilus parainfluenzae</i> (6.6%) and <i>S. pneumoniae</i> (4.3%); <i>S. aureus</i> was isolated in 2.6%. The MIC for moxifloxacin for <i>H. influenzae</i> , <i>H. parainfluenzae</i> , <i>S. pneumoniae</i> , <i>M. catarrhalis</i> and <i>S. aureus</i> did not change during the study period. A single moxifloxacin‐resistant <i>S. pneumoniae</i> isolate was identified at the end of the study period (MIC 4 mg/L). There were one to three moxifloxacin‐resistant isolates at different points of the study that were not persistent. Participants who had produced cultures of moxifloxacin‐resistant pseudomonas were excluded from the study. However, participants with moxifloxacin‐sensitive pseudomonas were included. During the 24th week of the study, the median MIC of moxifloxacin had increased to 4 mg/L, which returned to baseline at the end of the treatment period. The median MIC of the placebo group with pseudomonas‐sensitive moxifloxacin increased from 0.5 mg/L to 2 mg/L at the end of the treatment period. The study authors recommended not using moxifloxacin in patients with known pseudomonas colonisation owing to the possibility of developing rapid resistance. </p> <p><a href="./references#CD009764-bbs2-0009" title="SeemungalTA , WilkinsonTM , HurstJR , PereraWR , SapsfordRJ , WedzichaJA . Long‐term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. American Journal of Respiratory and Critical Care Medicine2008;178:1139‐47. ">Seemungal 2008</a> investigated 109 participants with twice daily erythromycin 250 mg over a 12‐month period. They encountered only one participant who developed resistance to <i>S. pneumoniae</i> at the end of the treatment period. All <i>H. influenzae</i> isolated (22/109) were found to be resistant to erythromycin. The microorganism milieu was as expected for the COPD population: <i>H. influenzae</i> (N = 22/36), <i>S. pneumoniae</i> (N = 6/36) and <i>M. catarrhalis</i> (N = 3/36). </p> <p>The other two studies, (<a href="./references#CD009764-bbs2-0002" title="BanerjeeD , HoneybourneD , KhairOA . The effect of oral Clarithromycin on bronchial airway inflammation in moderate‐to‐severe stable COPD: a randomised controlled trial. Treatments in Respiratory Medicine2004;3:59‐65. BanerjeeD , KhairO , HoneybourneD . The effect of oral clarithromycin on health status and sputum bacteriology in stable COPD. Respiratory Medicine2005;99:208‐15. ">Banerjee 2005</a> using long‐acting clarithromycin 500 mg daily (Klaricid XL 500 mg) and <a href="./references#CD009764-bbs2-0005" title="HeZY , OuLM , ZhangJQ , BaiJ , LiuGN , LiMH , et al. Effect of 6 months of erythromycin treatment on inflammatory cells in induced sputum and exacerbations in chronic obstructive pulmonary disease. Respiration2010;80:445‐52. ">He 2010</a> using erythromycin 125 mg every eight hours), found a similar milieu of respiratory pathogens. They did not observe significant differences in the colonisation rate of the organisms or emergence of resistance. However, these two studies were of a shorter duration than those mentioned above, six months and three months, respectively. </p> </section> <section id="CD009764-sec-0084"> <h4 class="title">Subgroup and sensitivity analyses</h4> <section id="CD009764-sec-0085"> <h5 class="title">Subgroup analyses</h5> <p>We performed subgroup analysis on our primary outcome only: number of people with one or more exacerbations. We subgrouped studies according to mean baseline FEV1 % predicted but only one study was included in the &gt; 50% predicted subgroup and thus we cannot draw any conclusions from this analysis (<a href="./references#CD009764-fig-0035" title="">Analysis 2.1</a>). We did not find any statistically significant impact of study duration (three to six months, six to 12 months and over 12 months) on this outcome (<a href="./references#CD009764-fig-0036" title="">Analysis 2.2</a>). We subgrouped studies according to their date of publication in five‐year groups from 2005 to 2009, 2010 to 2014 and 2015 onwards (<a href="./references#CD009764-fig-0037" title="">Analysis 2.3</a>). Six out of the eight studies appearing in this analysis were published between 2010 and 2014, so again, this analysis was inconclusive. When subgrouped according to frequency of antibiotic administration (once daily, 2 to 3 times daily, 2 to 3 times per week and pulsed), there was some evidence that pulsed antibiotics were less effective than regimens that require more frequent dosing, in keeping with our other findings (<a href="./references#CD009764-fig-0038" title="">Analysis 2.4</a>; test for subgroup differences: Chi² = 9.51, df = 3 (P = 0.02), I² = 68.4%). Finally, we did not find a statistically significant subgroup difference when we grouped studies according to exacerbation history as an inclusion criterion (studies in which participants were required to have had at least one exacerbation in the preceding year versus those in which exacerbation history was not an inclusion criterion) (<a href="./references#CD009764-fig-0039" title="">Analysis 2.5</a>). However, it should be noted that many of the studies included in the second subgroup recruited participants who had a positive exacerbation history, despite it not being a requirement for study entry. </p> </section> <section id="CD009764-sec-0086"> <h5 class="title">Sensitivity analyses</h5> <p>We applied our sensitivity analysis to our primary outcome only: number of people with one or more exacerbations. This resulted in the removal of all three arms of the single‐blind study <a href="./references#CD009764-bbs2-0004" title="BrillS , JamesP , CuthbertsonL , CooksonW , MoffattM , WedzichaJ . Haemophilus dominance of the stable COPD microbiome is associated with greater bacterial load and inflammation and is modulated by prophylactic antibiotic therapy. European Respiratory Journal2015;46:OA4746. BrillS , LawM , AllinsonJ , El‐EmirE , McHughT , DonaldsonG , et al. Bacterial resistance induction with prophylactic antibiotics in COPD. European Respiratory Journal2014;44:P4731. BrillSE , LawM , El‐EmirE , AllinsonJP , JamesP , MaddoxV , et al. Effects of different antibiotic classes on airway bacteria in stable COPD using culture and molecular techniques: a randomised controlled trial. Thorax2015;70(10):930‐8. BrillSE , LawM , El‐EmirE , AllinsonP , NazarethI , DonaldsonGC , et al. Effect of antibiotics on airway bacteria in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2014;198:A2874. ">Brill 2015</a>. This had a minimal impact on the effect estimate (0.54, 95% CI 0.38 to 0.77 versus OR 0.57, 95% CI 0.42 to 0.78). </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD009764-sec-0087" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009764-sec-0087">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009764-sec-0156">Español</a> </li> </nav> </div> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD009764-sec-0087"></div> <section id="CD009764-sec-0088"> <h3 class="title" id="CD009764-sec-0088">Summary of main results</h3> <p>In this review, we analysed a total of 14 completed studies, involving 3932 participants, that investigated the use of prophylactic antibiotics for the prevention of COPD exacerbations. All participants were adult (over the age of 40 years), with the mean age between 65 and 72 years. Most participants had at least moderate‐severity COPD and we only included studies if they confirmed this diagnosis with spirometry. The antibiotics investigated were azithromycin, erythromycin, clarithromycin, doxycyline, roxithromycin, and moxifloxacin. Nine studies involving 1925 participants investigated continuous macrolide antibiotic regimens, two studies involving 176 participants investigated intermittent azithromycin antibiotic regimens (administered three times a week), two studies involving 1732 participants investigated different pulsed antibiotic regimens (one macrolide and one quinolone) and one study involving 99 participants compared three treatment arms with placebo; one continuous doxycycline regimen, one intermittent azithromycin regimen and one pulsed moxifloxacin regimen. The study duration varied from three months to 36 months and all used intention‐to‐treat analysis. Most of the pooled results were of moderate quality. The risk of bias of the included studies was generally low, and we did not downgrade the quality of evidence for risk of bias. </p> <section id="CD009764-sec-0089"> <h4 class="title">Primary outcomes</h4> <p>Eight studies including 2716 participants were included in the meta‐analysis of the number of people with one or more exacerbations (<a href="#CD009764-fig-0003">Figure 3</a>). The results of this analysis indicated that the number of participants experiencing one or more exacerbations was significantly reduced with the use of prophylactic antibiotics (OR 0.57, 95% CI 0.42 to 0.78; participants = 2716; studies = 10; I<sup>2</sup> = 42%) .The subgroup analysis for this outcome suggested that there was a statistically significant difference between continuous and intermittent regimens and pulsed regimens for the number of people with one or more exacerbations, with pulsed antibiotic regimens having a smaller treatment effect. Similarly, the rate of exacerbations per patient per year with continuous and intermittent antibiotic use were significantly reduced (<a href="./references#CD009764-fig-0010" title="">Analysis 1.4</a>; moderate‐quality evidence). The median time to first exacerbation was lengthened with continuous and intermittent antibiotic prophylaxis (<a href="./references#CD009764-fig-0011" title="">Analysis 1.5</a>), however, only the continuous antibiotic regimens and one intermittent antibiotic regimen were associated with statistically significant delays. Pulsed antibiotic prophylaxis did not appear to be associated with the same benefits. </p> <p>Health‐related quality of life was explored in nine studies using different assessment tools, as detailed in the above results. The results were mixed, with some studies finding no or uncertain improvement in quality of life indicators with antibiotic prophylaxis whilst others found improvement in some quality of life domains. The most commonly used quality of life scale was the SGRQ. It was used in seven studies involving 2237 participants and our meta‐analysis suggested a statistically significant benefit in quality of life total score with antibiotic prophylaxis compared to placebo (MD ‐1.94, 95% CI ‐3.13 to ‐0.75; participants = 2237; high‐quality evidence) (<a href="./references#CD009764-fig-0015" title="">Analysis 1.9</a>). While this mean difference did not reach the accepted level of clinical significance (<a href="./references#CD009764-bbs2-0078" title="JonesP . St George's Respiratory Questionnaire Manual Version 2.3. www.healthstatus.sgul.ac.uk/SGRQ_download/SGRQ%20Manual%20June%202009.pdf (accessed prior to 20 July 2018). ">Jones 2009</a>), a responder analysis carried out in <a href="./references#CD009764-bbs2-0001" title="AlbertRK , ConnettJ , BaileyWC , CasaburiR , CooperJA , CrinerGJ , et al. Azithromycin for prevention of exacerbations of COPD. New England Journal of Medicine2011;365:689‐98. HanMK , TayobN , MurrayS , DransfieldMT , WashkoG , ScanlonPD , et al. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. American Journal of Respiratory and Critical Care Medicine2014;189(12):1503‐8. MartinezFJ , ConnettJ , VoelkerH , CrinerGJ , HanMK , MakeBJ , et al. Chronic azithromycin therapy decreases the risk of re‐hospitalization in patients with COPD. American Journal of Respiratory and Critical Care Medicine2013;187:A4383. O'ReillyPJ , JacksonPL , WellsJM , DransfieldMT , ScanlonPD , Blalock , JE . Sputum PGP is reduced by azithromycin treatment in patients with COPD and correlates with exacerbations. BMJ Open2013;3(12):e004140. WoodruffPG , ChatilaW , ConnettJE , CrinerGJ , CurtisJL , DransfieldMT , et al. Tumour necrosis factor receptor‐75 and risk of COPD exacerbation in the azithromycin trial. European Respiratory Journal2014;43:295–8. ">Albert 2011</a> demonstrated that more participants in the continuous azithromycin group (43%) than the placebo group (36%) had at least a four‐unit reduction in the SGRQ (P = 0.03). Again, with subgroup analysis, where an improvement in quality of life was identified, it appeared to be with continuous and intermittent antibiotic prophylaxis. No clear improvement was found with pulsed antibiotic regimens. </p> </section> <section id="CD009764-sec-0090"> <h4 class="title">Secondary outcomes</h4> <p>One study, <a href="./references#CD009764-bbs2-0013" title="SuzukiT , YaniM , YamayaM , Satoh NakagawaT , SekizawaK , IshidaS , et al. Erythromycin and common cold in COPD. Chest2001;120:730‐3. ">Suzuki 2001</a>, found a statistically significant reduction in hospital admissions with prophylactic erythromycin use, whilst three other studies found no significant reduction in hospital admissions (<a href="./references#CD009764-bbs2-0001" title="AlbertRK , ConnettJ , BaileyWC , CasaburiR , CooperJA , CrinerGJ , et al. Azithromycin for prevention of exacerbations of COPD. New England Journal of Medicine2011;365:689‐98. HanMK , TayobN , MurrayS , DransfieldMT , WashkoG , ScanlonPD , et al. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. American Journal of Respiratory and Critical Care Medicine2014;189(12):1503‐8. MartinezFJ , ConnettJ , VoelkerH , CrinerGJ , HanMK , MakeBJ , et al. Chronic azithromycin therapy decreases the risk of re‐hospitalization in patients with COPD. American Journal of Respiratory and Critical Care Medicine2013;187:A4383. O'ReillyPJ , JacksonPL , WellsJM , DransfieldMT , ScanlonPD , Blalock , JE . Sputum PGP is reduced by azithromycin treatment in patients with COPD and correlates with exacerbations. BMJ Open2013;3(12):e004140. WoodruffPG , ChatilaW , ConnettJE , CrinerGJ , CurtisJL , DransfieldMT , et al. Tumour necrosis factor receptor‐75 and risk of COPD exacerbation in the azithromycin trial. European Respiratory Journal2014;43:295–8. ">Albert 2011</a>; <a href="./references#CD009764-bbs2-0006" title="MygindLH , PedersenC , VestboJ , ChristensenJJ , Frimodt‐MollerN , KristiansenIS , et al. A randomised, placebo‐controlled 3 years study of prophylactic azithromycin in 575 patients with chronic obstructive pulmonary disease. European Respiratory Society 20th Annual Congress; 2010 Sep 18‐22; Barcelona. 2010. ">Mygind 2010</a>; <a href="./references#CD009764-bbs2-0010" title="SethiS , JonesPW , TheronMS , MiravitllesM , RubinsteinE , WedzichaJA , et al. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized control trial. Respiratory Research2010;11:10. ">Sethi 2010</a>). There was no statistically significant difference between antibiotic prophylaxis and placebo in FEV1, all‐cause mortality, or adverse events (moderate‐quality evidence) but, for both mortality and adverse events, confidence intervals were too wide to rule out an effect. However, specific adverse events reported in some of the studies may have clinical relevance, given their severity. </p> <p>The 6MWT was used to measure the functional capacity in two studies in the meta‐analysis involving 126 participants (<a href="./references#CD009764-fig-0029" title="">Analysis 1.23</a>). One study, considered to be at high risk of bias (<a href="./references#CD009764-bbs2-0014" title="TanC , HuangH , ZhangJ , HeZ , ZhongX , BaiJ . Effects of low‐dose and long‐term treatment with erythromycin on IL‐17 and IL‐23 in peripheral blood and induced sputum in patients with stable chronic obstructive pulmonary disease. Chest2016;149:387A. TanC , HuangH , ZhangJ , HeZ , ZhongX , BaiJ . Effects of low‐dose and long‐term treatment with erythromycin on interleukin‐17 and interleukin‐23 in peripheral blood and induced sputum in patients with stable chronic obstructive pulmonary disease. Mediators of Inflammation2016:4173962. [DOI: 10.1155/2016/4173962] ">Tan 2016</a>) investigated continuous antibiotics and demonstrated a statistically significant benefit in the 6MWT (MD 84.5 m (45.7 to 123.29) with use of antibiotics whilst the result was uncertain in a study using intermittent antibiotics (<a href="./references#CD009764-bbs2-0015" title="DjaminRS , UzunS , ErmensAAM , KerstensR , HoogstedenHC , AertsJGJV , et al. Which predictors in COPD patients with the frequent exacerbator phenotype predict the treatment response to maintenance therapy with azithromycin?. European Respiratory Journal2016;48:PA3713. UzunS , DjaminRS , AertsJGJV , Van DerEerdenMM . Patients with COPD Gold C &amp; D: the effect of long‐term treatment with azithromycin on exacerbation risk assessed by the Gold Framework. American Journal of Respiratory and Critical Care Medicine2014;189:A5967. UzunS , DjaminRS , KluytmansJA , MulderPG , Van't VeerNE , ErmensAA , et al. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double‐blind,placebo‐controlled trial. Lancet Respiratory Medicine2014;2(5):361‐8. UzunS , DjaminRS , MulderPGH , KluytmansJAJW , PelleAJ , Van't VeerNE , et al. Effect of azithromycin maintenance treatment in patients with frequent exacerbations of COPD (columbus): a randomized, double‐blind, placebo‐controlled trial. American Journal of Respiratory and Critical Care Medicine2014;189:A2884. ">Uzun 2014</a>). </p> <p>The development of antibiotic resistance was addressed in six studies involving 2486 participants. Due to the multitude of methodologies used to detect and report resistance, the data were not able to be pooled in a meta‐analysis. Of concern, four of these six studies identified evidence of antibiotic resistance. However, there was not sufficient evidence for us to predict how the use of prophylactic antibiotics would affect the resistance patterns in the community and studies with a longer duration of follow‐up will be required to assess this further. </p> </section> </section> <section id="CD009764-sec-0091"> <h3 class="title" id="CD009764-sec-0091">Overall completeness and applicability of evidence</h3> <p>The participants in the studies in this review were aged 40 years or over (mean age, 67 years) and had at least moderate‐severity COPD (mean FEV1 1.2 L). Three studies (<a href="./references#CD009764-bbs2-0001" title="AlbertRK , ConnettJ , BaileyWC , CasaburiR , CooperJA , CrinerGJ , et al. Azithromycin for prevention of exacerbations of COPD. New England Journal of Medicine2011;365:689‐98. HanMK , TayobN , MurrayS , DransfieldMT , WashkoG , ScanlonPD , et al. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. American Journal of Respiratory and Critical Care Medicine2014;189(12):1503‐8. MartinezFJ , ConnettJ , VoelkerH , CrinerGJ , HanMK , MakeBJ , et al. Chronic azithromycin therapy decreases the risk of re‐hospitalization in patients with COPD. American Journal of Respiratory and Critical Care Medicine2013;187:A4383. O'ReillyPJ , JacksonPL , WellsJM , DransfieldMT , ScanlonPD , Blalock , JE . Sputum PGP is reduced by azithromycin treatment in patients with COPD and correlates with exacerbations. BMJ Open2013;3(12):e004140. WoodruffPG , ChatilaW , ConnettJE , CrinerGJ , CurtisJL , DransfieldMT , et al. Tumour necrosis factor receptor‐75 and risk of COPD exacerbation in the azithromycin trial. European Respiratory Journal2014;43:295–8. ">Albert 2011</a>; <a href="./references#CD009764-bbs2-0006" title="MygindLH , PedersenC , VestboJ , ChristensenJJ , Frimodt‐MollerN , KristiansenIS , et al. A randomised, placebo‐controlled 3 years study of prophylactic azithromycin in 575 patients with chronic obstructive pulmonary disease. European Respiratory Society 20th Annual Congress; 2010 Sep 18‐22; Barcelona. 2010. ">Mygind 2010</a>; <a href="./references#CD009764-bbs2-0010" title="SethiS , JonesPW , TheronMS , MiravitllesM , RubinsteinE , WedzichaJA , et al. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized control trial. Respiratory Research2010;11:10. ">Sethi 2010</a>) included participants who experienced one to two exacerbations during the previous year. <a href="./references#CD009764-bbs2-0015" title="DjaminRS , UzunS , ErmensAAM , KerstensR , HoogstedenHC , AertsJGJV , et al. Which predictors in COPD patients with the frequent exacerbator phenotype predict the treatment response to maintenance therapy with azithromycin?. European Respiratory Journal2016;48:PA3713. UzunS , DjaminRS , AertsJGJV , Van DerEerdenMM . Patients with COPD Gold C &amp; D: the effect of long‐term treatment with azithromycin on exacerbation risk assessed by the Gold Framework. American Journal of Respiratory and Critical Care Medicine2014;189:A5967. UzunS , DjaminRS , KluytmansJA , MulderPG , Van't VeerNE , ErmensAA , et al. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double‐blind,placebo‐controlled trial. Lancet Respiratory Medicine2014;2(5):361‐8. UzunS , DjaminRS , MulderPGH , KluytmansJAJW , PelleAJ , Van't VeerNE , et al. Effect of azithromycin maintenance treatment in patients with frequent exacerbations of COPD (columbus): a randomized, double‐blind, placebo‐controlled trial. American Journal of Respiratory and Critical Care Medicine2014;189:A2884. ">Uzun 2014</a> included participants who had experienced three exacerbations within the last year. <a href="./references#CD009764-bbs2-0001" title="AlbertRK , ConnettJ , BaileyWC , CasaburiR , CooperJA , CrinerGJ , et al. Azithromycin for prevention of exacerbations of COPD. New England Journal of Medicine2011;365:689‐98. HanMK , TayobN , MurrayS , DransfieldMT , WashkoG , ScanlonPD , et al. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. American Journal of Respiratory and Critical Care Medicine2014;189(12):1503‐8. MartinezFJ , ConnettJ , VoelkerH , CrinerGJ , HanMK , MakeBJ , et al. Chronic azithromycin therapy decreases the risk of re‐hospitalization in patients with COPD. American Journal of Respiratory and Critical Care Medicine2013;187:A4383. O'ReillyPJ , JacksonPL , WellsJM , DransfieldMT , ScanlonPD , Blalock , JE . Sputum PGP is reduced by azithromycin treatment in patients with COPD and correlates with exacerbations. BMJ Open2013;3(12):e004140. WoodruffPG , ChatilaW , ConnettJE , CrinerGJ , CurtisJL , DransfieldMT , et al. Tumour necrosis factor receptor‐75 and risk of COPD exacerbation in the azithromycin trial. European Respiratory Journal2014;43:295–8. ">Albert 2011</a> and <a href="./references#CD009764-bbs2-0010" title="SethiS , JonesPW , TheronMS , MiravitllesM , RubinsteinE , WedzichaJA , et al. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized control trial. Respiratory Research2010;11:10. ">Sethi 2010</a> included participants who were on long‐term supplemental oxygen or systemic steroids, or both (see <a href="./references#CD009764-sec-0123" title="">Characteristics of included studies</a>, <a href="./full#CD009764-tbl-0001">summary of findings Table for the main comparison</a>). Hence, the results can be generalised only to this group of participants who are at the more severe end of the COPD spectrum. Such participants may also be more likely to be receiving high‐dose ICS, which have been associated with an increased risk of pneumonia (<a href="./references#CD009764-bbs2-0079" title="KewKM , SeniukovichA . Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2014, Issue 3. [DOI: 10.1002/14651858.CD010115.pub2] ">Kew 2014</a>). This may further decrease generalisability to broader COPD populations. </p> <p>Data from <a href="./references#CD009764-bbs2-0001" title="AlbertRK , ConnettJ , BaileyWC , CasaburiR , CooperJA , CrinerGJ , et al. Azithromycin for prevention of exacerbations of COPD. New England Journal of Medicine2011;365:689‐98. HanMK , TayobN , MurrayS , DransfieldMT , WashkoG , ScanlonPD , et al. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. American Journal of Respiratory and Critical Care Medicine2014;189(12):1503‐8. MartinezFJ , ConnettJ , VoelkerH , CrinerGJ , HanMK , MakeBJ , et al. Chronic azithromycin therapy decreases the risk of re‐hospitalization in patients with COPD. American Journal of Respiratory and Critical Care Medicine2013;187:A4383. O'ReillyPJ , JacksonPL , WellsJM , DransfieldMT , ScanlonPD , Blalock , JE . Sputum PGP is reduced by azithromycin treatment in patients with COPD and correlates with exacerbations. BMJ Open2013;3(12):e004140. WoodruffPG , ChatilaW , ConnettJE , CrinerGJ , CurtisJL , DransfieldMT , et al. Tumour necrosis factor receptor‐75 and risk of COPD exacerbation in the azithromycin trial. European Respiratory Journal2014;43:295–8. ">Albert 2011</a> suggested that prophylactic antibiotics may be most useful in patients who have given up smoking, who are not on any inhaler treatment (long‐acting beta agonist (LABA), long‐acting muscarinic antagonist (LAMA), or inhaled corticosteroid (ICS) in any combination), on oxygen therapy, or older than 65 years. </p> <p>Although these results were obtained from prespecified subgroup analyses, the sample sizes were much smaller than the randomised sample size. There were 22 analyses carried out giving a 62% chance of one analysis yielding a statistically significant result. For this reason, the authors are aware that there may be false positives in these results and recommend additional studies that are adequately powered to explore these subgroups. </p> <p>It is also important to note that the study participants had undergone strict exclusion criteria. Participants with tachycardia, arrhythmia, long QTc, as well as being on medication that could potentially increase the QTc (a long list), or baseline hearing deficit based on audiometry were excluded. Participants will likely have been excluded from the trial if they were currently prescribed an interacting medication that could not be stopped or substituted and this may have further limited the applicability of the evidence to the wider COPD population. There was regular monitoring throughout the study period and drugs were discontinued in the event of a significant adverse event. Furthermore, only two studies (<a href="./references#CD009764-bbs2-0001" title="AlbertRK , ConnettJ , BaileyWC , CasaburiR , CooperJA , CrinerGJ , et al. Azithromycin for prevention of exacerbations of COPD. New England Journal of Medicine2011;365:689‐98. HanMK , TayobN , MurrayS , DransfieldMT , WashkoG , ScanlonPD , et al. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. American Journal of Respiratory and Critical Care Medicine2014;189(12):1503‐8. MartinezFJ , ConnettJ , VoelkerH , CrinerGJ , HanMK , MakeBJ , et al. Chronic azithromycin therapy decreases the risk of re‐hospitalization in patients with COPD. American Journal of Respiratory and Critical Care Medicine2013;187:A4383. O'ReillyPJ , JacksonPL , WellsJM , DransfieldMT , ScanlonPD , Blalock , JE . Sputum PGP is reduced by azithromycin treatment in patients with COPD and correlates with exacerbations. BMJ Open2013;3(12):e004140. WoodruffPG , ChatilaW , ConnettJE , CrinerGJ , CurtisJL , DransfieldMT , et al. Tumour necrosis factor receptor‐75 and risk of COPD exacerbation in the azithromycin trial. European Respiratory Journal2014;43:295–8. ">Albert 2011</a> and <a href="./references#CD009764-bbs2-0015" title="DjaminRS , UzunS , ErmensAAM , KerstensR , HoogstedenHC , AertsJGJV , et al. Which predictors in COPD patients with the frequent exacerbator phenotype predict the treatment response to maintenance therapy with azithromycin?. European Respiratory Journal2016;48:PA3713. UzunS , DjaminRS , AertsJGJV , Van DerEerdenMM . Patients with COPD Gold C &amp; D: the effect of long‐term treatment with azithromycin on exacerbation risk assessed by the Gold Framework. American Journal of Respiratory and Critical Care Medicine2014;189:A5967. UzunS , DjaminRS , KluytmansJA , MulderPG , Van't VeerNE , ErmensAA , et al. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double‐blind,placebo‐controlled trial. Lancet Respiratory Medicine2014;2(5):361‐8. UzunS , DjaminRS , MulderPGH , KluytmansJAJW , PelleAJ , Van't VeerNE , et al. Effect of azithromycin maintenance treatment in patients with frequent exacerbations of COPD (columbus): a randomized, double‐blind, placebo‐controlled trial. American Journal of Respiratory and Critical Care Medicine2014;189:A2884. ">Uzun 2014</a>) performed CT chest to screen for participants with underlying bronchiectasis. This is a drawback as, although this review had a strict criteria for COPD diagnosis, many people with COPD (estimates range from 4% to 72%), especially those with recurrent infections, have a degree of underlying bronchiectasis (<a href="./references#CD009764-bbs2-0082" title="Martinez‐GarciaMA , MiravitllesM . Bronchiectasis in COPD patients: more than a comorbidity?. International Journal of Chronic Obstructive Pulmonary Disease2017;12:1401‐11. ">Martinez‐Garcia 2017</a>). Therefore, identifying the group with bronchiectasis and analysing this group as a subgroup would have given us valuable information on whether the group would benefit more from prophylactic antibiotics. Furthermore, it is not clear from the studies the extent to which participants had other treatments for their COPD optimised (for example, smoking cessation programmes, pulmonary rehabilitation, vaccination). </p> <p>In current clinical practice, prophylactic antibiotics tend to be used as a last resort because of concerns about antibiotic resistance in the community. If an informed decision is made to start prophylactic antibiotics in a particular patient, there needs to be baseline checks to confirm the identity of the infection (for example, sputum cultures), ECG, and consideration of audiometry, depending on the planned antibiotic, as well as ongoing monitoring of the same. </p> <p>Although all the included studies were conducted in the last 20 years, even over this time period, the care of people with COPD has changed markedly, as evidenced by regular guideline updates (<a href="./references#CD009764-bbs2-0073" title="Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2018 report). goldcopd.org/wp‐content/uploads/2017/11/GOLD‐2018‐v6.0‐FINAL‐revised‐20‐Nov_WMS.pdf (accessed prior to 20 July 2018). ">GOLD 2018</a>). The threshold for both admission and duration of hospital stay once admitted has changed and more care is carried out at home in many settings. For example, a retrospective analysis of data in the UK suggested that the mean duration of hospital stay for an emergency admission with COPD fell by approximately one day between 2006 and 2010, in keeping with international trends (<a href="./references#CD009764-bbs2-0075" title="HarriesTH , ThorntonHV , CrichtonS , SchofieldP , GilkesA , WhitePT . Length of stay of COPD hospital admissions between 2006 and 2010: a retrospective longitudinal study. International Journal of Chronic Obstructive Pulmonary Disease2015;10:603‐11. ">Harries 2015</a>). </p> <p>A further limitation of the evidence presented is that most of the included studies measured outcomes at or soon after discontinuation of antibiotics. We therefore cannot comment on any possible prolonged benefits or harms which might extend beyond the treatment period. Furthermore, drug interactions may also require consideration, particularly as macrolide antibiotics may interact with other commonly prescribed drugs in the COPD population, such as statins and theophylline (<a href="./references#CD009764-bbs2-0071" title="Joint Formulary Committee. British National Formulary. London: BMJ Group and Pharmaceutical Press, 2018. [http://www.medicinescomplete.com] ">BNF 2018</a>). </p> <p>Finally, the analyses of continuous and intermittent antibiotics were dominated by macrolide antibiotics (e.g. azithromycin and erythromycin). The majority of the evidence for pulsed antibiotics was contributed by studies of moxifloxacin, a quinolone. Therefore, care should be taken when drawing conclusions about the relative efficacy of continuous, intermittent and pulsed regimens as this comparison is confounded by the different classes of antibiotic used in the studies. </p> </section> <section id="CD009764-sec-0092"> <h3 class="title" id="CD009764-sec-0092">Quality of the evidence</h3> <p>Overall, we graded the quality of the evidence to be moderate, meaning "further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate". We presented our grade ratings in <a href="./full#CD009764-tbl-0001">summary of findings Table for the main comparison</a>. </p> <p>We downgraded three outcomes (mortality, serious adverse events, and all adverse events) for imprecision; the confidence intervals were not sufficiently narrow enough to rule out a potentially important effect. We downgraded two outcomes (number of participants with one or more exacerbations and exacerbation rate) for inconsistency; the I<sup>2</sup> was greater than 50% in both analyses. We downgraded FEV1 (mL) for indirectness as the studies contributing the majority of the weight in this analysis were of short duration. We were not able to create a funnel plot as no analyses contained 10 unique studies, so publication bias could not be formally assessed. Finally, while we rated four studies to be at high risk of bias in at least one domain, the overall methodological quality of the studies contributing data to the meta‐analyses was good, and therefore we did not downgrade any outcome for risk of bias. </p> </section> <section id="CD009764-sec-0093"> <h3 class="title" id="CD009764-sec-0093">Potential biases in the review process</h3> <p>We attempted to minimise bias during the review process by completing a comprehensive electronic search of all published and unpublished data, as well as handsearching the bibliographies from selected studies. The data were extracted and full‐text articles reviewed by three authors with disagreement being resolved by discussion. </p> <p>However, not all included studies clearly described the criteria used to diagnose an acute exacerbation of COPD. This may have led to us combining results from studies in which different criteria were used, which may impact the interpretability of these analyses. Furthermore, exacerbation rates in COPD vary markedly between seasons; shorter studies may therefore fail to accurately reflect the true year‐round exacerbation burden. In addition, our categorisation of continuous, intermittent, and pulsed regimens was a post hoc decision for the 2018 update, although taken before data analysis. We recognise that, due to sustained tissue concentrations of azithromycin, a three times a week regimen could be considered essentially continuous (<a href="./references#CD009764-bbs2-0084" title="MatznellerP , KrasniqiS , KinzigM , SörgelF , HüttnerS , LacknerE , et al. Blood, tissue, and intracellular concentrations of azithromycin during and after end of therapy. Antimicrobial Agents and Chemotherapy2013;57(4):1736‐42. ">Matzneller 2013</a>). Despite this, we suggest that intermittent regimens have different implications for patient adherence and costs and therefore maintained these subgroups for analysis. </p> </section> <section id="CD009764-sec-0094"> <h3 class="title" id="CD009764-sec-0094">Agreements and disagreements with other studies or reviews</h3> <p>Our findings are consistent with an earlier Cochrane review of prophylactic antibiotics in chronic bronchitis (<a href="./references#CD009764-bbs2-0091" title="StaykovaT , BlackPN , ChackoEE , PooleP . Prophylactic antibiotic therapy for chronic bronchitis. Cochrane Database of Systematic Reviews2003, Issue 1. [DOI: 10.1002/14651858.CD004105] ">Staykova 2003</a>), even though the definitions of cases are tighter in the present review. The study findings further strengthen and are in line with the findings of the previous version of this Cochrane review, published in 2013 (<a href="./references#CD009764-bbs2-0101" title="HerathS , PooleP . Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD). Cochrane Database of Systematic Reviews2013, Issue 11. [DOI: 10.1002/14651858.CD009764.pub2] ">Herath 2013</a>). </p> <p>A case‐based review article in the New England Journal of Medicine (NEJM) on antibiotic prevention of acute exacerbations of COPD recommends the use of azithromycin 250 mg three times a week to reduce exacerbation frequency in patients on maximal COPD treatment who were still having two or more exacerbations per year (<a href="./references#CD009764-bbs2-0097" title="WenzelRP , FowlerAA , EdmondMB . Antibiotic prevention of acute exacerbations of COPD. New England Journal of Medicine2012;367(4):340‐7. ">Wenzel 2012</a>). Careful selection, prior investigations, and proper follow‐up were emphasised, which is concordant with our findings and recommendations. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD009764-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/urn:x-wiley:14651858:media:CD009764:CD009764-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_t/tCD009764-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram: review update" data-id="CD009764-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_n/nCD009764-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram: review update</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/full#CD009764-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_n/nCD009764-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009764-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/urn:x-wiley:14651858:media:CD009764:CD009764-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_t/tCD009764-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD009764-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_n/nCD009764-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/full#CD009764-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_n/nCD009764-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009764-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/urn:x-wiley:14651858:media:CD009764:CD009764-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_t/tCD009764-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Antibiotics versus placebo, outcome: 1.1 Number of people with one or more exacerbations." data-id="CD009764-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_n/nCD009764-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Antibiotics versus placebo, outcome: 1.1 Number of people with one or more exacerbations. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/full#CD009764-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_n/nCD009764-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009764-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/urn:x-wiley:14651858:media:CD009764:CD009764-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_t/tCD009764-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="In the control group, 61 people out of 100 had one or more exacerbations over 12 weeks to 12 months, compared to 47 (95% CI 39 to 55) out of 100 for the antibiotic treatment group (Analysis 1.1)" data-id="CD009764-fig-0004" src="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_n/nCD009764-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>In the control group, 61 people out of 100 had one or more exacerbations over 12 weeks to 12 months, compared to 47 (95% CI 39 to 55) out of 100 for the antibiotic treatment group (<a href="./references#CD009764-fig-0007" title="">Analysis 1.1</a>) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/full#CD009764-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_n/nCD009764-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009764-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/urn:x-wiley:14651858:media:CD009764:CD009764-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_t/tCD009764-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Antibiotics versus placebo, outcome: 1.4 Rate of exacerbation per patient per year." data-id="CD009764-fig-0005" src="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_n/nCD009764-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Antibiotics versus placebo, outcome: 1.4 Rate of exacerbation per patient per year. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/full#CD009764-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_n/nCD009764-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009764-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/urn:x-wiley:14651858:media:CD009764:CD009764-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_t/tCD009764-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Antibiotics versus placebo, outcome: 1.9 HRQoL, SGRQ (total score)." data-id="CD009764-fig-0006" src="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_n/nCD009764-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Antibiotics versus placebo, outcome: 1.9 HRQoL, SGRQ (total score). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/full#CD009764-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_n/nCD009764-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009764-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/urn:x-wiley:14651858:media:CD009764:CD009764-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_t/tCD009764-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antibiotics versus placebo, Outcome 1 Number of people with one or more exacerbations." data-id="CD009764-fig-0007" src="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_n/nCD009764-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Antibiotics versus placebo, Outcome 1 Number of people with one or more exacerbations. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/references#CD009764-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_n/nCD009764-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009764-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/urn:x-wiley:14651858:media:CD009764:CD009764-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_t/tCD009764-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antibiotics versus placebo, Outcome 2 Number of people with one or more exacerbations requiring hospitalisation." data-id="CD009764-fig-0008" src="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_n/nCD009764-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Antibiotics versus placebo, Outcome 2 Number of people with one or more exacerbations requiring hospitalisation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/references#CD009764-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_n/nCD009764-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009764-fig-0009"> <p> <div class="table" id="CD009764-tblf-0001"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention arm</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Rate per patient per year</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P value compared to control</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>Continuous antibiotics</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Shafuddin 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Roxithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.2545</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Shafuddin 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Roxithromycin+doxycyline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.1709</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Shafuddin 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Antibiotics versus placebo, Outcome 3 Annualised exacerbation rate per patient per year during 12‐week active treatment. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/references#CD009764-fig-0009">Navigate to figure in review</a></div> </div> <div class="figure" id="CD009764-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/urn:x-wiley:14651858:media:CD009764:CD009764-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_t/tCD009764-CMP-001-04.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antibiotics versus placebo, Outcome 4 Rate of exacerbation per patient per year." data-id="CD009764-fig-0010" src="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_n/nCD009764-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Antibiotics versus placebo, Outcome 4 Rate of exacerbation per patient per year. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/references#CD009764-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_n/nCD009764-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009764-fig-0011"> <p> <div class="table" id="CD009764-tblf-0002"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>MEDIAN Time to 1st exacerbation (days) treatment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>MEDIAN Time to 1st exacerbation (days) placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P value</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Test used</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Hazard ratio</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Continuous antibiotic</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Albert 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>266 (227 to 313)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>174 (143 to 215)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>log‐rank test</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.73 (0.63, 0.84)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>He 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>155</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.032</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kaplan‐Meier survival analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not given</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Seemungal 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>271</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.02</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>log‐rank test</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not given</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Intermittent antibiotics</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Berkhof 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20th percentile time to the first exacerbation 105 (30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20th percentile time to the first exacerbation 66 (21)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>log‐rank test</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not given</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uzun 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>130 (95% CI 28 to 232)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59 (95% CI 31 to 87)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>log‐rank test</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not given</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Pulsed antibiotics</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sethi 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>364</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>336</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.062</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kaplan‐Meier survival analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not given</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Antibiotics versus placebo, Outcome 5 Time to the first exacerbation.</p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/references#CD009764-fig-0011">Navigate to figure in review</a></div> </div> <div class="figure" id="CD009764-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/urn:x-wiley:14651858:media:CD009764:CD009764-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_t/tCD009764-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antibiotics versus placebo, Outcome 6 Mean time to first exacerbation (days)." data-id="CD009764-fig-0012" src="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_n/nCD009764-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Antibiotics versus placebo, Outcome 6 Mean time to first exacerbation (days). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/references#CD009764-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_n/nCD009764-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009764-fig-0013"> <p> <div class="table" id="CD009764-tblf-0003"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Gold stage</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Rate of exacerbations per patient year on azithromycin (Mean +/‐ SD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Rate of exacerbations per patient year on placebo (Mean +/‐ SD)</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Albert 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 : FEV1 (80% ‐ 50%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.02 (+/‐ 0.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.68 (+/‐ 0.16)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Albert 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 : FEV1 (50% ‐ 30%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.53 (+/‐ 0.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.75 (+/‐ 0.13)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Albert 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 : FEV1 &lt; 30%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.75 (+/‐ 0.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.05 (+/‐ 0.28)</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Antibiotics versus placebo, Outcome 7 COPD exacerbations according to severity of COPD ‐ continuous antibiotics. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/references#CD009764-fig-0013">Navigate to figure in review</a></div> </div> <div class="figure" id="CD009764-fig-0014"> <p> <div class="table" id="CD009764-tblf-0004"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Gold stage</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Odds ratio for exacerbations, moxifloxacin vs placebo (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P value</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sethi 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 : FEV1 (80% ‐ 50%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.65 (0.39 to 1.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.091</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sethi 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 : FEV1 (50% ‐ 30%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.81 (0.58 to 1.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.192</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sethi 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 : FEV1 (&lt; 30%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.83 (0.54 to 1.28)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.459</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Antibiotics versus placebo, Outcome 8 COPD exacerbations according to severity of COPD ‐ pulsed antibiotics. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/references#CD009764-fig-0014">Navigate to figure in review</a></div> </div> <div class="figure" id="CD009764-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/urn:x-wiley:14651858:media:CD009764:CD009764-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_t/tCD009764-CMP-001-09.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antibiotics versus placebo, Outcome 9 HRQoL, SGRQ (total score)." data-id="CD009764-fig-0015" src="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_n/nCD009764-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Antibiotics versus placebo, Outcome 9 HRQoL, SGRQ (total score).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/references#CD009764-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_n/nCD009764-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009764-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/urn:x-wiley:14651858:media:CD009764:CD009764-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_t/tCD009764-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antibiotics versus placebo, Outcome 10 HRQoL, SGRQ (domains)." data-id="CD009764-fig-0016" src="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_n/nCD009764-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Antibiotics versus placebo, Outcome 10 HRQoL, SGRQ (domains).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/references#CD009764-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_n/nCD009764-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009764-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/urn:x-wiley:14651858:media:CD009764:CD009764-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_t/tCD009764-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antibiotics versus placebo, Outcome 11 HRQoL, LCQ (total)." data-id="CD009764-fig-0017" src="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_n/nCD009764-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Antibiotics versus placebo, Outcome 11 HRQoL, LCQ (total).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/references#CD009764-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_n/nCD009764-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009764-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/urn:x-wiley:14651858:media:CD009764:CD009764-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_t/tCD009764-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antibiotics versus placebo, Outcome 12 HRQoL, SF‐12 (domains)." data-id="CD009764-fig-0018" src="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_n/nCD009764-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Antibiotics versus placebo, Outcome 12 HRQoL, SF‐12 (domains).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/references#CD009764-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_n/nCD009764-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009764-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/urn:x-wiley:14651858:media:CD009764:CD009764-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_t/tCD009764-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antibiotics versus placebo, Outcome 13 HRQoL SF‐36 (domains)." data-id="CD009764-fig-0019" src="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_n/nCD009764-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 Antibiotics versus placebo, Outcome 13 HRQoL SF‐36 (domains).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/references#CD009764-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_n/nCD009764-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009764-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/urn:x-wiley:14651858:media:CD009764:CD009764-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_t/tCD009764-CMP-001-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antibiotics versus placebo, Outcome 14 HRQoL, LCQ (domains)." data-id="CD009764-fig-0020" src="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_n/nCD009764-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 Antibiotics versus placebo, Outcome 14 HRQoL, LCQ (domains).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/references#CD009764-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_n/nCD009764-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009764-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/urn:x-wiley:14651858:media:CD009764:CD009764-CMP-001-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_t/tCD009764-CMP-001-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antibiotics versus placebo, Outcome 15 HRQoL, CCQ (total)." data-id="CD009764-fig-0021" src="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_n/nCD009764-CMP-001-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1 Antibiotics versus placebo, Outcome 15 HRQoL, CCQ (total).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/references#CD009764-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_n/nCD009764-CMP-001-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009764-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/urn:x-wiley:14651858:media:CD009764:CD009764-CMP-001-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_t/tCD009764-CMP-001-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antibiotics versus placebo, Outcome 16 HRQoL, CRQ (domains)." data-id="CD009764-fig-0022" src="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_n/nCD009764-CMP-001-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1 Antibiotics versus placebo, Outcome 16 HRQoL, CRQ (domains).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/references#CD009764-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_n/nCD009764-CMP-001-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009764-fig-0023"> <p> <div class="table" id="CD009764-tblf-0005"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>GOLD stage</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Rate of hospitalisations per patient year on moxifloxacin (Mean +/‐SD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Rate of hospitalisations per patient year on placebo (Mean +/‐SD)</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Albert 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 : FEV1 (80% ‐ 50%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.50 +/‐0.12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.65 +/‐ 0.11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Albert 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 : FEV1 (50% ‐ 30%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.85 +/‐ 0.12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.96 +/‐ 0.12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Albert 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 : FEV1 &lt; 30%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.74 +/‐ 0.12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.03 +/‐ 0.27</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1 Antibiotics versus placebo, Outcome 17 Frequency of hospital admissions ‐ continuous antibiotics. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/references#CD009764-fig-0023">Navigate to figure in review</a></div> </div> <div class="figure" id="CD009764-fig-0024"> <p> <div class="table" id="CD009764-tblf-0006"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Frequency of hospitalisation (%) on moxifloxacin</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Frequency of hospitalisation (%) on placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P value</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sethi 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>131 (23.02%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>136 (23.45%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.46</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1 Antibiotics versus placebo, Outcome 18 Frequency of hospital admissions ‐ pulsed antibiotics. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/references#CD009764-fig-0024">Navigate to figure in review</a></div> </div> <div class="figure" id="CD009764-fig-0025"> <p> <div class="table" id="CD009764-tblf-0007"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median days of exacerbation, treatment arm</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median days of exacerbation, placebo arm</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P value</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>Continuous antibiotics</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Seemungal 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9 (6 to14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13 (6 to 24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.036 Mann‐Whitney test</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>Pulsed antibiotics</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mygind 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93 (total exacerbation days at home or hospitalised)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>111 (total exacerbations days at home or hospitalised)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.04</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.19</div> <div class="figure-caption"> <p>Comparison 1 Antibiotics versus placebo, Outcome 19 Duration of exacerbation.</p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/references#CD009764-fig-0025">Navigate to figure in review</a></div> </div> <div class="figure" id="CD009764-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/urn:x-wiley:14651858:media:CD009764:CD009764-CMP-001-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_t/tCD009764-CMP-001-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antibiotics versus placebo, Outcome 20 FEV1 (mL)." data-id="CD009764-fig-0026" src="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_n/nCD009764-CMP-001-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.20</div> <div class="figure-caption"> <p>Comparison 1 Antibiotics versus placebo, Outcome 20 FEV1 (mL).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/references#CD009764-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_n/nCD009764-CMP-001-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009764-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/urn:x-wiley:14651858:media:CD009764:CD009764-CMP-001-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_t/tCD009764-CMP-001-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antibiotics versus placebo, Outcome 21 FVC (L)." data-id="CD009764-fig-0027" src="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_n/nCD009764-CMP-001-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.21</div> <div class="figure-caption"> <p>Comparison 1 Antibiotics versus placebo, Outcome 21 FVC (L).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/references#CD009764-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_n/nCD009764-CMP-001-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009764-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/urn:x-wiley:14651858:media:CD009764:CD009764-CMP-001-22" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_t/tCD009764-CMP-001-22.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antibiotics versus placebo, Outcome 22 FEV1 % predicted." data-id="CD009764-fig-0028" src="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_n/nCD009764-CMP-001-22.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.22</div> <div class="figure-caption"> <p>Comparison 1 Antibiotics versus placebo, Outcome 22 FEV1 % predicted.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/references#CD009764-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_n/nCD009764-CMP-001-22.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009764-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/urn:x-wiley:14651858:media:CD009764:CD009764-CMP-001-23" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_t/tCD009764-CMP-001-23.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antibiotics versus placebo, Outcome 23 Exercise capacity (6MWT)." data-id="CD009764-fig-0029" src="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_n/nCD009764-CMP-001-23.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.23</div> <div class="figure-caption"> <p>Comparison 1 Antibiotics versus placebo, Outcome 23 Exercise capacity (6MWT).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/references#CD009764-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_n/nCD009764-CMP-001-23.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009764-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/urn:x-wiley:14651858:media:CD009764:CD009764-CMP-001-24" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_t/tCD009764-CMP-001-24.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antibiotics versus placebo, Outcome 24 All‐cause mortality." data-id="CD009764-fig-0030" src="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_n/nCD009764-CMP-001-24.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.24</div> <div class="figure-caption"> <p>Comparison 1 Antibiotics versus placebo, Outcome 24 All‐cause mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/references#CD009764-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_n/nCD009764-CMP-001-24.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009764-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/urn:x-wiley:14651858:media:CD009764:CD009764-CMP-001-25" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_t/tCD009764-CMP-001-25.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antibiotics versus placebo, Outcome 25 Respiratory‐related mortality." data-id="CD009764-fig-0031" src="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_n/nCD009764-CMP-001-25.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.25</div> <div class="figure-caption"> <p>Comparison 1 Antibiotics versus placebo, Outcome 25 Respiratory‐related mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/references#CD009764-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_n/nCD009764-CMP-001-25.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009764-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/urn:x-wiley:14651858:media:CD009764:CD009764-CMP-001-26" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_t/tCD009764-CMP-001-26.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antibiotics versus placebo, Outcome 26 Serious adverse events." data-id="CD009764-fig-0032" src="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_n/nCD009764-CMP-001-26.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.26</div> <div class="figure-caption"> <p>Comparison 1 Antibiotics versus placebo, Outcome 26 Serious adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/references#CD009764-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_n/nCD009764-CMP-001-26.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009764-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/urn:x-wiley:14651858:media:CD009764:CD009764-CMP-001-27" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_t/tCD009764-CMP-001-27.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antibiotics versus placebo, Outcome 27 Any adverse event." data-id="CD009764-fig-0033" src="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_n/nCD009764-CMP-001-27.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.27</div> <div class="figure-caption"> <p>Comparison 1 Antibiotics versus placebo, Outcome 27 Any adverse event.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/references#CD009764-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_n/nCD009764-CMP-001-27.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009764-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/urn:x-wiley:14651858:media:CD009764:CD009764-CMP-001-28" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_t/tCD009764-CMP-001-28.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antibiotics versus placebo, Outcome 28 Adverse events (specific)." data-id="CD009764-fig-0034" src="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_n/nCD009764-CMP-001-28.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.28</div> <div class="figure-caption"> <p>Comparison 1 Antibiotics versus placebo, Outcome 28 Adverse events (specific).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/references#CD009764-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_n/nCD009764-CMP-001-28.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009764-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/urn:x-wiley:14651858:media:CD009764:CD009764-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_t/tCD009764-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Subgroup analyses, Outcome 1 Subgroup analysis: number of people with one or more exacerbations by mean % predicted FEV1." data-id="CD009764-fig-0035" src="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_n/nCD009764-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Subgroup analyses, Outcome 1 Subgroup analysis: number of people with one or more exacerbations by mean % predicted FEV1. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/references#CD009764-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_n/nCD009764-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009764-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/urn:x-wiley:14651858:media:CD009764:CD009764-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_t/tCD009764-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Subgroup analyses, Outcome 2 Subgroup analysis: number of people with one or more exacerbations by treatment duration." data-id="CD009764-fig-0036" src="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_n/nCD009764-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Subgroup analyses, Outcome 2 Subgroup analysis: number of people with one or more exacerbations by treatment duration. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/references#CD009764-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_n/nCD009764-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009764-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/urn:x-wiley:14651858:media:CD009764:CD009764-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_t/tCD009764-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Subgroup analyses, Outcome 3 Subgroup analysis: number of people with one or more exacerbations by year carried out." data-id="CD009764-fig-0037" src="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_n/nCD009764-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Subgroup analyses, Outcome 3 Subgroup analysis: number of people with one or more exacerbations by year carried out. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/references#CD009764-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_n/nCD009764-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009764-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/urn:x-wiley:14651858:media:CD009764:CD009764-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_t/tCD009764-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Subgroup analyses, Outcome 4 Subgroup analysis: number of people with one or more exacerbations by regimen." data-id="CD009764-fig-0038" src="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_n/nCD009764-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Subgroup analyses, Outcome 4 Subgroup analysis: number of people with one or more exacerbations by regimen. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/references#CD009764-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_n/nCD009764-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009764-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/urn:x-wiley:14651858:media:CD009764:CD009764-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_t/tCD009764-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Subgroup analyses, Outcome 5 Subgroup analysis: number of people with one or more exacerbations by exacerbation history." data-id="CD009764-fig-0039" src="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_n/nCD009764-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Subgroup analyses, Outcome 5 Subgroup analysis: number of people with one or more exacerbations by exacerbation history. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/references#CD009764-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/media/CDSR/CD009764/image_n/nCD009764-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD009764-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Antibiotics versus placebo for COPD</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Antibiotics versus placebo for COPD (data from pulsed and continuous courses of antibiotics presented in the same table)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> Adults (aged 40 or over) with COPD presenting with 1 or more exacerbations in the previous year. The two larger studies (<a href="./references#CD009764-bbs2-0001" title="AlbertRK , ConnettJ , BaileyWC , CasaburiR , CooperJA , CrinerGJ , et al. Azithromycin for prevention of exacerbations of COPD. New England Journal of Medicine2011;365:689‐98. HanMK , TayobN , MurrayS , DransfieldMT , WashkoG , ScanlonPD , et al. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. American Journal of Respiratory and Critical Care Medicine2014;189(12):1503‐8. MartinezFJ , ConnettJ , VoelkerH , CrinerGJ , HanMK , MakeBJ , et al. Chronic azithromycin therapy decreases the risk of re‐hospitalization in patients with COPD. American Journal of Respiratory and Critical Care Medicine2013;187:A4383. O'ReillyPJ , JacksonPL , WellsJM , DransfieldMT , ScanlonPD , Blalock , JE . Sputum PGP is reduced by azithromycin treatment in patients with COPD and correlates with exacerbations. BMJ Open2013;3(12):e004140. WoodruffPG , ChatilaW , ConnettJE , CrinerGJ , CurtisJL , DransfieldMT , et al. Tumour necrosis factor receptor‐75 and risk of COPD exacerbation in the azithromycin trial. European Respiratory Journal2014;43:295–8. ">Albert 2011</a>; <a href="./references#CD009764-bbs2-0010" title="SethiS , JonesPW , TheronMS , MiravitllesM , RubinsteinE , WedzichaJA , et al. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized control trial. Respiratory Research2010;11:10. ">Sethi 2010</a>) recruited participants who required systemic steroids or antibiotics for exacerbations or participants on supplemental oxygen </p> <p><b>Settings:</b> Outpatients presenting to hospital clinics </p> <p><b>Intervention:</b> Administration of an oral prophylactic antibiotic continuously or intermittently </p> <p><b>Comparison:</b> Administration of a placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Antibiotics versus placebo</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of people with one or more exacerbations</b> </p> <p>WMD of follow‐up of 49 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>606 per 1,000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>468 per 1,000</b> </p> <p>(393 to 546)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.57</b> </p> <p>(0.42 to 0.78)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2716<br/> (8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Subgroup analysis of continuous versus intermittent versus pulsed antibiotics suggested that pulsed antibiotics were less effective at reducing exacerbations (P = 0.01 for subgroup difference; I<sup>2</sup> = 77.3%) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Rate of exacerbation per patient/year</b> </p> <p>WMD of follow‐up 54 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Rate ratio 0.67</b> </p> <p>(0.54 to 0.83)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1384</p> <p>(5 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate</b><sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Test for subgroup difference between continuous and intermittent antibiotics not significant (P = 0.38; I<sup>2</sup> = 0%) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HRQoL, SGRQ (total score)</b><br/> Scale from: 0 to 100. SGRQ comprises responses to 50 items, 0 being the best possible score and 100 the worst.<br/> WMD of follow‐up 48 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in SGRQ ranged across control groups from a <b>0.9 unit increase to a 5.7 unit decrease</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean HRQoL (SGRQ total score) in the intervention group was <b>1.94 lower</b> (3.13 lower to 0.75 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2237<br/> (7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>High</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The minimally clinically important response to treatment is described as 4 points</p> <p>Test for subgroup differences between continuous, intermittent and pulsed antibiotics not significant (P = 0.35; I² = 5.2%) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b><br/> WMD of follow‐up 70 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>78 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>68 per 1,000</b> </p> <p>(53 to 88)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.87</b> </p> <p>(0.66 to 1.15)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3309<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Test for subgroup differences between continuous, intermittent and pulsed antibiotics not significant (P = 0.60; I² = 0%) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b><br/> WMD of follow‐up 51 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>253 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>229 per 1,000</b> </p> <p>(200 to 262)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.88</b> </p> <p>(0.74 to 1.05)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2978<br/> (9 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See <a href="#CD009764-sec-0071">Effects of interventions</a> for specific adverse events related to the individual antibiotics. </p> <p>Test for subgroup differences between continuous, intermittent and pulsed antibiotics not significant (P = 0.60; I² = 0%) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Any adverse event</b> </p> <p>WMD of follow‐up 47 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>640 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>655 per 1,000</b><br/> (551 to 748) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 1.07</b><br/> (0.69 to 1.67) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>512<br/> (4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Test for subgroup differences between continuous, intermittent and pulsed antibiotics not significant (P = 0.28), I² = 21.9%) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FEV1 (mL)</b> </p> <p>WMD of follow‐up 26 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean FEV1 in the control group ranged from <b>1,000 to 2,320 mL</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean FEV1 in the intervention group was <b>20.21 mL higher</b> (26.19 lower to 66.61 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>658<br/> (6 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MCID for this outcomes was approximately 100 mLs. Mean difference and confidence interval lied within this MCID. </p> <p>Test for subgroup differences between continuous, intermittent and pulsed antibiotics not significant (P = 0.37; I² = 0.6%) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> was the mean control group risk across studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <sup><b>F</b> EV1: forced expiratory volume in 1 second; <b>HRQoL</b> : health‐related quality of life; <b>MCID</b>: minimum clinically important difference;</sup><b>OR:</b> Odds ratio; <sup><b>SGRQ</b>: St George's respiratory questionnaire</sup><b>WMD</b>: weight mean duration </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Clinical and statistical heterogeneity between studies (I<sup>2</sup> = 58%), partly explained by antibiotic regimen. Downgraded once for inconsistency </p> <p><sup>2</sup> Clinical and statistical heterogeneity between trials (I<sup>2</sup> = 52%). Downgraded once for inconsistency<br/> <sup>3</sup> Confidence intervals included the possibility that prophylactic antibiotics may increase or decrease mortality or adverse events. Downgraded once for imprecision </p> <p><sup>4</sup>Confidence interval included both a decrease or increase in FEV1 associated with the intervention. However, the mean difference and confidence interval lay within the MCID. No downgrade </p> <p><sup>5</sup>Studies contributing majority of weight in analysis reported outcome at approximately 3 months. Duration may be too short to detect a difference in lung function between groups. Downgraded once for indirectness </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Antibiotics versus placebo for COPD</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/full#CD009764-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009764-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary of study characteristics</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Country</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>No. of patients</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Age (range unless otherwise stated)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>% predicted FEV1 (range ) unless otherwise stated</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Duration of treatment</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009764-bbs2-0001" title="AlbertRK , ConnettJ , BaileyWC , CasaburiR , CooperJA , CrinerGJ , et al. Azithromycin for prevention of exacerbations of COPD. New England Journal of Medicine2011;365:689‐98. HanMK , TayobN , MurrayS , DransfieldMT , WashkoG , ScanlonPD , et al. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. American Journal of Respiratory and Critical Care Medicine2014;189(12):1503‐8. MartinezFJ , ConnettJ , VoelkerH , CrinerGJ , HanMK , MakeBJ , et al. Chronic azithromycin therapy decreases the risk of re‐hospitalization in patients with COPD. American Journal of Respiratory and Critical Care Medicine2013;187:A4383. O'ReillyPJ , JacksonPL , WellsJM , DransfieldMT , ScanlonPD , Blalock , JE . Sputum PGP is reduced by azithromycin treatment in patients with COPD and correlates with exacerbations. BMJ Open2013;3(12):e004140. WoodruffPG , ChatilaW , ConnettJE , CrinerGJ , CurtisJL , DransfieldMT , et al. Tumour necrosis factor receptor‐75 and risk of COPD exacerbation in the azithromycin trial. European Respiratory Journal2014;43:295–8. ">Albert 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>United States of America</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65 ‐ 66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39 ‐ 40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Azithromycin 250 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009764-bbs2-0002" title="BanerjeeD , HoneybourneD , KhairOA . The effect of oral Clarithromycin on bronchial airway inflammation in moderate‐to‐severe stable COPD: a randomised controlled trial. Treatments in Respiratory Medicine2004;3:59‐65. BanerjeeD , KhairO , HoneybourneD . The effect of oral clarithromycin on health status and sputum bacteriology in stable COPD. Respiratory Medicine2005;99:208‐15. ">Banerjee 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>United Kingdom</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65.1 ‐ 68.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42.5 ‐ 43.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clarithromycin ‐ long‐acting Klaricid XL 500 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009764-bbs2-0003" title="BerkhofFF , Doornewaard‐ten HertogNE , UilSM , KerstjensHAM , Van denBergJWK . Azithromycin and cough‐specific health status in patients with chronic obstructive pulmonary disease and chronic cough: a randomised controlled trial. Respiratory Research2013;14(1):125. BerkhofFF , TenHertogNE , UilSM , KerstjensHAM , Van DenBergJK , CACTUS study group. Randomized controlled trial of prophylactic azithromycin on cough‐specific health status in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2013;187:A2449. ">Berkhof 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Netherlands</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67 ‐ 68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47.4 ‐ 49.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Azithromycin 250 mg 3 times a week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><a href="./references#CD009764-bbs2-0004" title="BrillS , JamesP , CuthbertsonL , CooksonW , MoffattM , WedzichaJ . Haemophilus dominance of the stable COPD microbiome is associated with greater bacterial load and inflammation and is modulated by prophylactic antibiotic therapy. European Respiratory Journal2015;46:OA4746. BrillS , LawM , AllinsonJ , El‐EmirE , McHughT , DonaldsonG , et al. Bacterial resistance induction with prophylactic antibiotics in COPD. European Respiratory Journal2014;44:P4731. BrillSE , LawM , El‐EmirE , AllinsonJP , JamesP , MaddoxV , et al. Effects of different antibiotic classes on airway bacteria in stable COPD using culture and molecular techniques: a randomised controlled trial. Thorax2015;70(10):930‐8. BrillSE , LawM , El‐EmirE , AllinsonP , NazarethI , DonaldsonGC , et al. Effect of antibiotics on airway bacteria in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2014;198:A2874. ">Brill 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>United Kingdom</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>67.9 ‐ 70.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>44 ‐ 53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moxifloxacin 400 mg/day for 5 days every 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>13 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Doxycycline 100 mg daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Azithromycin 250 mg 3 times a week</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009764-bbs2-0005" title="HeZY , OuLM , ZhangJQ , BaiJ , LiuGN , LiMH , et al. Effect of 6 months of erythromycin treatment on inflammatory cells in induced sputum and exacerbations in chronic obstructive pulmonary disease. Respiration2010;80:445‐52. ">He 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68.8 ‐ 69.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42.1 ‐ 44.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Erythromycin 125 mg 3 times a day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009764-bbs2-0006" title="MygindLH , PedersenC , VestboJ , ChristensenJJ , Frimodt‐MollerN , KristiansenIS , et al. A randomised, placebo‐controlled 3 years study of prophylactic azithromycin in 575 patients with chronic obstructive pulmonary disease. European Respiratory Society 20th Annual Congress; 2010 Sep 18‐22; Barcelona. 2010. ">Mygind 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denmark</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>575</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71 (median)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38.4 (median)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Azithromycin 500 mg 3 days a month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD009764-bbs2-0007" title="NCT00524095 . Bronchiectasis in chronic obstructive pulmonary disease (COPD) patients: role of prophylaxis. clinicaltrials.gov/ct2/show/NCT00524095 (first received 3 September 2007). ">NCT00524095</a> (terminated; details given represent proposal) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>210</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>45 ‐ 85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Azithromycin 500 mg 3 times a week for 6 months, then fluticasone 500 μg twice a day for 6 months </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>1 year</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fluticasone 500 μg twice a day for 6 months, then azithromycin 500 mg 3 times a week for 6 months </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009764-bbs2-0008" title="BatistaCM . A bench to bedside investigation into defective innate immunity in chronic obstructive pulmonary disease. National Heart &amp; Lung Institute, Imperial College London, UK; 2018. NCT02628769 . A study to evaluate the anti‐inflammatory effects of solithromycin in chronic obstructive pulmonary disease. clinicaltrials.gov/ct2/show/NCT02628769 (first received 11 December 2015). ">NCT02628769</a> (terminated; details given represent proposal) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>United Kingdom</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Solithromycin 400 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28 days</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009764-bbs2-0009" title="SeemungalTA , WilkinsonTM , HurstJR , PereraWR , SapsfordRJ , WedzichaJA . Long‐term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. American Journal of Respiratory and Critical Care Medicine2008;178:1139‐47. ">Seemungal 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>United Kingdom</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66 ‐ 68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49.25 ‐ 50.55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Erythromycin 250 mg twice a day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009764-bbs2-0010" title="SethiS , JonesPW , TheronMS , MiravitllesM , RubinsteinE , WedzichaJA , et al. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized control trial. Respiratory Research2010;11:10. ">Sethi 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>International</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1157</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66.1 ‐ 66.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40.6 ‐ 42.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moxifloxacin 400 mg daily for 5 days every 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD009764-bbs2-0011" title="ShafuddinE , MillsGD , HolmesMD , PoolePJ , MullinsPR , BlackPN . A double‐blind, randomised, placebo‐controlled study of roxithromycin and doxycycline combination, roxithromycin alone, or matching placebo for 12 weeks in adults with frequent exacerbations of chronic obstructive pulmonary disease. Journal of Negative Results in Biomedicine2015;14:15. [DOI: 10.1186/s12952‐015‐0034‐8] ">Shafuddin 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Australia &amp; New Zealand</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>292</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>65.8 ‐ 67.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>32.53 ‐ 35.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Roxithromycin 300 mg daily and Doxycycline 100 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>12 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Roxithromycin 300 mg daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009764-bbs2-0012" title="SimpsonJL , PowellH , BainesKJ , MilneD , CoxsonHO , HansbroPM , et al. The effect of azithromycin in adults with stable neutrophilic COPD: a double blind randomised, placebo controlled trial. PLOS One2014;9(8):e105609. ">Simpson 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69.9 ‐ 71.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51.1 ‐ 56.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Azithromycin 250 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009764-bbs2-0013" title="SuzukiT , YaniM , YamayaM , Satoh NakagawaT , SekizawaK , IshidaS , et al. Erythromycin and common cold in COPD. Chest2001;120:730‐3. ">Suzuki 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Japan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69.1 ‐ 71.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.3 ‐ 1.47 L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Erythromycin 200 ‐ 400 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Riboflavin 10 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD009764-bbs2-0014" title="TanC , HuangH , ZhangJ , HeZ , ZhongX , BaiJ . Effects of low‐dose and long‐term treatment with erythromycin on IL‐17 and IL‐23 in peripheral blood and induced sputum in patients with stable chronic obstructive pulmonary disease. Chest2016;149:387A. TanC , HuangH , ZhangJ , HeZ , ZhongX , BaiJ . Effects of low‐dose and long‐term treatment with erythromycin on interleukin‐17 and interleukin‐23 in peripheral blood and induced sputum in patients with stable chronic obstructive pulmonary disease. Mediators of Inflammation2016:4173962. [DOI: 10.1155/2016/4173962] ">Tan 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>67.3 ‐ 69.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>42.1 ‐ 46.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Erythromycin 125 mg 3 times a day for 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>12 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Erythromcyin 125 mg 3 times a day for 6 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009764-bbs2-0015" title="DjaminRS , UzunS , ErmensAAM , KerstensR , HoogstedenHC , AertsJGJV , et al. Which predictors in COPD patients with the frequent exacerbator phenotype predict the treatment response to maintenance therapy with azithromycin?. European Respiratory Journal2016;48:PA3713. UzunS , DjaminRS , AertsJGJV , Van DerEerdenMM . Patients with COPD Gold C &amp; D: the effect of long‐term treatment with azithromycin on exacerbation risk assessed by the Gold Framework. American Journal of Respiratory and Critical Care Medicine2014;189:A5967. UzunS , DjaminRS , KluytmansJA , MulderPG , Van't VeerNE , ErmensAA , et al. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double‐blind,placebo‐controlled trial. Lancet Respiratory Medicine2014;2(5):361‐8. UzunS , DjaminRS , MulderPGH , KluytmansJAJW , PelleAJ , Van't VeerNE , et al. Effect of azithromycin maintenance treatment in patients with frequent exacerbations of COPD (columbus): a randomized, double‐blind, placebo‐controlled trial. American Journal of Respiratory and Critical Care Medicine2014;189:A2884. ">Uzun 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Netherlands</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64.7 ‐ 64.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44.2 ‐ 45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Azithromycin 500 mg three times a week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009764-bbs2-0016" title="WangP , YangJ , YangY , DingZ . Effect of azithromycin in combination with simvastatin in the treatment of chronic obstructive pulmonary disease complicated by pulmonary arterial hypertension. Pakistan Journal of Medicine Science2017;33(2):260‐4. ">Wang 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70.54 ‐ 72.43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Azithromycin 250 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Simvastatin 20 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 months</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>FEV1: forced expiratory volume in one second.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary of study characteristics</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/full#CD009764-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009764-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Antibiotics versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Number of people with one or more exacerbations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2716</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.42, 0.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Continuous antibiotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1325</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.36, 0.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Intermittent antibiotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>209</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.19, 0.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Pulsed antibiotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.68, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Number of people with one or more exacerbations requiring hospitalisation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Intermittent antibiotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Annualised exacerbation rate per patient per year during 12‐week active treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Continuous antibiotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Rate of exacerbation per patient per year <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1384</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.54, 0.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Continuous antibiotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1292</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.54, 0.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Intermittent antibiotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.42, 0.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Time to the first exacerbation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Continuous antibiotic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Intermittent antibiotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Pulsed antibiotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Mean time to first exacerbation (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>266</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐16.59 [‐46.05, 12.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Continuous antibiotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>266</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐16.59 [‐46.05, 12.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 COPD exacerbations according to severity of COPD ‐ continuous antibiotics <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 COPD exacerbations according to severity of COPD ‐ pulsed antibiotics <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 HRQoL, SGRQ (total score) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2237</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.94 [‐3.13, ‐0.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Continuous antibiotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>991</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.96 [‐3.45, ‐0.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Intermittent antibiotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>184</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.59 [‐8.83, ‐0.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 Pulsed antibiotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1062</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.22 [‐3.00, 0.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 HRQoL, SGRQ (domains) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 SGRQ activity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2077</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.99 [‐2.62, 0.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 SGRQ symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2077</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.07 [‐5.72, ‐2.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3 SGRQ impact</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2077</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.56 [‐5.02, ‐0.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 HRQoL, LCQ (total) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 Intermittent antibiotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 HRQoL, SF‐12 (domains) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 SF‐12 physical</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 SF‐12 mental</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 HRQoL SF‐36 (domains) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 SF‐36 general health</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1071</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.06 [0.70, 7.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 SF‐36 physical functioning</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1071</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.88 [‐1.01, 4.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.3 SF‐36 bodily pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1072</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [‐2.47, 3.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.4 SF‐36 vitality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1070</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.03 [‐0.38, 4.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.5 SF‐36 role emotional</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1072</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.75 [‐5.55, 4.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.6 SF‐36 social functioning</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1072</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.19 [‐2.40, 16.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.7 SF‐36 mental health</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1070</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.37 [‐1.13, 5.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.8 SF‐36 role physical</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1072</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.63 [‐9.82, 19.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 HRQoL, LCQ (domains) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 LCQ physical</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.12, 0.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 LCQ psychological</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.5 [0.22, 0.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.3 LCQ social</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.4 [‐0.15, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 HRQoL, CCQ (total) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 Continuous antibiotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 HRQoL, CRQ (domains) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 CRQ dyspnoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>275</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.42 [‐1.79, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2 CRQ fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>275</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.56 [‐1.74, 0.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.3 CRQ emotional function</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>275</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.66 [‐1.94, 0.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.4 CRQ mastery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>275</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.21 [‐1.29, 0.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Frequency of hospital admissions ‐ continuous antibiotics <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Frequency of hospital admissions ‐ pulsed antibiotics <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Duration of exacerbation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.1 Continuous antibiotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.2 Pulsed antibiotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 FEV1 (mL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>658</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>20.21 [‐26.19, 66.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.1 Continuous antibiotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>441</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐12.69 [‐77.66, 52.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.2 Intermittent antibiotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>184</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>53.95 [‐16.90, 124.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.3 Pulsed antibiotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>58.0 [‐129.63, 245.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 FVC (L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>514</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.12 [0.01, 0.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.1 Continuous antibiotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>363</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [‐0.04, 0.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.2 Intermittent antibiotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.17 [‐0.01, 0.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22 FEV1 % predicted <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1737</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [‐1.56, 2.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.1 Continuous antibiotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>437</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.43 [‐1.97, 4.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.2 Intermittent antibiotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.67 [‐1.33, 4.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.3 Pulsed antibiotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1149</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.35 [‐3.28, 0.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23 Exercise capacity (6MWT) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>126</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>67.67 [16.20, 119.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.1 Continuous antibiotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>84.20 [13.38, 155.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.2 Intermittent antibiotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>36.0 [‐15.53, 87.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">24 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3309</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.66, 1.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.1 Continuous antibiotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1409</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.49, 1.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.2 Intermittent antibiotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [0.01, 3.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.3 Pulsed antibiotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1724</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.64, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">25 Respiratory‐related mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2266</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.63, 2.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.1 Continuous antibiotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.44 [0.54, 3.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.2 Pulsed antibiotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1149</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.45, 2.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">26 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2978</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.74, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.1 Continuous antibiotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1671</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.68, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.2 Intermittent antibiotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.12, 2.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.3 Pulsed antibiotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.72, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">27 Any adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>512</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.69, 1.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.1 Continuous antibiotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>355</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.62, 1.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.2 Intermittent antibiotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.37, 2.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.3 Pulsed antibiotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>11.52 [0.60, 221.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">28 Adverse events (specific) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.1 Respiratory disorders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2350</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.33, 3.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.2 Gastrointestinal disorders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2522</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.43, 3.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.3 QTc prolongation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.39, 3.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.4 Hearing impairment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.39 [1.05, 1.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.5 Musculoskeletal disorders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1149</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.07 [0.32, 29.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.6 Hypersensitivity/skin rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1258</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.63 [0.63, 4.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.7 Nervous system disorders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [0.38, 4.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.8 Cardiovascular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.05 [0.18, 23.51]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Antibiotics versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/references#CD009764-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009764-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Subgroup analyses</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Subgroup analysis: number of people with one or more exacerbations by mean % predicted FEV1 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2716</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.42, 0.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Mean FEV1 % ≥ 50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [0.05, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Mean FEV1 % &lt; 50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2686</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.44, 0.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Subgroup analysis: number of people with one or more exacerbations by treatment duration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2716</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.42, 0.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 ≥ 3 months to &lt; 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.28, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 ≥ 6 months to &lt; 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1185</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.24, 1.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 ≥ 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1318</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [0.25, 0.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Subgroup analysis: number of people with one or more exacerbations by year carried out <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2716</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.42, 0.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 2005 to 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.17, 0.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 2010 to 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2508</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.39, 0.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 2015 to 2019</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.29, 1.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Subgroup analysis: number of people with one or more exacerbations by regimen <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2716</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.42, 0.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Once daily antibiotic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.34, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Twice or three times daily antibiotic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.17, 0.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Three times a week antibiotic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>209</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.19, 0.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 Pulsed antibiotic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.68, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Subgroup analysis: number of people with one or more exacerbations by exacerbation history <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2716</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.42, 0.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Inclusion criteria of ≥ 1 exacerbation in preceding year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2358</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.43, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Exacerbation history not an inclusion criteria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>358</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.27, 0.69]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Subgroup analyses</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009764.pub3/references#CD009764-tbl-0004">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD009764.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD009764-note-0004">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD009764-note-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD009764-note-0003">Français</a> </li> <li class="section-language"> <a class="" href="ms#CD009764-note-0002">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD009764-note-0001">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009764\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009764\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009764\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009764\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009764\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009764\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009764\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009764\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009764\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009764\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009764\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009764\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009764\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009764\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009764\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009764\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009764\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009764\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=JmNqPX1V&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009764.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009764.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD009764.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD009764.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009764.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740716037203"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009764.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740716037207"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009764.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d95b41b09f409',t:'MTc0MDcxNjAzNy4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 